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Abstract 
Nanotopographical patterning of biomaterial substrates has great potential for 
biofunctionalisation of devices for clinical applications, such as in orthopaedics. 
Nanotopography comprising 120 nm diameter nanopits with a partially 
disordered arrangement of up to +/- 50 nm offset from a square lattice with 300 
nm centre to centre spacing (NSQ50, fabricated by electron beam lithography) 
has been characterized as being osteogenic. Following the finding of 
osteogenesis of mesenchymal stromal cells derived from human bone marrow 
(MSCs) on the NSQ50 nanotopography, MSCs cultured on ε-polycaprolactone 
(PCL) embossed with the NSQ50 pattern was used for this study on molecular 
mechanisms underlying NSQ50 induced MSC osteogenesis: the functional coupling 
of gene expression and osteogenesis, the molecular regulatory events driving 
gene expression and osteogenesis, and the possible link of metabolomics with 
molecular signalling of MSCs on the NSQ50 surface. 
Temporal analysis of gene expression for MSCs on the NSQ50 surface revealed 
that MSC fate commitment and osteogenic differentiation was transcriptionally 
controlled. The cell cycle and growth regulating transcription factor C-MYC was 
found to be significantly repressed, whereas the osteogenic transcription factor 
RUNX2 was up-regulated at 5 days of cell culture, and this was followed up-
regulation of the osteoblast specific transcription factor osterix (OSX) at days 11 
and 13. Following this transcription factor activation, osteoblast specific marker 
genes were induced with increased alkaline phosphatase (ALP) observed at day 
16, increased osteopontin (OPN) at day 20 and increased osteocalcin (OCN) at 
day 28. These data suggested that transcription factors regulated MSC 
osteogenic commitment at the early stage, and induced osteogenic specific 
marker gene expression at the late stages of cell culture on the NSQ50 surface, 
resulting in osteogenesis of the MSCs. 
Signalling pathway analysis illustrated that bone morphogenetic protein 2 (BMP2) 
was the initial signalling molecule that triggered osteogenic differentiation of 
MSCs by inducing RUNX2 expression via the canonical SMAD pathway. BMP2 and 
its transmembrane receptor type 1A (BMPR1A) were stimulated by 
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nanotopographical cues by 3 days of cell culture on the NSQ50 surface, whereas 
the induction of other transmembrane receptors, including the low density 
lipoprotein-receptor related protein 5 (LRP5) and integrin subunits α3, α4, β1, 
and β3 were not observed. Inhibition of BMP2 signalling by the BMP2 antagonist 
noggin resulted in down-regulation of RUNX2 and ALP. Further analysis of BMP2 
signalling revealed that BMP2 also modulated expression of the microRNA (miR)-
23b which targets RUNX2. The effect of BMP2 signalling on the expression of 
RUNX2 was enhanced by co-localizing with integrin αvβ5 (the vitronectin (VN) 
receptor) which was found to be up-regulated after 5 days cell culture. 
Metabolomics data for MSCs on the NSQ50 surface during early osteogenic 
differentiation was analysed. MSC cellular metabolite analysis revealed possible 
changes in bioenergetic balance with shifts towards more mitochondrial 
oxidative process, possibly indicating a switch in MSCs on the surface towards 
lineage-specific commitment. Further analysis of the metabolomics data 
illustrated PPARG ligands from the polyunsaturated fatty acid family was down-
regulated, suggesting the inhibition of adipocyte differentiation in MSCs on the 
surface. The down-regulation of unsaturated fatty acids could also be involved in 
the regulation of Ca2+ channels which positively regulate BMP2 expression. The 
metabolomics data, together with gene expression and signalling pathway 
analysis demonstrated that MSCs on the NSQ50 surface initiated osteogenic 
commitment after 3 days of cell culture, with BMP2 initiating osteogenic 
transcription factor stimulation of mature and functional osteoblasts on the 
surface. 
	  
	   	  
4	  
	  
Table of Contents 
AUTHOR’S	  DECLARATION	  ...........................................................................................................	  1	  
ABSTRACT	  ..................................................................................................................................	  2	  
TABLE	  OF	  CONTENTS	  ..................................................................................................................	  4	  
LIST	  OF	  FIGURES	  .......................................................................................................................	  11	  
LIST	  OF	  TABLES	  .........................................................................................................................	  14	  
ABBREVIATIONS	  .......................................................................................................................	  15	  
ACKNOWLEDGEMENTS	  .............................................................................................................	  18	  
CHAPTER	  1.	   INTRODUCTION	  ..................................................................................................	  19	  
SUMMARY	  ..................................................................................................................................	  20	  
	  
1.1	   BONE	  TISSUE	  BIOLOGY	  ...........................................................................................................	  21	  
1.1.1	   BONE	  STRUCTURE	  AND	  FUNCTION	  ................................................................................................	  21	  
1.1.2	   OSTEOBLAST	  AND	  BONE	  MATRIX	  ..................................................................................................	  22	  
1.1.3	   OSTEOCLAST	  AND	  BONE	  RESORPTION	  ...........................................................................................	  25	  
1.1.4	   MODELLING	  AND	  REMODELLING	  ..................................................................................................	  25	  
1.2	   BONE	  TISSUE	  REGENERATION	  ..................................................................................................	  27	  
1.2.1	   BONE	  TISSUE	  ENGINEERING	  .........................................................................................................	  28	  
1.2.2	   BIOMATERIALS	  FOR	  BONE	  TISSUE	  REGENERATION	  ...........................................................................	  31	  
1.2.3	   STEM	  CELLS	  FOR	  BONE	  TISSUE	  REGENERATION	  ................................................................................	  34	  
1.2.3.1	   Embryonic	  stem	  cells	  .........................................................................................................	  35	  
	  
1.2.3.2	   Induced	  pluripotent	  stem	  cells	  (iPSCs)	  ..............................................................................	  36	  
	  
1.2.3.3	   Multipotent	  mesenchymal	  stromal	  cells	  (MSCs)	  ...............................................................	  37	  
	  
5	  
	  
1.3	   MSCS	  DIFFERENTIATION	  PROCESS	  ............................................................................................	  38	  
1.3.1	   MSCS	  SELF-­‐RENEWAL	  AND	  REGULATION	  .......................................................................................	  38	  
1.3.2	   MSCS	  DIFFERENTIATION	  ............................................................................................................	  40	  
1.3.3	   TRANSCRIPTIONAL	  CONTROL	  OF	  MSCS	  OSTEOGENIC	  DIFFERENTIATION	  ...............................................	  41	  
1.3.3.1	   Runt-­‐related	  transcription	  factor	  2	  (RUNX2)	  .....................................................................	  41	  
	  
1.3.3.2	   Osterix	  (OSX)	  .....................................................................................................................	  42	  
	  
1.3.3.3	   Homeobox	  proteins	  (DLX5	  and	  MSX2)	  ..............................................................................	  43	  
	  
1.4	   MOLECULAR	  SIGNALS	  AND	  PATHWAYS	  OF	  OSTEOGENIC	  DIFFERENTIATION	  .........................................	  44	  
1.4.1	   BMP2	  SIGNALLING	  ...................................................................................................................	  44	  
1.4.2	   WNT	  SIGNALLING	  ......................................................................................................................	  46	  
1.5.	   NANOTOPOGRAPHY	  ............................................................................................................	  49	  
1.5.1	   EFFECTS	  OF	  NANOTOPOGRAPHY	  ON	  MSCS	  DIFFERENTIATION	  ...........................................................	  49	  
1.5.2	   BIOPHYSICAL	  AND	  BIOCHEMICAL	  EVENTS	  UNDERLYING	  THE	  EFFECTS	  OF	  NANOTOPOGRAPHY	  ...................	  51	  
1.5.2.1	   Focal	  adhesions	  .................................................................................................................	  51	  
	  
1.5.3.2	   Indirect	  mechanotransduction	  ..........................................................................................	  53	  
	  
1.5.3.3	   Direct	  mechanotransduction	  ............................................................................................	  54	  
	  
1.6	   AIMS	  OF	  THE	  PROJECT	  ...........................................................................................................	  57	  
CHAPTER	  2.	   METHODS	  AND	  MATERIALS	  ................................................................................	  59	  
SUMMARY	  ..................................................................................................................................	  60	  
	  
2.1	   NSQ50	  NANOTOPOGRAPHY	  ...................................................................................................	  60	  
	  
2.2	   MESENCHYMAL	  STORMAL	  CELLS	  ..............................................................................................	  61	  
2.2.1	   CELL	  ISOLATION	  FROM	  HUMAN	  BONE	  MARROW	  .............................................................................	  61	  
2.2.2	   CELL	  CULTURE	  AND	  HARVEST	  .......................................................................................................	  62	  
2.3	   OLIGONUCLEOTIDES	  (PRIMERS)	  SYNTHESIS	  .................................................................................	  63	  
	  
2.4	   TOTAL	  RNA	  EXTRACTION	  .......................................................................................................	  65	  
	  
2.5	   COMPLEMENTARY	  DNA	  (CDNA)	  SYNTHESIS	  ..............................................................................	  65	  
6	  
	  
2.5.1	   TOTAL	  RNA	  REVERSE	  TRANSCRIPTION	  ..........................................................................................	  65	  
2.5.2	   MICRORNA	  REVERSE	  TRANSCRIPTION	  ..........................................................................................	  66	  
2.6	   NUCLEIC	  ACIDS	  QUANTIFICATION	  AND	  QUALITY	  CONTROL	  ..............................................................	  66	  
2.6.1	   QUANTITATIVE	  REVERSE	  TRANSCRIPTION	  PCR	  (QRT-­‐PCR)	  ...............................................................	  67	  
2.7	  	   PROTEIN	  ANALYSIS	  ...............................................................................................................	  70	  
2.7.1	   PROTEIN	  PREPARATION	  ..............................................................................................................	  70	  
2.7.1.1	   Total	  protein	  preparation	  ..................................................................................................	  70	  
	  
2.7.1.2	   Membrane	  protein	  preparation	  ........................................................................................	  71	  
2.7.2	   PROTEIN	  QUANTIFICATION	  ..........................................................................................................	  71	  
2.7.3	   PROTEIN	  SEPARATION	  (SDS-­‐PAGE	  SEPARATION)	  ...........................................................................	  72	  
2.7.4	   PROTEIN	  ANALYSIS	  (I)	  –	  IMMUNOPRECIPITATION	  ............................................................................	  72	  
2.7.5	   PROTEIN	  ANALYSIS	  (II)	  –	  WESTERN	  BLOTTING	  ................................................................................	  72	  
2.8	   IMMUNOCYTOCHEMISTRY	  (ICC)	  ..............................................................................................	  73	  
2.8.1	   ICC	  FOR	  PROTEINS	  OF	  INTEREST	  ...................................................................................................	  73	  
2.8.2	   IMAGING	  .................................................................................................................................	  74	  
2.9	   BUFFERS	  AND	  ANTIBODIES	  IN	  PROTEIN	  WORK	  .............................................................................	  74	  
	  
2.10	   ALIZARIN	  RED	  STAINING	  ......................................................................................................	  75	  
	  
2.11	   METABOLOMICS	  ................................................................................................................	  75	  
CHAPTER	  3.	   TEMPORAL	  SEQUENCE	  GENE	  EXPRESSION	  OF	  MSCS	  ON	  NSQ50	  SURFACE	  ...........	  77	  
SUMMARY	  ..................................................................................................................................	  78	  
	  
3.1	  	   INTRODUCTION	  ...................................................................................................................	  78	  
	  
3.2	   METHODOLOGY	  AND	  EXPERIMENTAL	  DESIGN	  .............................................................................	  80	  
3.2.1	   QUANTITATIVE	  REAL	  TIME	  PCR	  (QRT-­‐PCR)	  ..................................................................................	  81	  
3.2.1.1	   Taqman	  and	  SYBR	  Green	  qRT-­‐PCR	  ....................................................................................	  81	  
	  
3.2.1.2	   Three	  modes	  of	  SYBR	  Green	  qRT-­‐PCR	  ...............................................................................	  84	  
	  
3.2.1.3	   Endogenous	  control	  gene	  GAPDH	  .....................................................................................	  84	  
7	  
	  
3.2.2	   EXPERIMENTAL	  DESIGN	  ..............................................................................................................	  85	  
3.2.2.1	   Assessment	  of	  bone	  marrow	  derived	  mesenchymal	  stromal	  cells	  ...................................	  85	  
	  
3.2.2.2	   Work	  flow	  of	  gene	  expression	  measurement	  ...................................................................	  86	  
	  
3.2.2.3	   Genes	  and	  time	  points	  chosen	  for	  temporal	  sequence	  gene	  expression	  .........................	  88	  
	  
3.3	   RESULTS	  .............................................................................................................................	  90	  
3.3.1	   EFFECT	  OF	  NSQ50	  TOPOGRAPHY	  ON	  C-­‐MYC	  EXPRESSION	  ...............................................................	  90	  
3.3.2	   	  RUNX2	  TEMPORAL	  SEQUENCE	  EXPRESSION	  PATTERN	  DURING	  NSQ	  50	  INDUCED	  MSC	  OSTEOGENIC	  
DIFFERENTIATION	  ......................................................................................................................	  91	  
3.3.3	   OSTERIX	  (OSX)	  TEMPORAL	  SEQUENCE	  EXPRESSION	  PATTERN	  DURING	  NSQ	  50	  INDUCED	  MSC	  OSTEOGENIC	  
DIFFERENTIATION	  ......................................................................................................................	  92	  
3.3.4	   ALP	  EXPRESSION	  PATTERN	  DURING	  NSQ50	  INDUCED	  MSCS	  OSTEOGENIC	  DIFFERENTIATION	  .................	  94	  
3.3.5	   OPN	  EXPRESSION	  PATTERN	  DURING	  NSQ50	  INDUCED	  MSC	  OSTEOGENIC	  DIFFERENTIATION	  ..................	  95	  
3.3.6	   OCN	  EXPRESSION	  PATTERN	  DURING	  NSQ50	  INDUCED	  MSC	  OSTEOGENIC	  DIFFERENTIATION	  ..................	  96	  
3.3.7	   THE	  VALIDATION	  OF	  KEY	  GENES	  EXPRESSION	  ..................................................................................	  97	  
3.3.8	   THE	  FORMATION	  OF	  BONE	  NODULES	  ............................................................................................	  99	  
3.4	   DISCUSSION	  AND	  CONCLUSION	  ..............................................................................................	  101	  
3.4.1	   THE	  TRANSCRIPTIONAL	  CONTROL	  OF	  MSCS	  ON	  NSQ50	  SURFACE.	  ..................................................	  101	  
3.4.2	   BONE	  MARKER	  GENES	  EXPRESSION	  ON	  NSQ50	  SURFACE	  ..............................................................	  103	  
3.4.3	   TEMPORAL	  SEQUENCE	  GENE	  EXPRESSION	  COUPLES	  WITH	  MSC	  OSTEOGENIC	  DIFFERENTIATION	  ON	  NSQ50	  
SURFACE	  ...............................................................................................................................	  103	  
3.4.4	   THE	  EFFECT	  OF	  PLANAR	  CONTROL	  ON	  OSTEOGENIC	  GENE	  EXPRESSION	  ..............................................	  105	  
3.4.5	   CONCLUSIONS	  .......................................................................................................................	  107	  
CHAPTER	  4.	   MOLECULAR	  MECHANISMS	  UNDERLYING	  OSTEOGENESIS	  OF	  MSCS	  ON	  NSQ50	  
SURFACE	  ....................................................................................................................	  108	  
SUMMARY	  ................................................................................................................................	  109	  
	  
4.1	   INTRODUCTION	  ..................................................................................................................	  109	  
	  
4.2	   METHODOLOGY	  .................................................................................................................	  112	  
	  
4.3	   RESULTS	  ...........................................................................................................................	  114	  
8	  
	  
4.3.1	   TRANSMEMBRANE	  RECEPTOR	  RESPONSE	  TO	  THE	  NSQ50	  SURFACE	  .................................................	  114	  
4.3.1.1	   Effect	  of	  the	  NSQ50	  surface	  on	  integrins	  .......................................................................	  114	  
	  
4.3.1.2	   Effect	  of	  NSQ50	  surface	  on	  Wnt	  signalling	  .....................................................................	  116	  
	  
4.3.1.3	   Effect	  of	  the	  NSQ50	  surface	  on	  BMPs	  receptor	  expression	  ...........................................	  117	  
4.3.2	   INDUCTION	  OF	  THE	  BMP2	  –	  SMAD	  PATHWAY	  ON	  THE	  NSQ50	  SURFACE	  .......................................	  119	  
4.3.2.1	   Activation	  of	  BMP2	  (ligand	  of	  BMPR1A)	  signalling	  .........................................................	  119	  
	  
4.3.2.2	   Induction	  of	  SMADs	  -­‐	  the	  mediators	  of	  canonical	  BMP2	  signalling	  ...............................	  121	  
	  
4.3.2.3	   Lack	  of	  change	  in	  the	  SMAD	  independent	  pathway	  of	  BMP2	  signalling	  in	  MSCs	  on	  the	  
NSQ50	  surface	  ..................................................................................................................	  123	  
4.3.3	   THE	  EFFECT	  OF	  BMP2	  SIGNALLING	  IN	  MSCS	  ON	  NSQ50	  SURFACE	  ON	  OSTEOGENIC	  DIFFERENTIATION	  .	  124	  
4.3.3.1	   The	  effect	  of	  BMP2	  signalling	  on	  early	  bone	  marker	  RUNX2	  expression	  .......................	  124	  
	  
4.3.3.2	   The	  effect	  of	  BMP2	  signalling	  on	  the	  mature	  osteoblast	  marker	  gene	  OPN	  expression	  126	  
	  
4.3.3.3	   The	  effect	  of	  low	  serum	  on	  RUNX2	  expression	  in	  MSCs	  on	  the	  NSQ50	  surface	  ............	  129	  
4.3.4	   THE	  EXPRESSION	  OF	  MIRNAS	  IN	  MSCS	  ON	  THE	  NSQ50	  SURFACE	  ..................................................	  131	  
4.3.4.1	   Prediction	  analysis	  of	  miRNAs	  targeting	  RUNX2	  and	  OSX	  genes	  ...................................	  131	  
	  
4.3.4.2	   The	  expression	  of	  miRNAs	  on	  NSQ50	  surface	  ................................................................	  131	  
4.3.5	   THE	  RELATION	  OF	  BMP2	  SIGNALLING	  TO	  OTHER	  OSTEOGENIC	  REGULATORY	  EVENTS	  IN	  MSCS	  ON	  THE	  
NSQ50	  SURFACE	  ...................................................................................................................	  134	  
4.3.5.1	   BMP2	  signal	  and	  miRNAs	  ...............................................................................................	  134	  
	  
4.3.5.2	   Crosstalk	  of	  BMP2	  and	  integrin	  αvβ5	  signalling	  .............................................................	  135	  
	  
4.3.5.2.1	   The	  effect	  of	  integrins	  αvβ5	  on	  RUNX2	  expression	  .....................................................	  135	  
	  
4.3.5.2.2	   The	  co-­‐localization	  of	  the	  BMP2	  receptor	  and	  integrins	  .............................................	  138	  
	  
4.3.5.2.3	   The	  functional	  relation	  of	  BMP2	  signalling	  and	  integrins	  on	  NSQ50	  ..........................	  140	  
	  
4.3.5.2.4	   The	  functional	  relation	  of	  integrins	  to	  BMP	  signalling	  ................................................	  142	  
	  
4.4	   DISCUSSION	  AND	  CONCLUSION	  ..............................................................................................	  143	  
4.4.1	   BMP2	  SIGNALLING	  ................................................................................................................	  143	  
4.4.2	   THE	  ROLE	  OF	  INTEGRINS	  IN	  OSTEOGENESIS	  OF	  MSCS	  ON	  NSQ50	  SURFACE.	  .....................................	  144	  
9	  
	  
4.4.3	   CROSS-­‐TALK	  BETWEEN	  BMP2	  SIGNALLING	  AND	  INTEGRINS.	  ..........................................................	  146	  
4.4.4	   MIRNAS.	  .............................................................................................................................	  146	  
4.4.5	   CONCLUSIONS.	  ......................................................................................................................	  147	  
CHAPTER	  5.	   METABOLOMICS	  ...............................................................................................	  149	  
RATIONALE	  ...............................................................................................................................	  150	  
	  
5.1	   INTRODUCTION	  ..................................................................................................................	  150	  
5.1.1	   METABOLIC	  PROFILE	  OF	  PLURIPOTENT	  STEM	  CELLS	  (ESC	  AND	  IPSCS)	  ..............................................	  150	  
5.1.2	   METABOLIC	  PROFILE	  OF	  MSCS	  .................................................................................................	  152	  
5.1.3	   THE	  LINKS	  OF	  METABOLISM	  TO	  EPIGENETICS	  AND	  GENE	  EXPRESSION	  ................................................	  153	  
5.2	   METHODOLOGY	  AND	  DATA	  ANALYSIS	  .....................................................................................	  154	  
5.2.1	   METHODOLOGY	  .....................................................................................................................	  154	  
5.2.2	   DATA	  ANALYSIS	  .....................................................................................................................	  154	  
5.3	   RESULTS	  ...........................................................................................................................	  156	  
5.3.1	   CLUSTERING	  ANALYSIS	  OF	  METABOLITES	  IN	  MSCS	  ON	  NSQ50	  .......................................................	  156	  
5.3.2	   BIOENERGETICS	  OF	  MSCS	  ON	  THE	  NSQ50	  SURFACE	  ....................................................................	  161	  
5.3.3	   THE	  LACK	  OF	  ANAEROBIC	  GLYCOLYTIC	  PHENOTYPE	  OF	  MSCS	  ON	  NSQ50	  AT	  EARLY	  STAGE	  OSTEOGENESIS	  .....	  
	   	  ...........................................................................................................................................	  161	  
5.3.4	   THE	  INCREASED	  MITOCHONDRIAL	  ACTIVITY	  FOR	  BIOENERGETICS	  OF	  MSCS	  ON	  NSQ50	  SURFACE	  ..........	  163	  
5.3.5	   THE	  DOWN-­‐REGULATION	  OF	  UNSATURATED	  FATTY	  ACIDS	  ..............................................................	  166	  
5.3.6	   THE	  RELATION	  OF	  UNSATURATED	  FATTY	  ACIDS	  TO	  SIGNALLING	  PATHWAYS	  ........................................	  170	  
5.3.6.1	   Unsaturated	  fatty	  acids	  induce	  Peroxisome	  proliferator-­‐activated	  receptor	  gamma	  
(PPARG)	  activity	  ................................................................................................................	  170	  
	  
5.3.6.2	   The	  roles	  of	  fatty	  acids	  on	  Ca2+	  signalling	  .......................................................................	  172	  
	  
5.4	   DISCUSSION	  AND	  CONCLUSION	  ..............................................................................................	  174	  
5.4.1	   DISCUSSION	  ..........................................................................................................................	  174	  
5.4.2	   CONCLUSION	  ........................................................................................................................	  176	  
CHAPTER	  6.	   CONCLUSIONS	  AND	  FUTURE	  WORK	  ..................................................................	  178	  
10	  
	  
SUMMARY	  ................................................................................................................................	  179	  
	  
6.1	   CONCLUSIONS	  ...................................................................................................................	  179	  
6.1.1	   FUNCTIONAL	  COUPLING	  OF	  GENE	  EXPRESSION	  AND	  OSTEOGENIC	  DIFFERENTIATION	  ............................	  179	  
6.1.2	   TRANSCRIPTIONAL	  CONTROL	  OF	  MSC	  OSTEOGENIC	  DIFFERENTIATION	  .............................................	  180	  
6.1.3	   BMP2	  SIGNALLING	  AND	  OSTEOGENESIS	  OF	  MSCS	  ON	  THE	  NSQ50	  SURFACE	  ...................................	  180	  
6.1.4	   IMPLICATING	  INTEGRIN	  ΑVΒ5	  IN	  OSTEOGENESIS	  OF	  MSCS	  ON	  THE	  NSQ50	  SURFACE	  .........................	  181	  
6.1.5.1	  SYNERGIC	  EFFECTS	  OF	  THE	  INTERPLAY	  OF	  BMP2	  AND	  INTEGRIN	  ΑVΒ5	  ON	  OSTEOGENESIS	  OF	  MSCS	  ON	  THE	  
NSQ50	  SURFACE	  ...................................................................................................................	  181	  
6.1.6	   METABOLISM	  OF	  MSCS	  ON	  THE	  NSQ50	  SURFACE	  ......................................................................	  182	  
6.2	   FUTURE	  WORK	  ..................................................................................................................	  183	  
REFERENCES	  ...........................................................................................................................	  185	  
	   	  
11	  
	  
List of Figures 
Figure	  1.1	   Diagram	  of	  long	  bone	  anatomy	  and	  structure.	  ...............................................	  22	  
Figure	  1.2	   Organization	   of	   bone	   tissue	   from	   its	   smallest	   components	   (right)	   to	   whole	  
tissues	  (left).	  ....................................................................................................	  24	  
Figure	  1.3	   Bone	  remodelling	  cycle.	  ..................................................................................	  27	  
Figure	  1.4	   Growth	  of	   research	  on	  bone	   tissue	  engineering	   reflected	  on	   the	  number	  of	  
publications	  since	  1985	  on	  PubMed.	  ..............................................................	  30	  
Figure	  1.5	   Schematic	  diagram	  describing	  MSCs	  self-­‐renewal	  and	  differentiation.	  ..........	  40	  
Figure	  1.6	   Diagram	  of	  indirect	  and	  direct	  mechanotransduction	  effectors.	  ....................	  56	  
Figure	  2.1	   The	  feature	  of	  NSQ50	  nanopits	  .......................................................................	  61	  
Figure	  2.2	   Example	  of	  relative	  standard	  curve	  for	  the	  OPN	  gene.	  ...................................	  68	  
Figure	  2.3	   Example	  of	  SYBR	  green	  qRT-­‐PCR	  melting	  curves	  generated	  during	  OPN	  gene	  
amplification.	  ..................................................................................................	  70	  
Figure	  3.1	   The	  selective	  mode	  of	  gene	  expression	  in	  MSC	  multilineage	  differentiation.	  79	  
Figure	  3.2	   Fluorescent	  chemistries	  used	  in	  TaqMan	  and	  SYBR	  Green	  qRT-­‐PCR.	  .............	  83	  
Figure	  3.3	   Ct	   value	   of	   GAPDH	   measured	   for	   MSCs	   cultured	   on	   NSQ50	   and	   planar	  
surfaces	  at	  different	  time	  points.	  ....................................................................	  85	  
Figure	  3.4	   MSCs	   expanded	   in	   tissue	   culture	   flask	   negatively	   express	   tissue	   specific	  
markers	  after	  two	  passaging.	  ..........................................................................	  86	  
Figure	  3.5	   Diagram	  of	  parallel	  work	  flow	  for	  gene	  expression	  measurement.	  ................	  87	  
Figure	  3.6	   Gene	  expression	  analysis	  of	  C-­‐MYC	  in	  MSCs	  on	  NSQ50	  compared	  to	  those	  on	  
planar	  control.	  .................................................................................................	  90	  
Figure	  3.7	   Temporal	  sequence	  gene	  expression	  analysis	  of	  RUNX2	  in	  MSCs	  on	  NSQ50.	  92	  
Figure	  3.8	   Temporal	  gene	  expression	  analysis	  of	  OSX	  in	  MSCs	  on	  NSQ50.	  .....................	  93	  
Figure	  3.9	   Effects	  of	  NSQ50	  surface	  on	  homeodomain	  factors	  MSX2	  and	  DLX5.	  ............	  94	  
Figure	  3.10	   Gene	  expression	  analysis	  of	  ALP	  in	  MSCs	  on	  NSQ50.	  .....................................	  95	  
Figure	  3.11	   Gene	  expression	  analysis	  of	  OPN	  in	  MSCs	  on	  NSQ50.	  ....................................	  96	  
Figure	  3.12	   Gene	  expression	  analysis	  of	  OCN	  in	  MSCs	  on	  NSQ50.	  ....................................	  97	  
12	  
	  
Figure	  3.13	   RUNX2	  is	  abundant	  in	  cells	  cultured	  on	  the	  NSQ50	  surface	  for	  9	  days.	  .........	  98	  
Figure	  3.14	   OPN	  and	  OCN	  are	  abundant	  in	  cells	  cultured	  on	  NSQ50	  surface	  for	  28	  days.	  99	  
Figure	  3.15	   Calcium	  deposition	  by	  MSCs	  on	  NSQ50.	  ......................................................	  100	  
Figure	  3.16	   Temporal	   sequence	   genes	   expression	  pattern	   functionalized	  NSQ50	   surface	  
induced	  osteogenic	  differentiation.	  .............................................................	  105	  
Figure	  4.1	   The	  effect	  of	  NSQ50	  surface	  on	  the	  expression	  of	  integrins	  in	  MSCs.	  .........	  115	  
Figure	  4.2	   The	   effect	   of	   the	   NSQ50	   surface	   on	   Wnt	   signalling	   at	   early	   stage	   MSCs	  
osteogenic	  differentiation.	  ...........................................................................	  117	  
Figure	  4.3	   The	   effect	   of	   the	   NSQ50	   surface	   on	   BMP	   receptor,	   BMPR1A	   at	   the	   early	  
stages	  of	  MSCs	  osteogenic	  differentiation.	  ..................................................	  118	  
Figure	  4.4	   The	  effect	  of	  NSQ50	  surface	  on	  BMP2	  expression	  at	   the	  early	  stage	  of	  MSC	  
osteogenic	  differentiation.	  ...........................................................................	  120	  
Figure	  4.5	   BMP2	   protein	   expression	   in	   MSCs	   cultured	   on	   the	   NSQ50	   and	   planar	  
surfaces.	  .......................................................................................................	  121	  
Figure	  4.6	   The	  induction	  of	  the	  BMP2	  canonical	  pathway	  mediator	  SMAD	  on	  the	  NSQ50	  
surface.	  .........................................................................................................	  122	  
Figure	  4.7	   Lack	  of	  activation	  of	  TGF-­‐beta	  activated	  kinase	  1	  binding	  protein	  tab1	  in	  the	  
SMAD	  independent	  pathway	  of	  BMP2	  signalling.	  .......................................	  124	  
Figure	  4.8	   RUNX2	  responses	  to	  the	  BMP2	  antagonist	  noggin.	  .....................................	  126	  
Figure	  4.9	   OPN	  responses	  to	  the	  BMP2	  antagonist	  noggin.	  .........................................	  128	  
Figure	  4.10	   RUNX2	  expressions	  in	  low	  serum	  and	  normal	  medium.	  ..............................	  130	  
Figure	  4.11	   The	  prediction	  of	  miRNAs	  targeting	  RUNX2	  and	  OSX	  using	  TargetScan.	  .....	  132	  
Figure	  4.12	   The	  expression	  of	  miRNAs	  targeting	  RUNX2	  and	  OSX	  in	  MSCs	  on	  the	  NSQ50	  
surface.	  .........................................................................................................	  133	  
Figure	  4.13	   The	  effects	  of	  BMP2	  signalling	  on	  miRNAs.	  .................................................	  135	  
Figure	  4.14	   The	  effect	  of	  integrins	  on	  RUNX2	  expression.	  .............................................	  137	  
Figure	  4.15	   Integrins	  co-­‐localize	  with	  the	  BMP2	  receptor	  when	  MSCs	  are	  cultured	  on	  the	  
NSQ50	  surface.	  .............................................................................................	  139	  
Figure	  4.16	   The	  effect	  of	  BMP2	  signalling	  on	  integrin	  expression.	  .................................	  141	  
Figure	  4.17	   The	  effect	  of	  VN	  on	  integrin	  αvβ5	  and	  BMPR1A	  expression.	  .......................	  143	  
13	  
	  
Figure	  5.1	   The	  lipids	  profile	  of	  MSCs	  on	  the	  NSQ50	  surface	  for	  cells	  cultured	  at	  3,	  5,	  and	  
7	  days.	  ..........................................................................................................	  157	  
Figure	  5.2	   The	  amino	  acid	  profile	  of	  MSCs	  on	  the	  NSQ50	  surface	  for	  cells	  cultured	  at	  3,	  
5,	  and	  7	  days.	  ...............................................................................................	  158	  
Figure	  5.3	   The	  nucleotides	  and	  other	  metabolites	  profile	  of	  MSCs	  on	  the	  NSQ50	  surface	  
for	  cells	  cultured	  at	  3,	  5,	  and	  7	  days.	  ...........................................................	  159	  
Figure	  5.4	   The	  non-­‐pathway	  mapping	  metabolites	  profile	  of	  MSCs	  on	  the	  NSQ50	  surface	  
for	  cells	  cultured	  at	  3,	  5,	  and	  7	  days.	  ...........................................................	  160	  
Figure	  5.5	   Metabolites	   in	   MSCs	   on	   the	   NSQ50	   surface	   involved	   in	   the	   glycolysis	  
pathway.	  ......................................................................................................	  162	  
Figure	  5.6	   The	  effect	  of	   the	  NSQ50	   surface	  on	   the	  glycolytic	  bioenergetics	  pathway	   in	  
MSCs.	  ...........................................................................................................	  163	  
Figure	  5.7	   NSQ50	  surface	  shifting	  bioenergetics	  of	  MSCs	  to	  mitochondria.	  ................	  165	  
Figure	  5.8	   Fatty	   acids	   involved	   in	   biosynthesis	   of	   unsaturated	   fatty	   acids	   in	   MSCs	  
cultured	  on	  NSQ50	  surface	  for	  3,	  5	  and	  7	  days.	  ...........................................	  167	  
Figure	  5.9	   Heatmap	   clustering	   of	   fatty	   acids	   in	   MSCs	   on	   the	   NSQ50	   surface	   for	   cells	  
cultured	  at	  3,	  5,	  and	  7	  days.	  .........................................................................	  168	  
Figure	  5.10	   Down-­‐regulation	  of	   fatty	  acids	   involved	   in	  biosynthesis	  of	  unsaturated	   fatty	  
acids	  in	  MSCs	  cultured	  on	  NSQ50	  surface	  for	  3,	  5	  and	  7	  days.	  ....................	  169	  
Figure	  5.11	   The	  down-­‐regulation	  of	  PPARG	  ligands	  in	  MSCs	  on	  the	  NSQ50	  surface.	  .....	  171	  
Figure	  5.12	   The	  expression	  of	  long	  chain	  saturated	  fatty	  acids	  involved	  in	  the	  regulation	  
of	  Ca2+	  signalling	  in	  MSCs	  on	  the	  NSQ50	  surface.	  ........................................	  173	  
	  
	   	  
14	  
	  
List of Tables 
Table	  2.1	   Components	  of	  transport	  medium	  for	  bone	  marrow.	  ....................................	  62	  
Table	  2.2	   Components	  of	  modified	  basal	  medium	  for	  MSC	  culture.	  ..............................	  62	  
Table	  2.3	   Primers	  for	  genes	  encoding	  proteins.	  .............................................................	  64	  
Table	  2.4	   Primers	  for	  miRNAs.	  ........................................................................................	  65	  
Table	  2.5	   PCR	  cyclic	  parameters	  for	  SYBR	  Green	  qRT-­‐PCR.	  ............................................	  68	  
Table	  2.6	   The	  components	  of	  RIPA	  lysis	  buffer.	  .............................................................	  71	  
Table	  2.7	   Buffers	  used	  for	  protein	  work.	  ........................................................................	  74	  
Table	  2.8	   Antibodies	  used	  for	  protein	  work.	  ..................................................................	  75	  
Table	  3.1	   Genes	  associated	  with	  MSCs	  functional	  relationship	  between	  	  .........................	  
	   proliferation	  and	  osteogenic	  differentiation.	  .................................................	  89	  
Table	  4.1	   Genes	  and/or	  proteins	  investigated	  for	  the	  analysis	  of	  osteogenic	  	  ...................	  
	   signalling	  pathway	  in	  MSCs	  on	  NSQ50	  surface.	  ...........................................	  113	  
 
	   	  
15	  
	  
Abbreviations 
acetyl-CoA   acetyl coenzyme A 
ACVR2A   activin A receptor II A 
ALP    alkaline phosphatase 
ANOVA    analysis of variance 
ATP    adenosine triphosphate 
BMP2     bone morphogenetic protein 2 
MSCs     mesenchymal stromal cells 
BMPR1A   BMP receptor type 1 A  
BMU     basic multicellular unit 
BRAM1   BMP receptor associated molecule 1 
Ca2+    Calcium 
CaP     calcium phosphate  
CCD     cleidocranial dysplasia 
CD markers    surface antigen markers  
CDK     cyclin dependent kinase 
cDNA    Complementary DNA 
CFU-F    colony forming unit-fibroblast 
CTNNBIP1   beta-catenin-interacting protein 1  
DEX    dexamethasone 
dsDNA    doubled strand DNA  
EB    embryonic body 
EBL    electron beam lithography 
ECM    extracellular matrix 
endosteum    inner membranous sheath  
ERK    extracellular signal-regulated kinase  
ERK1/2   extracellular signal-related kinase 1/2  
ESCs    embryonic stem cells 
ETC    Electron Transport Chain 
FBS    fetal bovine serum 
FGF2    fibroblast growth factor2  
FGFs     fibroblast growth factors  
16	  
	  
FRET    fluorescence resonance energy transfer  
GAPDH   Glyceraldehyde 3-phosphate dehydrogenase 
Gla     3-gammacarboxy-glutamic acid residues 
GLUT1/3   glucose transporter 1/3 
GSK-3β   glycogen synthase kinase 3β  
HA    hydroxyapatite  
HACD4   histone deacetylase 4  
HDs     homeodomain proteins 
HIF-1    hypoxia-inducible factor 1 
HILIC    hydrophilic interaction liquid chromatography 
HK    hexokinase 
IGFs     insulin-like growth factors  
iPSCs     induced pluripotent stem cells  
Jnk    c-jun-n-terminal kinase 
LC-MS    liquid chromatography and mass spectrometry 
LINC     linker of cytoskeleton and nucleoskeleton  
LRP5/6 Low-density lipoprotein receptor-related protein 5 or 
6  
M-CSF    macrophase colony-stimulating factor  
MAPKK1   mitogen-activated protein kinase kinase 1  
MAR     matrix attachment region  
miRNA    MicroRNA  
mRNA    messenger RNA  
MSCs     Multipotent mesenchymal stromal cells 
NADH    Nicotinamide adenine dinucleotide 
NFkB     nuclear factor kappa beta  
NGS     next generation sequencing   
NSQ50    near square50 surface  
OCN     osteocalcin  
OPN    osteopontin 
OSE2    osteoblast specific cis-acting element  
OSX    Osterix 
OxPhos   Oxidative Phosphorylation 
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PI3K    phosphatidylinositol 3-kinase 
p38 MAPK    include MAP kinase p38  
PCL    polycarprolactone  
periosteum    fibrous structure  
PFK1    phosphofructokinase 1 
PGA     polyglycolide 
PGKs    glycolytic phosphoglycerate kinases 
Pi     phosphate 
PKs    pyruvate kinases 
PLA     polylactide  
PMMA     polymethylmethacrylate 
PPARG   Peroxisome proliferator-activated receptor gamma 
PPi     pyrophosphate 
PPP    pentose phosphate pathway 
rhBMP2   recombinant human BMP2 
qRT-PCR    quantitative real time PCR  
R-SMADs    receptor-regulated Smads  
RANKL    receptor activator NFkB of ligand  
RGD     arg-gly-asp 
ROS    Reactive Oxygen Species 
RT-PCR    reverse transcription PCR  
RUNX2   runt-related transcription factor 2  
SAM     self-assembled monolayer  
Smurf1   Smad-ubiquitination-regulatory factor 1  
SQ    symmetries of square  
TAK1    TGF-beta activated kinase 1  
Tcf/Lef    T cell factor/Lymphoid enhancer binding factor  
TGF-β    transforming growth factor-β  
Tm     melting temperature  
VN    vitronectin 
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Summary 
This thesis aimed to address issues of fundamental understanding of how a 
nanotopography (NSQ50) which has been identified as osteoinductive (Dalby et 
al., 2007d) initiates osteogenesis. Mesenchymal stromal cells (MSCs) cultured on 
the NSQ50 nanotopography embossed polycaprolactone (PCL) were used for 
functional analysis of osteogenesis in MSCs. Cell growth modulators, 
transcription factors regulating MSC fate determination and osteogenic 
differentiaton, signalling molecules modulating these transcription factors and 
osteogenic differentiation itself were explored. Metabolites likely influencing 
MSC early stage osteogenic differentiation on the NSQ50 surface were also 
investigated. 
This chapter will introduce main themes for the thesis including bone tissue 
biology and stem cells, specifically MSCs as a major allogeneic cell resource for 
bone tissue regeneration. General background on biomaterial and tissue 
engineering are also described. Mechanisms underlying MSC osteogenic 
differentiation are introduced. More specific background is provided within each 
chapter. Chapter 2 contains the methods used during the course of this research. 
Chapter 3 describes quantitative real time PCR (qRT-PCR) experiments and 
verification of functionally coupling gene expression with osteogenic 
differentiation of MSCs on the NSQ50 surface. In chapter 4, molecular signalling 
and pathways stimulating MSC osteogenic differentiation on the NSQ50 surface, 
such as BMP2 signalling, are investigated. Furthermore, the role of BMP2 
signalling interplay with integrins and regulating microRNAs (miRNA) are 
explored. Chapter 5 is concerned with metabolism and possible regulatory roles 
of metabolites in MSC osteogenic determination on the NSQ50 surface. Finally, 
chapter 6 presents the final conclusions of this thesis and the thinking for future 
work. 
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1.1 Bone tissue biology 
1.1.1 Bone structure and function 
In the adult human body, the skeleton is comprised of 213 bones and serves a 
variety of functions. The skeleton is the framework of the human body and it 
provides mechanical protection for vital internal organs. Skeletal bones offer the 
sites for muscle and tendon attachment, and thus support the body’s movement 
and locomotion. Bone tissue contains 99% of the calcium and 85% of the 
phosphorus found within the whole body and maintains the body’s mineral 
homeostasis. In addition, bone tissue provides the environment for bone 
marrow, which produces new blood cells and works as a vital part of the 
lymphatic system (Brandi, 2009; Taichman, 2005). 
Macroscopically, there are two types of bones (Figure 1.1): one is the compact 
bones that constitute about 80% of the skeleton, and the other is spongy 
(trabecular) bones which make up the rest of the skeleton. Both compact bone 
and spongy bone are composed of osteons. Compact osteons are cylindrical in 
shape and form a branching network within the compact bone, which helps 
provide the strength of bone. Spongy osteons are a honeycomb-like network, and 
the spaces between trabecular plates and rods are filled with bone marrow cells. 
The compact bone has an outer fibrous structure (periosteum) which contains 
the blood vessels, nerve endings, osteoblasts and osteoclasts, and inner 
membranous sheath (endosteum) contacting the bone marrow space, spongy 
bone, and blood vessel canals. Like the periosteum, endosteum also contains 
blood vessels, and osteoblasts and osteoclasts (Brandi, 2009). 
The periosteum of compact bone consists of an outer fibrous layer and inner 
osteogenic layer. The inner osteogenic layer contains osteoprogenitor cells that 
can develop into osteoblasts. Therefore, the activity of periosteum plays an 
important role for bone growth and fracture repair. 
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Figure 1.1 Diagram of long bone anatomy and structure. 
The long bone diagram shows: (a) long bone is composed of 
proximal epiphysis, diaphysis and distal epiphysis. (b) In the 
proximal epiphysis, most bone tissue is spongy bone arranged in a 
honeycomb-like network, and the spaces between trabecular plates 
and rods are filled with bone marrow. (c) Compact bone constitutes 
the diaphysis of the long bones. Compact bone contains branching 
networks surrounded by the outer fibrous structure (periosteum) 
which contains the blood vessels, nerve endings and osteoblasts 
and osteoclasts. The endosteum of compact bone contacts with 
bone marrow and contains blood vessels and osteoblasts and 
osteoclasts. (Cummings, 2004).  
1.1.2 Osteoblast and bone matrix 
Osteoblasts are bone forming cells which produce and secrete proteins forming 
the bone matrix (Benayahu et al., 1995). They are then responsible for  
subsequent matrix mineralization (Boskey, 1998). 
Osteoblasts are derived from mesenchymal stem cells that give rise to 
osteoprogenitor cells. The fully differentiated (mature) osteoblasts produce type 
I collagen, the major component of bone matrix (Brodsky and Persikov, 2005). 
Type I collagen is a polymeric protein initially secreted by osteoblasts in the 
23	  
	  
form of a precursor that contains peptide extensions at both the amino-terminal 
and carboxyl ends. Further cellular processing results in the extra propeptides 
extensions being removed and the formation of mature type I collagen, which 
then assembles into a collagen fibril. Collagen molecules are interconnected by 
the formation of pyridinoline cross-links to form the primary matrix structure of 
bone (Viguet-Carrin et al., 2006). 
Osteoblasts also synthesize a number of noncollagenous proteins which 
incorporate into the bone matrix, including osteocalcin (OCN), osteonectin, 
osteopontin (OPN), vitronection, fibronectin and bone sialoprotein, alkaline 
phosphatase (ALP), etc. These proteins are produced in minor amounts 
compared to collagens, however they serve diverse functions in bone formation 
and turn over. ALP has been thought to play a role in bone mineralization by 
releasing phosphate and deficiency in ALP results in hypophosphatasia, a 
condition characterized by defective bone mineralization (Whyte, 1994). OCN is 
very specific marker for bone turn over and is an extracellular matrix (ECM) 
component the osteoblast use to capture calcium (Ducy et al., 1996). The 
others, such as OPN, vitronection, fibronectin and bone sialoprotein serve as 
attachment factors interacting with integrins (OPN, as well as containing cell 
attachment peptide motifs is also involved in calcium acquisition (Kvansakul et 
al., 2004). Together these proteins serve to allow osteoblast adhesion and to 
sequester calcium and phosphate into the osteoblast environment – the 
recruitment of cells, calcium and phosphate leads to mineralization (Boskey, 
1998; Buchet et al., 2013). 
Mature bone matrix is a composite of polymeric collagen reinforced with 
nanocrystals made of hydroxyapatite mineral (HCa5O13P3). The nanocrystals 
provide mechanical stiffness and load-bearing strength to bone, while 
collagenous proteins make bone elastic and flexible. Bone matrix is highly 
ordered, well aligned structure over multiple size scales (Figure 1.2). Collagen 
proteins (~2 nm in diameter) self-assemble into fibrillar structures which then 
further accumulate into fibrils (~500 nm in diameter). Bone minerals 
(nanocrystals) deposit in ‘hole’ zones where are left at the ends of fibils when 
they stack into fibers (Landis, 1995). 
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Figure 1.2 Organization of bone tissue from its smallest components (right) 
to whole tissues (left). 
Bone is a composite of collagen fibers reinforced with calcium 
phosphate nanocrystals arranged in a semi-regular pattern. Other 
components include minor proteins and growth factors. Mineralized 
collagen is aggregated into small fibrils, which further combine to 
form fibers a few microns in diameter and several mm long. In 
trabecular (spongy) bone the mineralized fibers are semi-randomly 
laid out in struts forming an open cell foam. Cortical bone is 
composed of circular osteons which feature aligned sheets of 
mineralized fibers wrapped around a central hollow core. (Picture 
taken from Kane et al, 2013). 
Osteoblasts eventually terminally differentiate and are trapped in mineralized 
matrix forming osteocytes. Osteocytes are the most abundant cell type in bone, 
they are regularly spaced throughout the matrix and maintain connections with 
each other, with the cells on the bone surface and even with cells of the bone 
marrow through their multiple cytoplasmic extensions (Marotti, 1996). The 
communication networks through bone tissue make osteocytes ideal candidates 
for mechanosensory cells being able to detect and transduce stress signals into 
bone biological activity (Aarden et al., 1994; Rubin and Lanyon, 1987). 
Buried osteoblasts on the top of unmineralized matrix that covers the quiescent 
bone (i.e., bone that is not undergoing remodeling), are termed bone lining cells 
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(Parfitt, 1994). Lining cells secret collagenase to remove the unmineralized 
collagen layer, while producing ‘homing’ signals to guide osteoclast precursors 
to a specific location on bone for bone resorption (Parfitt et al., 1996). 
1.1.3 Osteoclast and bone resorption 
Osteoclasts, unlike osteoblasts, are derived from the monocyte / macrophage 
haematopoietic lineage in bone marrow (Boyle et al., 2003). The formation of 
osteoclasts requires the presence of marrow stromal cells and osteoblasts which 
produce cytokines, such as receptor activator of NFkB ligand (RANKL) and 
macrophage colony-stimulating factor (M-CSF). RANKL is critical for osteoclast 
differentiation and formation, while M-CSF is required for proliferation, survival 
and cytoskeleton rearrangement of osteoclasts and their precursors (Cohen, 
2006). 
Mature osteoclasts are multinucleated cells with finger-shaped projections of 
the membrane (ruffled border) which mediate the resorption of the calcified 
bone matrix (Roodman, 1996). The ruffled border is surrounded by a specialized 
area (clear zone) which delineates and seals off the area of the attachment of 
osteoclast to the bone surface. Osteoclasts bind to bone matrix mainly through 
membrane receptor integrins αvβ3, which links to bone matrix noncollagenous 
protein, such as OPN (Ross and Teitelbaum, 2005). Hydrogen ions are released by 
an ATP-driven proton pump located in the ruffled border membrane to dissolve 
mineral components of bone matrix at the resorption site, and then the protein 
components, mainly collagen, are digested by matrix metalloproteinases and 
cathepsins K, B and L secreted by osteoclast. Through the process of 
endocytosis, some of the digested products of bone resorption are taken into the 
osteoclast (Wilson et al., 2009). 
1.1.4 Modelling and remodelling 
Bone is highly specialized and dynamic organ that undergoes continuous 
regeneration. During development and growth，bones adapt their shape and size 
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in response to physiological and / or mechanical influences by a process known 
as modelling. In the modelling process, bones grow or reshape by removal or 
addition of bone to the appropriate surface through the independent action of 
osteoblasts and osteoclasts (Brandi, 2009; Yajima et al., 2008). Physiologically, 
bone modelling is less frequent than remodelling in adults. Modelling occurs with 
aging where bone normally widens in response to periosteal apposition of new 
bone and endosteal resorption of old bone. However, in the modelling process, 
bone formation and resorption are not coupled, which differ from bone 
remodelling (Kobayashi et al., 2003).  
Bone remodelling is described as a process that involves the removal of old bone 
by osteoclasts followed by the deposition of new bone by osteoblasts at the 
same location. Bone tissue is renewed by remodelling throughout life to prevent 
bone microdamage, so as to maintain bone strength and mineral homeostasis (de 
Baat et al., 2005). Bone remodelling is achieved using a unique temporary 
structure, known as a basic multicellular unit (BMU) that contains a well-
orchestrated spatial and temporal relationship of different cell types in four 
distinct phases (Figure 1.3). Removal of old bone is composed of quiescence and 
resorption phases in which monocyte-macrophage osteoclast precursors lift 
lining cells off the bone surface and fuse to form multinucleated pre-osteoclasts 
which bind to bone surface to resorb bone. Following bone resorption is the bone 
formation process which constitutes reversion and formation phases. In reversal, 
bone resorption is inhibited by mononuclear cells and pre-osteoblasts are 
recruited into the cavity to initiate the bone formation phase to form new bone. 
At the end of each remodelling cycle, a new osteon is created, and the 
remodeling process is equivalent in compact and spongy bone (Parfitt, 1994). 
In bone remodelling, the transition of bone resorption to formation occurring in 
the reversal phase is crucial. Signals are required to couple the end of resorption 
with the recruiting of osteoblast precursors at the site of resorption hence 
inducing bone formation. It has been proposed that factors released from bone 
matrix during resorption involved in the coupling process, include transforming 
growth factor-β (TGF-β), bone morphogenetic proteins (BMPs), insulin-like 
growth factors (IGFs) and fibroblast growth factors (FGFs) (Henriksen et al., 
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2014; Henriksen et al., 2009). TGF-β is an inducer of bone matrix protein 
synthesis in bone formation. It is released from bone matrix while bone is 
resorbed, and inhibits RANKL to decrease osteoclasts resorption (Bonewald and 
Mundy, 1990). 
 
Figure 1.3 Bone remodelling cycle. 
The bone remodelling cycle contains four phases. In the quiescence 
phase, lining cells degrade unmineralized matrix and guide pre-
osteoblasts bind to bone matrix noncollagenous proteins. In the 
resorption phase, osteoblasts release hydrogen ions and enzymes to 
digest minerals and collagenous components in matrix. In the 
reversal phase, at resorption cavities coupling signals are released 
to decrease osteoclasts activity and recruit pre-osteoblasts into the 
cavities. In the formation phase, osteoblasts synthesize new 
collagenous proteins and mineralize matrix by releasing calcium 
and phosphate. (Picture taken from Brandi, 2009). 
1.2 Bone tissue regeneration 
The aim of tissue regeneration is to restore, maintain or enhance damaged 
tissues and / or organs function. Nowadays, regenerative medicine has brought 
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high expectations for a number of intractable diseases, such as osteoporosis, 
Parkinson disease, Alzheimer’s disease, spine injures or cancer (Novikova et al., 
2003; Oryan et al., 2014; Tataria et al., 2006). Like any other tissues/organs, 
bone tissue regeneration is a complex, fine-tuned physiological process. 
Although bone possesses the intrinsic capacity of self-regeneration in response to 
injury throughout adult life, it is either obviously impaired or simply insufficient 
if the injury is too great. In the common clinical setting, bone fracture healing 
often results in impaired bone formation owing to delayed union or fracture non-
union (Audige et al., 2005), while in some other bone diseases, such as larger 
bone defects, avascular necrosis and osteoporosis, a large quantity of bone 
regeneration is required, which is beyond the normal potential of bone tissue 
self-regeneration. Many strategies have been evolved to augment bone tissue 
regeneration in clinical practice, including autologous bone grafts, allografts, 
xenografts and bone-graft substitutes, growth factors (Dinopoulos et al., 2012; 
Giannoudis et al., 2005), and distraction osteogenesis and bone transport 
(Aronson, 1997). Among those strategies, bone graft substitutes have attracted 
intensive investigation in the effort to overcome the drawbacks of autologous 
bone grafts and allografts, as bone graft substitutes combine scaffolds and bone 
cells and even osteoinductive proteins and growth factors to generate bone 
tissue constructs in vitro for subsequent transplantation (Dinopoulos et al., 
2012). 
1.2.1 Bone tissue engineering 
Bone tissue engineering, as an alternative solution for bone graft substitutes, 
first emerged in the 1980s and the technology evolved from principle of 
biomaterials used in bone tissue implantation (Vacanti, 2006). Nowadays, bone 
tissue engineering aims to produce new functional bone tissue de novo, by 
loading osteogenic cells on scaffolds (usually a biocompatible material), and 
with the applications of multidisciplinary techniques to promote cells 
proliferation and differentiation into bone tissue in vitro (Sachlos and 
Czernuszka, 2003). 
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Bone tissue engineering contains a few key components to achieve regenerative 
bone, including (Hardouin et al., 2000): 
1. Scaffolds: In the context of bone tissue engineering, scaffolds are 
designed using biocompatible materials, such as polymers, ceramics to provide 
bone tissue specific environment and architecture for bone cell and tissue 
growth (Butler et al., 2000; Jones et al., 2009). 
2. Cells: cells seeded on scaffold are essential factor of bone tissue 
engineering. They could be progenitor cells, such as MSCs or mature bone cells 
(e.g. osteoblasts). The ideal cell source should be easily isolated and expanded 
into high numbers, and after seeding on scaffold these cells can specifically 
proliferate and differentiate into bone tissue (Heath, 2000).  
3. Morphogenic signals: Growth factors are secreted by many cell types and 
service as stimulus to induce morphogenic signals for cell adhesion, proliferation 
and differentiation. Thus, these molecules play important roles in tissue 
engineering. For example, growth factors such as BMP2, TGF-b, have been used 
bone tissue engineering to enhance bone growth (Jadlowiec et al., 2003; Rose 
and Oreffo, 2002). 
4. Vascularization:	   Both compact and spongy bones contains vascularized 
network, which is essential to supply nutrients, and clear metabolic by-products 
for bone growth. In the context of bone tissue engineering, it is vital to 
integrate a vascularization network into engineered bone constructs, which 
maintains the survival of large masses of cells and facilitates the integration of 
bone tissue constructs with host tissue (Das and Botchwey, 2011).   
Although bone tissue engineering is an ideal strategy to eliminate the limitations 
of current clinically used treatments related to autografts, allografts and 
xenografts in bone diseases, only a few engineered bone grafts have been 
approved for clinical practice at the moment and their implementation as part 
of routine treatment for bone replacement in hospital is controversial (Hollister 
and Murphy, 2011). The main drawback of this approach is the involvement of 
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cell manipulation, which limits the widespread use in clinical practice. However, 
as a very promising strategy, research in this field has grown tremendously in the 
last decade. The numbers of publications in this field has increased year on year 
since 1985 (Figure 1.4A). The understanding and imitation of natural bone tissue 
developmental principles may be key to the future success of bone tissue 
engineering. Most researches have focused on scaffolds / biomaterials and stem 
cells in the last four years (Figure 1.4B). Properly designing scaffolds / 
biomaterials is important for mimicking bone tissue microenvironment’s physical 
properties and initiating ectopic bone formation (Butler et al., 2000; Habibovic 
and de Groot, 2007), and the use of multipotent stem cells can support bone 
healing process at different stages of bone tissue development (Drosse et al., 
2008). 
A B
 
Figure 1.4 Growth of research on bone tissue engineering reflected on the 
number of publications since 1985 on PubMed. 
(A) Published research articles on bone tissue engineering (blue); 
published review articles on bone tissue engineering (red). (B) 
Break-down of articles published on bone tissue engineering focus 
since 2010. These publications are identified by a PubMed search 
using the terms: “bone tissue engineering research articles”, “bone 
tissue engineering review articles” “bone tissue engineering 
scaffolds”, “bone tissue engineering cells”, “bone tissue 
engineering growth factors” and “bone tissue engineering others”. 
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1.2.2 Biomaterials for bone tissue regeneration 
Materials used in replacing human bone can be traced back to the prehistoric 
period. More recently, it is thought iron dental implants were used in Europe by 
200 AD, and these implants integrated into bone after implantation (Artico et 
al., 2003). In the 1980s, biomaterials were defined as “non-viable materials used 
in a medical devices, intended to interact with biological systems” (Williams, 
1999), and later on a comprehensive definition for the term of biomaterial was 
described as: “A biomaterial is a substance that has been engineered to take a 
form which, alone or as part of a complex system, is used to direct, by control of 
interactions with components of living systems, the course of any therapeutic or 
diagnostic procedure, in human or veterinary medicine” (Williams, 2009). These 
definitions echoed the evolution and progression of biomaterials as medical 
devices in the past half century, and biomaterials were further characterized to 
three generations according to materials properties and clinical applications 
(Hench, 1980; Hench and Polak, 2002). 
1. The first generation biomaterials for bone tissue implantation. 
The first generation of biomaterials are bioinert and thus are not rejected by the 
human body, while appropriate physical properties matches the requirements to 
support host tissues. This has resulted in a large set of implantable materials 
varying from metallic materials (Long and Rack, 1998), ceramic materials 
(Boutin, 1972; Christel et al., 1988) to polymers (Fisher and Dowson, 1991; 
Lewis, 1997) used in clinical applications. The main shortcoming of the first 
generation of biomaterials is the uncontrollable interface between implant 
material and living tissue. A layer of unspecific proteins is adsorbed onto the 
material surface after implantation, resulting in unspecific signalling to the 
cellular environment. Consequently, a layer of fibrous tissue grows on material 
surface, and with time such fibrous tissue encapsulates the implant, leading to 
the separation of implant from the host tissue (Hench, 1980). 
2. The second generation biomaterials for bone tissue implantation. 
32	  
	  
To overcome the interfacial problems associated with first generation 
biomaterials, research within the field of biomaterials has focused on developing 
bioactive materials, which elicit specific biological responses from the host 
tissue (Hench and Polak, 2002). The key feature of the second generation 
biomaterials is the ability to interact with cells to stimulate specific cellular 
responses for appropriate tissue adherence and bonding (Hench, 1980).  
Typical bioactive materials are ceramics which share similar structure and 
surface features with bone mineral phase, thus enabling binding to the bone 
without mediation of a fibrous interface (Schepers et al., 1991). The most 
commonly used ceramics are hydroxyapatite (HA), calcium phosphate (CaP) 
based materials and their combinations. These materials have been 
demonstrated to be biocompatible and osteoinductive (Pollick et al., 1995; 
Ripamonti, 1991; Yamasaki and Sakai, 1992; Yuan et al., 1998). Although the 
biological mechanisms of the osteoinduction from these materials are not fully 
understood, two hypotheses have been proposed. One is that the materials 
surface features absorb and present osteoinductive factors to the cells, the 
other is the releasing of calcium and phosphate ions exert osteoinductive effects 
on stem cell differentiation into bone cells (Barradas et al., 2011; Yuan et al., 
2011).  
Materials bioactivity can also be achieved for non-bioactive materials by either 
coating the surface of the implant with a bioactive ceramic or modifying the 
surface of the material to obtain the bioactivity. All metallic materials are non-
specifically bioactive. Coating ceramics on metals can be achieved by 
electrophoretic deposition (Ducheyne et al., 1990), laser ablation (Serra, 2001), 
or plasma spraying (Ducheyne and Healy, 1988). However, these coating 
processes cannot generate covalent links with the materials, and are not cost-
effective. A number of methods of chemical surface modification have been 
developed to produce apatite or CaPs layer chemically linked on metal surface, 
including thermochemical treatment (Kokubo, 1996), chemical etching (Ohtsuki 
et al., 1997), self-assembled monolayer (SAM) (Wheeler et al., 1997). These 
methods are mainly applied on titanium and its alloys. 
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Besides the above biomaterials, many polymers are characterized as the second 
generation of biomaterial in orthopaedics and bone regeneration, as they can 
bio-resorbed. Polymers such as polyglycolide (PGA), polylactide (PLA) and 
polycarprolactone (PCL) can be degraded and resorbed by hydrolysis of their 
backbone chains due to enzymatic activities in living environment (Ciccone et 
al., 2001). The biodegradable property of polymers enables the interface 
between material and tissue to be controlled with time. The advantage of 
polymeric material over metallic implants is the potential reduction of the stress 
shielding effect, and their mechanical strength can be improved by self-
reinforcing process through that polymer matrix is strengthened with oriented 
fibres or fibrils of the same material (Tormala, 1992; Vasenius et al., 1994). 
3. The third generation biomaterials for bone tissue implantation. 
The feature of third generation biomaterials is described as the materials ability 
to stimulate reproducible, specific cellular response at the molecular level 
resulting in regeneration of living tissue (Hench and Polak, 2002) . This requires 
materials possessing both increased, controllable bioactivity and biodegradable 
properties. The bioactivity of a material enables cells specifically to respond to 
the material at the molecular level and prompt cell invasion, attachment, 
proliferation and differentiation. Research and development of the third 
generation of biomaterials is ongoing, and the strategies to endow biodegradable 
and bio-absorbable materials with enhanced bioactivity have attracted 
particular attention. Although there are no conclusions as yet in the literature, 
these strategies show promising options for the third generation material in bone 
tissue engineering and bone regeneration: 
• Composite polymers: Enhanced bioactivity of biodegradable polymeric 
materials can be achieved by combination of polymers with specific 
biomolecules that allow cell guidance and stimulation towards a particular 
response. The composite materials possess the advantages of each component 
(i.e., polymer biodegradability and biomolecule bioactivity), and demonstrate 
success in bone regeneration that exceeds the results when these materials are 
used separately. For example, addition of HA to various polymers, including PLA 
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(Wei and Ma, 2004), PLGA (Kim et al., 2006a), chitosan (Chesnutt et al., 2009) 
and collagen (Rodrigues et al., 2003; Wahl and Czernuszka, 2006) resulted in 
enhanced bone formation in vitro and in vivo. 
• Advanced hydrogels: Hydrogels are water-swollen polymeric materials 
with a distinct three-dimensional structure, and have been used in clinical tissue 
repair and regeneration due to their capacity for mimicking ECM structure and 
delivering required bioactive agents that promote tissue regeneration (Lee and 
Mooney, 2001; Slaughter et al., 2009). Modification of hydrogels with growth 
factors and peptide sequences such as transforming growth factor ß3 (TGFβ3), 
peptides RAD and RGD resulted in increases in production of ECM proteins and 
promoted cell-material interactions (Guarino et al., 2007; Na et al., 2007). 
Hydrogels fabricated by self-assembling peptides to form completely biological, 
biocompatible and biodegradable scaffolds for bone regeneration have gained 
attention recently (Semino, 2008). These hydrogels mimic the nature of ECM and 
demonstrate osteoinductivity, while the breaking down into amino acids results 
in safe and easily clearance in vivo (Kirkham et al., 2007; Kyle et al., 2010; 
Misawa et al., 2006). 
Bioactivity for biodegradable polymers can also be elaborated by surface feature 
modification. Nano-featured materials / scaffolds have demonstrated 
significantly influence on osteoinductivity (Murugan and Ramakrishna, 2006). 
Specifically, nanotopographical materials stimulate bone formation and enhance 
bone-implant integration, leading to better tissue repair and regeneration (Dalby 
et al., 2007b; Dalby et al., 2007d). (described in more details in section 1.6). 
1.2.3 Stem cells for bone tissue regeneration 
A variety of cell types have been investigated in terms of cell source for bone 
tissue engineering in the last decades with different advantages and restrictions. 
Ideally, cells need to be sufficient quantities after limit expansion in vitro, 
constant expression of specific bone markers and secreting bone matrix proteins. 
Autologous osteoblasts are the most obvious choice for bone tissue engineering. 
However, relatively few cells can be harvested from the isolation of the tissue, 
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and low expansion rate of osteoblasts in vitro limit the available cells seeded on 
scaffold. Moreover, osteoblasts dissociated from diseased states or elderly 
patients may not be appropriate for the cell source of tissue engineering (Heath, 
2000). Alternatives include the use of allologous or xenologous osteoblastic cells. 
However, human allologous cells are in short supplies, and using xenologous cells 
have experienced serious immunogenicity and the possibilities of transmission of 
infectious agents (Platt, 1996). These limitations have restricted their 
applications on tissue engineering, and the xenologous cells are only suitable for 
in vitro studies. 
Studies on stem cells have demonstrated that they are more promising cell 
sources for bone tissue engineering. Stem cells are characterized as 
unspecialized cells capable of renewing themselves by cell division and being 
able to differentiate into specialized cell types under certain physiological or 
experimental conditions. Stem cells, in general, are classified into three 
catagories: embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) 
and adult stem cells. Despite these three stem cell populations being obtained 
from different sources and having different advantages, they all hold great 
potential for regenerative medicine and have attracted significant attention in 
bone repair and regeneration (Gruenloh et al., 2011; Illich et al., 2011; 
Kuznetsov et al., 2011). 
1.2.3.1 Embryonic stem cells 
Embryonic stem cells are derived from embryo following fertilization up until the 
ninth week of gestation and, can differentiate into any cell type. ESCs are highly 
proliferative and are pluripotent. Therefore they can be used as a single source 
for the derivation of multiple lineages present in bone tissue, including 
osteogenic cells, osteoclasts, vascular cells and nerve cells (Hoffman and 
Carpenter, 2005). To achieve osteogenesis from ESCs, two culture approaches 
have been developed. One is embryonic body (EB)–mediated osteogenic 
differentiation, from which osteogenesis is predominantly derived from the 
three dimensional cell spheroids, and then followed by addition of osteogenic 
reagents, such as ascorbic acid, dexamethasone (DEX), etc. (Buttery et al., 
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2001; Karp et al., 2006). However, this approach is restricted to lineage specific 
differentiation of ESCs within EBs, which results in a limited number of 
osteoblasts. A new approach has been developed in which ESCs are directly 
differentiated into the osteogenic lineage bypassing EB formation. In this 
method, ESC colonies are immediately isolated into single cells and cultured in 
the presence of osteogenic supplements (Hwang et al., 2008; Karp et al., 2006). 
ESCs cultured on scaffolds have showed enhanced effectiveness compared to 
ESCs on culture dishes for the aim of bone tissue regeneration. For example, 
ESCs cultured on three-dimensional PLGA scaffolds demonstrated strong, 
abundant expression of ALP and OCN compared to the same cells cultured on 
culture dishes. Implantation of the ESCs-PLGA scaffold construct showed new 
bone formation within and around implanted scaffolds in vivo (Tian et al., 2008). 
1.2.3.2 Induced pluripotent stem cells (iPSCs) 
Induced pluripotent cells (iPSCs) are induced stem cells derived from adult cells 
that have been genetically reprogramed to express defined ESCs transcription 
factors (i.e., Oct4, Sox2, Klf4 and Myc) (Takahashi et al., 2007a). Human iPSCs 
possess the primary properties of human ESCs in terms of morphology, gene 
expression, surface antigens, proliferation and differentiation into all cell types 
of the three germ layers (Takahashi et al., 2007b). Recent studies have 
demonstrated that iPSCs hold great potential as an alternative cell source for 
bone tissue regeneration. Transient transduction of the osteogenic transcription 
factor RUNX2 into iPSCs resulted in increases in ALP activity and calcium levels 
during osteoblast differentiation (Tashiro et al., 2009). Further study showed 
that culturing iPSCs in osteogenic medium along with resveratrol  protects iPSCs 
derived osteocyte-like cells from DEX induced apoptosis, results in osteogenic 
differentiation and bone formation in vivo (Kao et al., 2010). Transplantation of 
human iPSCs - macrochanneled polycaprolactone constructs into mice 
demonstrated the induction of mineral deposition within the cell-scaffold 
implant, suggesting the utilization of iPSCs for bone tissue engineering (Jin et 
al., 2013). 
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1.2.3.3 Multipotent mesenchymal stromal cells (MSCs) 
MSCs were first described as a minor subpopulation of bone marrow cells which 
are plastic-adherent, fibroblast-like, clonogenic cells (colony forming unit-
fibroblast CFU-F), with high capacity for proliferation in vitro (Friedenstein et 
al., 1974; Friedenstein et al., 1968). Later on, the same group demonstrated 
that the CFU-F are a heterogeneous population of stem and progenitor cells with 
multipotent lineage potential being able to differentiate into skeletal tissues 
(i.e., osteoblasts, chondrocytes, adipocytes, and stroma) (Owen and 
Friedenstein, 1988). Further research has shown that MSCs exist in many adult 
tissues, including peripheral blood (Kuznetsov et al., 2001), dental pulp (Shi and 
Gronthos, 2003), and adipose (Zuk et al., 2002), etc. Apart from plastic-
adherent and multipotent differentiation potential, MSCs are characterized by 
the presence of a set of surface antigen markers (CD markers) (Dominici et al., 
2006). However, these CD markers are inconsistent and varying for MSCs derived 
from different tissues and expanded using different culture methods (P et al., 
2011). It is a consensus view that the more primitive, most stem cell-like 
population of cells from the whole stromal compartment can be isolated using 
various can be isolated using various CD markers (i.e., positive for STRO-1, 
CD105, CD29, CD73, CD271, CD146 etc., and negative for CD34, CD45, CD14 etc.) 
(Arvidson et al., 2011). Many groups refer to unselected cells as mesenchymal 
stem cells, although mesenchymal stroma is perhaps more accurate. 
Unlike ESCs and iPSCs, MSCs, specifically derived from bone marrow (BMSCs), 
have been recognized and studied for their potential in osteogenic 
differentiation and bone formation for many years (Tavassoli and Crosby, 1968). 
Using BMSCs as a cell source for bone repair and regeneration has been the focus 
of many studies in over the last two decades. This is, because BMSCs are easy to 
collect and expand in vitro to obtain sufficient cell numbers for tissue 
regeneration (Bianco et al., 2001). Moreover, MSCs possess immunosuppressive 
properties making them suitable for allogeneic transplantation (Arinzeh et al., 
2003; Bartholomew et al., 2002). The incorporation of BMSCs into various 
biomaterials / scaffolds in animal models has demonstrated promising bone 
regeneration. Loading MSCs onto ceramic scaffolds and then transplanting the 
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construct into segmental defects in the femora of rats resulted in bone 
formation in the interface between the host and the construct, and across the 
defect (Bruder et al., 1998). Similar studies to incorporate MSCs into biopolymer 
scaffolds such as PLGA in rat (Ishaug-Riley et al., 1997), PCL, PEGT in mouse 
models (Mendes et al., 2003) also enhanced new bone formation. A study in 
humans using MSCs-macroporous HA constructs to recover large bone defects (up 
to 7 cm) in three patients revealed the potential reliability of MSC based 
constructs in bone tissue regeneration (Quarto et al., 2001). 
1.3 MSCs differentiation process 
1.3.1 MSCs self-renewal and regulation 
Self-renew refers to stem cells maintaining their undifferentiated stem state by 
generating identical copies of themselves through mitotic division. Bone marrow 
derived MSCs (in the context of growth we refer to selected, primitive, stem 
cells rather than whole stroma where non-stem cells will have lost their self-
renewal capacity) have been verified to possess a significant but variable self-
renewal capacity upon expansion culture conditions. For instance, some reports 
indicate serial passage is not a problem with subcultivation of primary MSCs 
derived from human bone marrow growing up to 15 passages (MSCs in 
subcultivations exhibit exponential phase of growth until finally in the stationary 
phase) while retaining their osteogenic potency at every passage (Bruder et al., 
1997). However, other researchers have reported that prolonged in vitro 
expansion results in reduction or losing the qualities of MSCs. For example, MSCs 
expanded in vitro over 5 passages significantly reduced their capacity of 
releasing vascular endothelial growth factor that protects ischemia injury 
(Crisostomo et al., 2006). It was proposed that extensive cell culture induced 
MSCs senescence due to growth arrest and apoptosis (Stenderup et al., 2003). 
Currently, specific in clinical studies, properties of MSCs in vitro expansion 
remain inconsistent due to different cell culture conditions, and the expansion 
passages used in most studies are less than five (Ikebe and Suzuki, 2014). 
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Multipotent MSC undergoes asymmetric division to give rise to two daughter 
cells: the identical copy of MSC and the less potent precursor, and then the 
precursor cells go through symmetric division to produce more precursor cells 
with less self-renewal potential and growing differentiation potential (transit 
amplification) (Figure 1.5) (Baksh et al., 2004). 
The maintenance of MSCs self-renewal is not well understood. While we 
understand that ESCs remain pluripotent through expression of e.g. oct-4, sox2, 
nanog and rex-1, and there is some evidence that MSCs may use similar factors 
(possibly to regulate C-MYC involved in growth) (Boiani and Scholer, 2005; Boyer 
et al., 2006; Park et al., 2012; Ringrose and Paro, 2007). Perhaps more likely, 
some growth factors and cytokines are also implicated in the maintenance of 
MSCs stemness. For instance, fibroblast growth factor2 (FGF2) has shown 
capacity to enhance MSCs growth rate, and the effect of FGF2 is more 
noticeable in low density cultures than in high density cultures (Tsutsumi et al., 
2001). Further study of FGF2 effect on MSCs self-renewal demonstrated that 
secreted FGF2 engages with its cell surface receptor directly without first being 
released into culture medium, suggesting a possible autocrine regulatory loop 
underlying FGF2 proliferation function (Zaragosi et al., 2006). In the same study, 
it was proposed that extracellular signal-related kinase 1/2 (ERK1/2) pathway is 
implicated in FGF2 mediated self-renewal, as inhibition of mitogen-activated 
protein kinase kinase 1 (MAPKK1) results in decrease in MSCs clonogenic 
potential, but without influencing differentiation potential. 
Studies using biomaterials that can control MSC self-renewal have also 
implicated ERK1/2 as well as c-jun-n-terminal kinase (jnk), another MAPK (Dalby 
et al., 2014; McMurray et al., 2011). There is also a theory that MSCs undergoing 
self renewal pool unsaturated metabolites to increase redox plasticity (first 
observed in ESCs) (Yanes et al., 2010) while reducing metabolism involved in 
amino acid biosynthesis and energy demand (Dalby et al., 2014). There is also 
evidence that microRNAs may work to suppress expression of phenotypical 
mRNAs and hence proteins (McMurray et al., 2011). 
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Figure 1.5 Schematic diagram describing MSCs self-renewal and 
differentiation. 
MSCs self-renewal occurs in the stem cell compartment, in which 
MSCs undergo asymmetric division (A) to produce two daughter 
cells: the copy of MSC and multipotent precursor, which then goes 
through symmetric division (S) to give rise to more precursors 
possessing less self-renewal and restricted differentiation capacity. 
In the committed compartment, the Tri- or Bi-potent precursors 
symmetrically divide into Unipotent precursors with pre-
determined cell fate, which eventually give rise to multilineage 
specialized cells. Under specific inductive cues, dedifferentiation 
may occur (open arrow) from specialized cells to generate more 
potent cells. (Taken from Baksh et al, 2004). 
1.3.2 MSCs differentiation 
It has long been recognized that MSCs have multiple lineages differentiation 
capacity and can give rise to bone, cartilage, tendon, muscle, adipose tissue and 
hematopoietic-supporting stroma under defined environmental cues. Global gene 
expression analysis of three specific lineages derived from MSCs also 
demonstrated that osteoblasts and adipocytes shared more up-regulated genes 
during their terminally lineage specific differentiation (235 genes), compared to 
3 genes shared between osteoblasts and chondrocytes and 10 genes shared 
41	  
	  
between chondrocytes and adipocytes (Song et al., 2006). These data perhaps, 
speculatively, indicate that osteoblast and adipocyte might share a common MSC 
precursor (i.e., the bi-potent precursor), and chondrocytes originate from a 
different precursor-this could further indicate the heterogeneous cell mixture 
we define as MSCs. Upon inductive cues, these multipotent precursors 
symmetrically divide into partially committed or pre-determined unipotent 
precursors (progenitor) which eventually develop into lineage specific cell types 
(Figure1.5). 
1.3.3 Transcriptional control of MSCs osteogenic differentiation 
It is a putative view that MSCs fates are determined by transcriptional activities 
which are induced through major developmental pathways. Transcription factors 
including runt-related transcription factor 2 (RUNX2), osterix (OSX) and distal-
less homeobox 5 (dls5) / msh homeobox 2 (MSX2), establish a regulatory network 
and molecular switches for bone development and osteoblast differentiation.  
1.3.3.1 Runt-related transcription factor 2 (RUNX2) 
RUNX2, one of the Runt-related transcription factors, has been characterized as 
the principal osteogenic master gene. RUNX2 controls osteoblast differentiation 
and bone formation by binding to the osteoblast specific cis-acting element 
(OSE2), which is located at the promoter of osteoblast marker genes, such as 
collagen type I, OPN, bone sialoprotein and OCN (Ducy et al., 1997).  
The osteogenic regulatory function of RUNX2 has been demonstrated in vivo and 
in vitro in many studies in the last two decades (Harada and Rodan, 2003). 
RUNX2-deficiency in mice (RUNX2-/-) results in a lethal phenotype due to the 
complete lack of osteoblast activity and bone formation (Komori et al., 1997). 
The phenotype in mice lacking only one allele of RUNX2 is identical to human 
ossification disease cleidocranial dysplasia (CCD) and genetic analysis of CCD 
patients revealed that heterozygous mutations of RUNX2 is the cause of the 
disease (Otto et al., 1997). Enforced expression of RUNX2 in MSCs induce 
osteoblast specific gene expression, and increases matrix mineralization in vitro. 
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Transplantation of the MSCs with overexpressed RUNX2 into skull defect mice 
model results in an average of 85% osseous closure at four weeks, while controls 
with scaffold only and with nontransduced MSC-scaffold constructs showed no 
defect healing effect (Zheng et al., 2004). These data suggest RUNX2 expression 
is sufficient to promote osteogenic differentiation and osteogenesis. However, 
transgenic mice with overexpression of RUNX2 in osteoblasts showed osteopenia 
with multiple fractures which were enriched with OPN and invaded by 
osteoclasts, although there was an absence of enhanced osteoclastogenesis. 
Further examination of the transgenic mice revealed that mature osteoblasts 
were diminished greatly, despite pre-mature osteoblasts expressing OPN 
increasing in adult bone (Liu et al., 2001). These results indicate that the effect 
of RUNX2 on osteogenic differentiation and bone formation is developmental 
stage-dependent, RUNX2 accelerates osteogenic differentiation at early stage 
and inhibits terminal differentiation at late stage. 
Recent studies suggest RUNX2 not only guides MSCs osteogenic differentiation 
but also plays regulatory roles in cell growth control. RUNX2 null cells exhibit a 
higher rate of proliferation than wild type, and RUNX2 expression is regulated by 
the cell cycle with maximum expression in G1 phase. Forced elevation of RUNX2 
in preosteoblasts inhibits their proliferation suggesting RUNX2 promotes cells to 
exit from cell cycle (Galindo et al., 2005; Pratap et al., 2005). Further evidence 
was observed that RUNX2 targets at cyclin dependent kinase (CDK) inhibitors p21 
and p27; overexpression of RUNX2 resulting in down-regulation of CDK, thus 
supressing progression into S-phase and promoting cell cycle exit (Thomas et al., 
2004; Westendorf et al., 2002). 
1.3.3.2 Osterix (OSX) 
OSX was recently identified as a zinc finger containing transcription factor 
expressed in all developing bones. OSX-null mice demonstrate similar phenotype 
to the RUNX2 knockout, indicating OSX is required for MSC differentiation into 
osteoblasts (Nakashima et al., 2002). Further investigation showed that RUNX2 
expression in OSX-null mice is observed, while RUNX2-null mice do not express 
OSX, suggesting OSX acts downstream of RUNX2 (Nakashima and de 
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Crombrugghe, 2003; Nakashima et al., 2002). Recent studies demonstrated the 
potent effects of OSX on osteogenesis. Some suggested that OSX alone is 
sufficient for osteogenesis and the expression of OSX is in a RUNX2 independent 
manner (Tai et al., 2004; Tu et al., 2006). Others indicated that the effect of 
OSX on terminal osteogenic differentiation relies on coordination of other 
transcription factors, such as RUNX2, DLX5 and MSX2, which recruit OSX to 
regulate osteogenesis at different stage (Kim et al., 2006b; Kurata et al., 2007; 
Matsubara et al., 2008). It has been recently suggested that OSX is induced by 
DLX5 or MSX2 when RUNX2 is absent (Liu et al., 2007a; Matsubara et al., 2008).  
1.3.3.3 Homeobox proteins (DLX5 and MSX2) 
Distal-less homeobox protein 5 (DLX5) and Msh homeobox homologous 2 (MSX2) 
belonging to homeobox family, also play transcriptionally regulatory roles in 
osteoblast differentiation and skeletal development (Chen et al., 1996; Satokata 
et al., 2000). Studies on DLX5-null mutant mice demonstrated a delayed 
ossification of the skull and abnormal osteogenesis (Acampora et al., 1999; 
Depew et al., 1999). Targeted activation of both DLX5 and DLX6 in mice resulted 
in skeletal defects, and overexpression of DLX5 in the apical ectodermal ridge of 
Dlx5/6 null mice can fully rescue limb development (Robledo et al., 2002). 
Cellular studies have also shown DLX5 is expressed at all stages of osteoblast 
differentiation, and acts as cofactor of RUNX2 to activate bone markers BSP and 
OCN (Hassan et al., 2004; Holleville et al., 2007; Ryoo et al., 1997). 
In contrast to DLX5, MSX2 is stage-specifically expressed in osteoblast. MSX2 is 
mainly expressed in osteoprogenitors and is down-regulated in osteoblast 
differentiation (Hassan et al., 2004; Lynch et al., 1998). It is proposed that MSX2 
represses RUNX2 activity and thus down-regulates osteoblast gene expression in 
mature osteoblasts (Newberry et al., 1998; Shirakabe et al., 2001). However, 
studies on MSCs osteogenic differentiation indicate MSX2 promote MSCs 
osteoblast proliferation and differentiation by inhibiting PPARG (Cheng et al., 
2003; Ichida et al., 2004). Interestingly, both MSX2 and DLX5 can induce OSX 
activity in RUNX2 independent manner during BMP2 induced osteogenic 
differentiation (Lee et al., 2003; Matsubara et al., 2008). 
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1.4 Molecular signals and pathways of osteogenic 
differentiation 
1.4.1 BMP2 signalling 
Bone morphogenetic proteins (BMPs) constitute the largest subfamily of 
transforming growth factor ß (TGFß) superfamily. To date, over 20 BMPs have 
been identified and characterised with varying functions. Among those, BMP2 
plays an essential role in skeletal development and bone tissue regeneration 
(Tsuji et al., 2006). Temporal specific addition of BMP2 in MSC cultures 
significantly increases OCN expression (Huang et al., 2010b), and temporal 
expression of BMP2 is necessary and sufficient for bone formation (Noel et al., 
2004). In vivo genetic analysis using mouse models also demonstrated that loss of 
BMP2 (rather than BMP4 or BMP7) results in severe osteogenic impairment 
(Bandyopadhyay et al., 2006). A similar study also indicated that the BMP2 signal 
is a necessary component for bone repair. BMP2-deficient mice have 
spontaneous limb fracture which cannot be repaired with time and other 
osteogenic stimuli (Tsuji et al., 2006). 
The BMP2 signal exerts its effect to enhance osteogenic differentiation and bone 
formation in two signal transducing pathways. The canonical pathway (known as 
the SMAD-dependent pathway) is initiated when it binds with type I and type II 
BMP receptors to form ligand-receptors complexes. Within this complex, the 
type II receptor has the ability to phosphorylate and subsequently activate the 
type I receptor, leading to phosphorylation of receptor-regulated SMADs (R-
SMADs). Once phosphorylated, bmp specific R-SMADs, including SMAD 1, 5 and 8, 
interact with common SMAD (SMAD4), which facilitates the translocation of R-
SMADs and co-SMAD complex into the nucleus to integrate with RUNX2 to directly 
induce osteogenesis (Javed et al., 2009; Lee et al., 2000; Phimphilai et al., 
2006). In parallel with the interaction with RUNX2, BMP2 induced SMAD proteins 
can up-regulate OSX (Matsubara et al., 2008).  
Besides the canonical pathway, the BMP2 signal is able to trigger multiple 
downstream pathways through activation of the signalling molecules TGF-beta 
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activated kinase 1 (TAK1) and its binding protein TAB1. This signal transduction 
route is known as the non-canonical or SMAD-independent pathway and its 
downstream cascades include MAP kinase p38 (p38 MAPK) and ERK (Gallea et al., 
2001; Lai and Cheng, 2002), and nuclear factor kappa beta (NFkB). The 
activation of the TAK1/TAB1 complex is achieved by the interaction of the BMP 
receptor associated molecule 1 (BRAM1) and the TAK1/TAB1 complex, in which 
BRAM1 directly associates with the cytoplasmic tail of the BMP receptor (Lu et 
al., 2007; Yu et al., 2002). Like the canonical pathway, the BMP non-canonical 
pathway is also important for osteogenic differentiation and bone formation 
(Hoffmann et al., 2005). In vivo study has shown that the p38 MAPK pathway is 
required for normal skeletongenesis in mice, and TAK1 is a crucial activator for 
p38 MAPK in osteoblasts. Further analysis revealed that the interaction of TAK1 
with p38 MAPK phosphorylates RUNX2 resulting in regulation of osteoblast 
genetic programme (Greenblatt et al., 2010). The regulatory effect of the BMP2 
induced non-canonical pathway was also observed in primary cultured calvaria 
derived osteoblastic cells (Guicheux et al., 2003). In this study, BMP2 induced 
p38 and Jnk activation resulting in osteogenic differentiation. Inhibition of p38 
and Jnk led to down-regulation of alkaline phosphatase and OCN respectively. 
These data also suggested that p38 MAPK and Jnk have a distinct role in 
osteogenic differentiation. 
BMP2 acting as a signal for osteogenic development is mediated by type I and 
type II serine/threonine transmembrane receptors, and is regulated at different 
molecular levels (Koenig et al., 1994). Active BMP2 contains 7 cysteines with 6 of 
them forming three intramolecular disulfide bonds and the seventh cysteine 
being used for dimerization with another monomer by forming a covalent 
disulfide bond. It has been observed that BMP2 dimerizes with other BMPs, such 
as BMP5, 6 or 7 to form heterodimers, leading to be more effective activator of 
the signalling pathway than its homodimer (Little and Mullins, 2009). In addition, 
the binding of BMP2 to different receptor complexes results in activation of 
distinct downstream pathways. BMP2 binds to its high affinity receptor type I, 
upon which receptor type II is recruited into the complex, leading to the 
activation of SMAD-independent pathways; while the SMAD-dependent pathway 
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is activated by BMP2 binding to a preformed complex of type Ia and type II 
(Hartung et al., 2006; Nohe et al., 2002). BMP2 signalling is regulated by BMP 
antagonists and co-receptors. Noggin, one of the best understood antagonists 
can bind to BMP2 and other BMPs to block their receptor epitopes on the ligands. 
Interestingly, noggin is induced by BMP2, 4 and 7 in osteoblasts, serving as a 
negative feedback loop attenuating BMP2 signalling (Gazzerro and Canalis, 
2006). The downstream pathways of BMP2 signalling are also regulated by 
intracellular regulatory proteins. For example, in the SMAD-dependent pathway, 
smurf1 (SMAD-ubiquitination-regulatory factor 1) and smurf2 antagonize BMP2 
signalling by interacting with R-SMADs and targeting them for degradation, and 
thus control the levels of R-SMADs of cells (Arora and Warrior, 2001).  
The regulation of BMP2 signalling may occur also in non-transcriptional manner. 
MicroRNA (miRNA) functions at the posttranscriptional level by negatively 
regulating translation of its target gene. Recent study has shown that miR-210 
inhibits activin type I receptor in a BMP4-dependent manner in ST2 cells and thus 
promotes differentiation of osteoblasts (Mizuno et al., 2009). Moreover, integrins 
are major transmembrane receptors for mechanosensing, integrin signals are 
transduced through the FAK-Ras-ERK pathway and cooperated with BMP pathway 
by enhancing SMAD1 expression (Miyazono et al., 2005). Therefore, mechanical 
stimuli may also play an important role in BMP2 signalling. 
1.4.2 Wnt signalling 
It has been long recognized that Wnt signalling is implicated in osteogenic 
differentiation and bone formation. The signal activates three pathways (i.e., 
canonical, non-canonical, and calcium ion channel related) to regulate cell 
growth, differentiation and function, however, the canonical pathway, also 
known as β-catenin pathway, appears more important for osteogenesis 
(Westendorf et al., 2004). The canonical pathway is initiated by the binding of 
Wnt proteins to frizzled receptor (Fz, a G protein-coupled receptor like protein) 
and a co-receptor LRP5/6 (low-density lipoprotein receptor-related protein 5 or 
6), resulting in the inhibition of GSK-3β (glycogen synthase kinase 3β) activity. 
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Consequently, the pathway mediator, β-catenin is stabilized and accumulated in 
cytosol, leading to its translocation to nucleus where β-catenin interacts with 
the Tcf/Lef (T cell factor/Lymphoid enhancer binding factor) to regulate the 
expression of canonical Wnt target genes (Hay et al., 2005; Levy et al., 2004). 
The canonical Wnt signal positively regulates osteogenesis in multiple 
mechanisms. Loss-of-function mutation of LRP5, the co-receptor of Wnt 
signalling, was recently identified as the cause of osteoporosis-pesudoglioma, 
which is characterized low bone density and skeletal fragility (Gong et al., 2001; 
Little et al., 2002). In these studies, LRP5 expression was demonstrated by 
osteoblasts in situ. The bone formation marker, OCN was significantly increased 
in gain-of-function of LRP5 mutation, whereas levels of fibronectin, known as 
target of Wnt signalling were also markedly elevated (Gradl et al., 1999). In 
vitro experiments also demonstrated disruption of the endogenous LRP5 inhibitor 
dickkipf 1 (DKK1) enhances Wnt signalling and stimulates osteogenesis. 
Stimulation of canonical Wnt signalling can also be achieved by stabilizing β-
catenin, the signalling mediator of canonical Wnt pathway. Studies using GSK-3β 
inhibitors which stimulate canonical Wnt signalling by stabilizing β-catenin 
demonstrated that Wnt signalling promotes mesenchymal precursors 
differentiation into osteoblasts (Jackson et al., 2005; Kulkarni et al., 2006). 
Moreover, activation of canonical Wnt signalling represses mesenchymal 
precursors differentiation into adipocytes, which in turn stimulates 
osteoblastogenesis, as these two cell types are given rise to from the same 
precursor (Bennett et al., 2005). 
BMP2 and Wnt proteins are important signalling molecules in both tissue healing 
and development. They have profound effects in the control of bone tissue 
regeneration. The application of these signalling molecules and their signalling 
cascades within scaffolds represent powerful tool for controlling stem cell 
differentiation and function (Place et al., 2009; Rosen, 2011). Studies on 
modification of biomaterials surface demonstrated that surfaces feature alone, 
specifically nanotopography can promote MSCs osteogenic response by inducing 
cell-nanotopography interface reactions and a serial subsequent signalling 
cascades (Dalby et al., 2007b; Dalby et al., 2006b; Popat et al., 2007). 
48	  
	  
Nanotopography aids in revealing new discoveries in cell function, signalling 
molecules and cascades, which in turn contribute to the design of new 
generation scaffolds and the development of tissue engineering.  
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1.5. Nanotopography 
Bone tissue matrix is composed of abundant proteins with nanoscale structures 
(described in section 1.2.2, figure 1.2) to be organized into varying micro-and 
submicro-scale topographical features to which cells respond in a manner known 
as contact guidance. The phenomenon of contact guidance was first observed in 
1911 (Harrison, 1911), and then was described as topographical features on 
micrometer lead cells and tissue to alignment and migration (Curtis and Varde, 
1964; Flemming et al., 1999; Friedl, 2004; Weiss and Garber, 1952). Recent 
developments in advanced nanofabrication techniques have enabled the 
fabrication of biomaterials with nanoscale features to mimic the nanostructures 
found in natural ECM. Cells respond to nanotopographies with diverse reactions 
depending on substrate chemistry, stiffness and topographical dimensions and 
conformation (i.e., grooves, pits and pillars etc.). It is noteworthy that the 
influence of nanotopography on cellular behaviors is more complex than that of 
micro-scale topography, as the nanofeatures are more compatible, sizewise, to 
precise structures at the cell surface. For example, epidermal growth factor 
receptors (EGFRs) in BHK cell were organized into receptor clusters with ranging 
from dimers to high order oligomers, and the average size of receptor clusters is 
less than 24 nm in radius (Ariotti et al., 2010). Also, the distance between 
integrin alpha and beta subunits is around 23 nm (Shattil and Newman, 2004). 
Therefore, nanofeatures have the distinct advantage of the possible to replicate 
features found in nature bone tissue and thus trigger osteogenic responses and 
bone formation in vitro. 
1.5.1 Effects of nanotopography on MSCs differentiation 
An easily observed cell response to nanotopography is the alteration of cell 
morphology. This response has been noted in many cell types on many different 
features (Bettinger et al., 2008; Choi et al., 2007; Yim et al., 2005). MSCs and 
other cell types have shown alignment and elongation on nanograting features in 
the direction of groove axis (Yim et al., 2007), and the responses couple with 
enhanced migration and reduction in adhesion size (Janson et al., 2014; 
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Kulangara et al., 2012). Other nano-features such as nanopillars and nanopits 
prompt more subtle effects on cell morphology. The growth of MSCs on nanopits 
results in increased formation of filopodia and modification of focal adhesion 
morphology, leading to changes in cell spreading and	   organisation of the 
cytoskeleton (Dalby et al., 2006a; Dalby et al., 2006b). The effects of 
nanofeatures on MSCs morphology might rely on the dimension of feature. MSCs 
seeded on titanium (Ti) surfaces with pillar structures of either 15, 55, or 100 
nm heights demonstrated that the smallest feature (15 nm of height) prompted 
well-spread MSCs with highly organized cytoskeleton and larger focal adhesion 
formation, and these responses decreased with increase in feature size (i.e., the 
100 nm height showed poorly defined cytoskeleton organization and few, 
smallest focal adhesions) (Sjostrom et al., 2009). The smallest feature size cells 
have been seen to respond to, again on Ti, were 8 nm high islands with 25 nm 
diameters – remarkably close to the size of an integrin adhesion site (5 nm high 
and 23 nm wide). At this size cells used nanopodia rather than full filopodia 
(McNamara et al., 2014). 
A notable effect of nanotopography on MSCs is the control of MSCs fate 
commitment. A study by Matthew Dalby in 2007 (Dalby et al., 2007d) 
demonstrated that MSCs fate was determined by nanopit symmetry and order. In 
this study, nanopit with 120 nm diameter and 100 nm in depth were patterned 
on substrates of polymethylmethacrylate (PMMA) by electron beam lithography 
(EBL), and arranged in ordered pattern with symmetries of square (SQ) and 
hexagonal, in partly disordered pattern with pits placed randomly by up to ±50 
nm (NSQ50) and ±20 nm (NSQ20) on both x and y axes from their position in a 
true square array, and in a random pattern with pits placed within a repeating 
random 1 mm2 tile to fill 1 cm2. MSCs cultured on these nanopit features, planar 
substrates in the presence of DEX (positive control), a soluble factor capable of 
inducing osteogenesis, and planar substrates without DEX (negative control) 
were analysed for the effects of nanopit geometries on MSCs osteogenic fates. 
MSCs cultured on NSQ50 surface demonstrated osteoblast genotype (up-
regulation of OPN and OCN) and subsequent formation of bone nodules after 28 
days. Moreover, mineral was produced by MSC on the NSQ50 surface in the 
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absence of osteogenic supplements similarly to that of MSCs cultured on the 
planar control with osteogenic supplement. MSCs cultured on other nanopit 
patterns did not show significant osteogenic phenotype compared to MSCs 
cultured on planar surface. A follow up study (McMurray et al., 2011), 
demonstrated that the same size of nanopit described above arranged in square 
symmetry maintained MSCs stemness and growth up to eight weeks. These 
complementary findings suggest the potential for selective, controllable 
determination of MSC fate and terminal differentiation based only on the 
symmetry of nanopography. 
1.5.2 Biophysical and biochemical events underlying the effects 
of nanotopography 
1.5.2.1 Focal adhesions 
Interactions of cells with their surrounding ECM play an essential role in cell 
shape, attachment, migration and other cellular functions. Cells interact with 
ECM by the formation of specialized structures, termed focal adhesions, where 
transmembrane receptors assemble and bind to ligand components of the ECM. 
At these sites, numerous cytoplasmic proteins, including structural and signalling 
proteins, assemble at the cytoplasmic face through transmembrane receptors 
clustering to provide both physical and regulatory links between the ECM and 
cellular microfilament system (Geiger et al., 2009).	  
Integrins are the main transmembrane receptors constituting focal adhesions. 
Integrins are a large family of 24 α/β heterodimeric transmembrane glycoprotein 
receptors resulting from different pairings among eighteen α and eight β 
subunits in humans. The large extracellular domains of both α and β subunits 
bind to ECM proteins, whereas their short cytoplasmic tails interact directly or 
indirectly with cytoskeleton-signalling networks. On the extraplasmic face, the 
diversity of the integrin family enables them to recognize and bind a wide 
variety of soluble and surface-bound components of the ECM, including 
collagens, fibronectin, VN and laminin. In general, integrins bind to ligands by 
recognizing the motifs on ligands such as RGD, LDV and GFOGER (Humphries et 
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al., 2006) and this is mediated by divalent cations. Integrin binding to ligands on 
rigid surfaces results in force generation at focal adhesions which is the key 
element in the assembly and remodeling of ECM. 
Upon interaction with components and surface structures of ECM or following 
physical or chemical stimulations, the formation of focal adhesions is complex 
and regulated by both intracellular and extracellular events. The cytoplasmic 
domain of integrins plays a critical role in the processes. The β chain of the 
cytoplasmic region contains information to direct integrins to focal adhesions, 
and removal of the cytoplasmic β domain results in failure to localize to focal 
adhesions (Hayashi et al., 1990). The major biochemical grouping regulating 
formation of focal adhesions is the Rho GTPase family which stimulates actin-
myosin contraction and contributes to the assembly of stress fibres and focal 
adhesions (Chrzanowska-Wodnicka and Burridge, 1996). Other extracellular 
events which control integrin clustering and focal adhesion formation include 
the chemical nature of ECM (Greenwood and Murphy-Ullrich, 1998), the density 
and organization of the specific ligands (Cavalcanti-Adam et al., 2007), and the 
topography of ECM (Le Saux et al., 2011). 
Specific to nanotpography, a study, using well-defined gold nanodots on a rigid 
template coated with cyclic RGDfK peptide demonstrated that, in many cell 
types, the universal length scale for integrin clustering and activation is 58 to 73 
nm. Spacing the adhesive nanodots over 73 nm resulted in limited cell 
attachment, spreading, and reducing focal adhesions formation and actin stress 
fibres (Arnold et al., 2004). Focal adhesion formation regulated by other 
nanotopographies, such as pits or islands was also observed, and it was 
evidenced that over 50-60 nm of space between nanofeatures impaired cell 
adhesion and response (Cavalcanti-Adam et al., 2006; Dalby et al., 2003). 
Further studies demonstrated that stem cell differentiation is linked to focal 
adhesion formation which is modulated by nanotopography (Biggs et al., 2008; 
Park et al., 2007). 
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1.5.3.2 Indirect mechanotransduction 
Focal adhesions are mechanosensitive and protein-rich structures (Figure 
1.6A)(Campbell, 2008). The cytoplasmic domains of integrins bind to various 
proteins which are important for the regulation of integrin affinity to its 
extracellular ligands and cytoskeletal interaction. Some proteins, such as 
chaperon, tyrosine kinease FAK, directly bind to α chain of cytoplasmic 
integrins, while most cytoskeletal proteins (talin, α-actinin) and regulatory 
proteins can directly bind to the β tail domain of integrins.	  These biochemical 
properties and physical structures make integrins a suitable candidate for 
bidirectional signalling transmission across plasma membranes despite having no 
enzymatic activity themselves (Calderwood et al., 2000; Evans and Calderwood, 
2007). Integrins transmit mechanical signals into the cell, providing information 
on cell location, local environment, adhesive state, and surrounding matrix. 
These signals determine cellular responses such as survival, migration, 
proliferation and differentiation (Calderwood, 2004; Hynes, 2002).  
Nanotopography regulated cellular functions via focal adhesions/integrins may 
thus involve indirect, biochemical, mechanotransduction. A study on 
nanoimprinting using nanocolloidal substrates	   demonstrated that inhibiting 
integrin β1 subunits increased the ability of fibroblasts to nanoimprint (develop 
the shape of the topographies they are cultured on within the cytoskeleton-
topographical mirroring), while blocking β3 subunits resulted in a decrease in 
nanoimprinting of the topography into the cell cytoskeleton (Wood et al., 2008). 
Osteoprogenitor cells derived from bone marrow cultured on nanogrooved 
surfaces with dimensions of 240 nm or 540 nm deep and 12.5 um width (25 µm 
pitch) demonstrated more focal adhesion formation with lower proportions of 
mature adhesions relative to that on planar surface. Osteogenic markers were 
assessed and showed down-regulation on nanogrooves compared to the planar 
control. The authors proposed that the correlation of the down-regulation of 
osteogenic markers to less focal adhesion maturation indicated the implication 
of ERK 1/2 negative feedback pathways following integrin-mediated FAK 
activation (Cassidy et al., 2014). Another study demonstrated that if the groove 
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width was increased to 50 µm (100 µm pitch) and so the cells perceived steps 
rather than alignment cues, the focal adhesion size increased and osteogenesis 
was observed (Biggs et al., 2009; Biggs et al., 2008). In fact, it appears that for 
osteogenesis, the formation of very large, super-mature adhesions (adhesion > 5 
µm long), is a pre-requisite (Biggs et al., 2009). A number of reports have 
indicated the importance of cytoskeletal tension in driving osteogensis and such 
increases in intracellular tension would need to be stabilised through large 
adhesions (Dalby et al., 2014; Kilian et al., 2010). 
1.5.3.3 Direct mechanotransduction 
In direct mechanotransduction, cells are described as being able to have 
‘tensegrity architecture’ to allow long distance force transfer relying on force 
balance in the cytoskeletal network in which different structural elements, such 
as microtubules bearing most of the compressive and contractile microfilaments 
and ECM molecules bearing most of the tension, are interconnected. Moreover, 
cytoskeletal networks link to nuclear scaffolds, chromatin and DNA inside 
nucleus through LINC (linker of cytoskeleton and nucleoskeleton) complexes 
linking the nucleus to the cytoskeleton and MAR (matrix attachment regions) 
that link telemetric DNA to the nucleoskeletal lamins (Kilian et al., 2010; 
McBeath et al., 2004). Therefore, from ECM receptors to nuclear scaffolds, the 
‘hard-wired’ tensegrity network may allow and transfer of mechanical forces in 
such way that not only activate membrane signalling events (indirect 
mechanotransduction), but also result in structures rearrangement in the 
cytoplasm and nucleus (Figure 1.6B) (Ingber, 2003; Maniotis et al., 1997). 
Direct mechanotransduction is supported by some key experimental findings in 
recent years. Stress mapping technologies enable visualization force of 
transmission in the cytoplasm and confirm that transmembrane receptor 
deformation by small forces could propagate to long distance sites from the 
force application, even to the sites at near the nucleus and at the opposite pole 
of the cell (Hu et al., 2003; Hu et al., 2004). Mechanical signals transmission is 
rapid and faster than diffusion-based chemical signals (Na et al., 2008). More 
importantly, a nuclear anchoring complex that links the cytoskeleton and 
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nucleocytoskeleton was identified, containing nesprins, suns and lamins – the 
LINC complex (Crisp et al., 2006; Haque et al., 2006). 
In general, nesprins are rod-like proteins and locate at the outer nuclear 
membrane, which connects microfilaments to suns on the inner nuclear 
membrane; and this complex further binds to lamin A in the nuclear scaffolds. 
Lamins might connect to the genetic machinery and to DNA both directly and by 
binding to other nuclear proteins, including lamin B receptor and emerin that 
associated with many regulatory proteins stimulating downstream chromatin 
modification, transcriptional regulation and mRNA processing (Wang et al., 
2009). Consequently, physical connections between cytoskeletal filaments and 
the nuclear anchoring complex enable ‘tugging’ of the cytoskeleton on the 
nucleus to effect changes in gene expression by chromatin modification. 
Nanotopographies have been shown to have effects on the nucleus. Fibroblasts 
cultured on nanocolumns showed repositioning of the chromosome 3 in the 
interphase nuclei (Dalby et al., 2007a). The authors suggested that the 
repositioning of the chromosome is due to a decrease in cell spreading and 
nuclear area. Fibroblasts cultured on hexagonally arrayed nanopits, also 
demonstrated that the inter-centromeric distance was reduced for both 
chromosomes 3 and 11, and the cells were markedly less spread than controls 
(Dalby et al., 2007c). Similar has also been seen in MSCs (Tsimbouri et al., 2013). 
Chromosome repositioning may affect gene expression, for example from hetero- 
to euchromatin would de-repress silenced chromosomes resulting in the 
relaxation of condensed chromatins and subsequently enhance gene expression 
(Lanctot et al., 2007). 
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Figure 1.6 Diagram of indirect and direct mechanotransduction effectors. 
Box A (Taken from Campbell, 2008) shows the structure of integrin 
mediated focal adhesion complexs which enable physical cues 
outside of membrane to be transmitted into the cytoplasm. The 
ECM at the top of the diagram is made up of molecules such as 
fibronectin. Integrins,membrane-crossing αβ heterodimers, bind to 
ECM components using their extracellular regions. The short 
flexible intracellular tail regions of integrins are linked to the actin 
cytoskeleton by talin. Filamin A which has an actin-binding domain 
and 24 Ig-like domains, cross-links actin filaments as well as binding 
to integrin tails. Other important associated molecules include 
kinases Src, PIPKIγ, FAK and phosphatases. Paxillin and vinculin 
facilitate the formation of the dynamic complexes by cross-linking 
several different proteins. Box B (Taken from Wang, et. al. 2009) 
shows a local force outside the membrane directly transmits into 
the nucleus through focal adhesions. A local force applied to 
integrins through the ECM is concentrated at focal adhesions and 
channeled to filamentous (F)-actin, which is bundled by α-actinin 
and made tense by myosin II, which generates prestress. F-actins 
are connected to microtubules (MTs) through actin-crosslinking 
factor 7 (ACF7), and to intermediate filaments (IFs) through plectin 
1. Plectin 1 also connects IFs with MTs and IFs with nesprin 3 on the 
outer nuclear membrane. Nesprin 1 and nesprin 2 connect F-actin 
to the inner nuclear membrane protein SUN1; nesprin 3 connects 
plectin 1 to SUN1 and SUN2. Owing to cytoplasmic viscoelasticity, 
force propagation from the ECM to the nucleus might take up to ~1 
ms. The sun proteins connect to the lamins that form the lamina 
and nuclear scaffold, which attaches to chromatin and DNA (for 
example, through matrix attachment regions (MARs)). Nuclear actin 
and myosin102 (and nuclear titin) might help to form the nuclear 
scaffold, control gene positioning and regulate nuclear prestress. 
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1.6 Aims of the project 
Recent advances in nanofabrication techniques enable fabrication of 
biomaterials with nanoscale features. Studies in the present group and others 
have demonstrated nanotopography alone can control MSCs proliferation and 
differentiation. As non-invasive physical cues, nanopography is a powerful tool 
for studies in stem cells function and in turn the discoveries can be used as 
guidances for stem cell therapy and the design of new scaffolds in terms of bone 
tissue engineering. 
A nanotopography, namely NSQ50 was identified by Matthew Dalby in the 
present group (Dalby et al., 2007b) as osteoinductive, which specifically  
promotes MSC osteogenic differentiation. MSCs fate determination and specific 
lineage differentiation are controlled by selective gene expression. An 
osteogenic differentiation model was established by Lian and Stein (Lian and 
Stein, 1992), in which osteoblastic phenotype is functionally coupled with a 
sequential expression of cell cycle and growth genes and bone marker genes. We 
hypothesize the NSQ50 nanotopography induced MSCs osteogenesis would obey 
Lian’s model and MSCs osetogenic commitment and bone marker genes 
expression on the surface would be controlled by transcription factors. Thus the 
primary aim of this project is to look into the functional coupling of sequential 
gene expression and MSCs phenotype development so that the major transit 
point of MSCs osteoblast phenotype development on the nanotopography would 
be established. 
The genotype alteration of MSCs on the nanotopography is governed by 
nanotopographical cues. Cells sense the extrinsic signals mainly through 
transmembrane receptors. The major theories for the mechanisms of cells 
responding to nanotopography include: 1) Spatial biasing of focal adhesions 
formation and the subsequent signalling connection with cytoskeleton proteins. 
2) Dynamic actin polymerization rearranges cytoskeleton to guide cell migration 
and morphological alterations. However, major biochemical signallings, which 
have been well studied for osteogenic differentiation and bone formation in vivo 
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and in vitro, have yet been well defined at the instance of nanotopography. 
Thus, the second aim of the project is to identify signalling and other regulatory 
molecules (i.e., miRNAs) and the pathways that drive transcription factors 
alteration to determine MSCs fate and osteogenic differentiation on the surface.   
It has been emerged that a great different energy production between stem cells 
and their terminal differentiation. The NSQ50 nanotopography mimicking the 
structure of bone tissue ECM and non-invasively inducing osteogenesis of MSCs 
provides an ideal tool for the investigation of metabolic alteration during MSCs 
osteogenic commitment and differentiation. Thus, the third aim of this project 
is to characterize bioenergetics process of MSCs on the NSQ50 surface, and to 
probe the intricacy of metabolic and biochemical regulation in MSCs osteogenic 
commitment and differentiation. 
It is hope that this project would extend the understanding of nanotopography 
induced MSCs osteogenic differentiation, and in turn, the findings would provide 
guidance for future application in terms of bone tissue engineering. 
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Summary 
This chapter describes the experimental methods used in this thesis. The 
methods are described in sequence of application, from MSCs cultured on NSQ50 
nanotopography to functional analysis of the effects of the NSQ50 surface on 
MSC osteogenic differentiation. Thus, it begins with embossing the NSQ50 
surface into PCL and MSC cell culture, describing the NSQ50 nanotopography 
features, MSC isolation and cell culture methods. Next, oligonucleotides, protein 
analysis methods are described. Immunostaining, qRT-PCR and Western blotting 
are then introduced as techniques for the functional analysis of the NSQ50 
surface on MSC osteogenesis, and finally methods for metabolites measurement 
are introduced. 
2.1 NSQ50 nanotopography 
A ‘near square’ arrangement of nanopillars with 120 nm in diameter, 100 nm 
height and with an average 300 nm centre-to-centre spacing with up to ± 50 nm 
offset from a square lattice (NSQ50) were fabricated by electron beam 
lithography on a silicon master with topography area of 1 x 1cm2. This was used 
as a shim to allow replication of nanopits into polycaprolactone (PCL) (cut from 
sheets of the polymer  ε-polycaprolactone) by embossing on a hotplate at 70oC, 
and then the PCL sheets with embossed NSQ50 surface was used as substrates for 
MSC cell culture. Planer PCL sheets used as control substrates for MSCs culture 
were embossed against a microscope cover slip with surface roughness less than 
0.5 nm. 
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Figure 2.1 The feature of NSQ50 nanopits  
The NSQ50 nanopit is 120 nm in diameter, 100 nm depth with 
partially disordered arrangement of up to +/- 50 nm offset from a 
square lattice and 300 nm center-to-center spacing (taken from 
Matthew Dalby, 2007). 
2.2 Mesenchymal stormal cells 
2.2.1 Cell isolation from human bone marrow 
The original MSCs were isolated from bone marrow obtained from patients 
undergoing routine arthroplasty, with ethical approval. Bone marrow was stored 
in transport media (Table 2.1) after arthroplasty. For MSC isolation, the aspirates 
were diluted 1:2 with 10 ml modified basal medium (Table 2.2), removing as 
many residues as possible and then centrifuged at 1400 rpm for 10 minutes. After 
centrifugation, media was discarded and the pellet resuspend in 10 ml of fresh 
media. The above washing process was repeated until the cell pellet changed to a 
white color (i.e. most of the blood cells were removed from the bone marrow). 
The cell pellet was resuspended in 10 ml modified media (table 2.2) and overlaid 
on 7.5 ml Ficoll gradient media, followed by centrifugation at 1513 rpm for 45 
minutes. The mononucleated cells were collected at the interphase. Cells were 
gently washed with 10 ml medium and medium was removed by centrifugation at 
1400 rpm for 10 minutes. Following three washes, cells were collected and seeded 
into TC75 vented flasks for culture. 
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2.2.2 Cell culture and harvest 
MSCs were maintained in modified basal media at 37oC until 90% confluence was 
reached (medium was changed every 5 days). Cells were passaged with a dilution 
ratio 1:3, and cells of passage 1 or 2 were used in this work. 
For seeding cells on to the substrates, cells were seeded onto NSQ50 PCL and 
planar PCL sheets with density of 1x104 cells/cm2 and then cultured in medium 
for different time points. Cells on PCL sheets were harvested using trypsin for 
downstream nucleotide assays, or using cell scrapers for downstream protein 
assays or were fixed for microscopy. Harvested cells were immediately stored at 
-80oC for further use. 
Table 2.1 Components of transport medium for bone marrow. 
Components Volume/Amount 
1xPBS 200 ml 
EDTA 0.6 g 
Penicillin 1 mg 
pH: 7.2, Filter before use. 
	  
Table 2.2 Components of modified basal medium for MSC culture. 
Components Volume 
DMEM 430 ml 
FBS 50 ml 
Penicillin (Conc. 0.1mg/ml) 10 ml  
100mM sodium pyruvate (1mM/ml) 5 ml 
Non-Essential amino acids (100x) 5 ml 
Filter before use 
63	  
	  
2.3 Oligonucleotides (primers) synthesis 
Oligonucleotide primers were designed using primer3 or other online resources 
(NCBI; Oligodesign, invitrogen UK). The sequences were then sent to eurofins 
mwg|operon for synthesis on a scale of 30 nmol. Primers were purified using 
high purity salt-free (HPSF) technology (MWG) based on reverse phased 
chromatography and the quality of primers was assessed by matrix assisted laser 
desorption ionisation - time of flight (MALDI-TOF) analysis. Primer stock 
concentrations at 100 µM were obtained for each primer by resuspending the 
lyophilised powder in ddH2O and a working concentration of 6.6 µM was prepared 
from the stocks. Primers were stored at -20oC until further use. Primers for 
genes encoding proteins and primers for miRNA genes used in this thesis are 
listed in table 2.3 and 2.4 respectively. 
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Table 2.3 Primers for genes encoding proteins. 
Gene name 
(ID number) 
Primer sequence PCR 
product 
size 
Efficiency 
(%) 
GAPDH  
(ID: 2597) 
Forward: TCAAGGCTGAGAACGGGAA 
Reverse: TGGGTGGCAGTGATGGCA 
376bp 94 
RUNX   
(ID: 860) 
Forward: CAGACCAGCAGCACTCCATA 
Reverse: CAGCGTCAACACCATCATTC 
178bp 92 
OSX  
(ID:121340) 
Forward: CAAAGCAGGCACAAAGAAGC 
Reverse: CCAGGAGCCATAGGGGTG 
295bp 86 
C-MYC 
(ID: 4609) 
Forward: TTTCTACTGCGACGAGGAGG 
Reverse: GGCAGCAGCTCGAATTTCTT 
105bp 89 
OPN 
(ID: 6696) 
Forward: ACAGCCGTGGGAAGGACAGT 
Reverse: GACTGCTTGTGGCTGTGGGT 
76bp 98 
OCN 
(ID: 632) 
Forward: GCCCTCACACTCCTCGCC 
Reverse: CTACCTCGCTGCCCTCCTG 
130bp 85 
ALP 
(ID: 250) 
Forward: ACAACTACCAGGCGCAGTCT 
Reverse: TCAGAACAGGACGCTCAGG 
260bp 92 
BMP2 
(ID: 650) 
Forward: GTCCTGAGCGAGTTCGAGT 
Reverse: ACCTGAGTGCCTGCGATAC 
120bp 96 
BMPR1A 
(ID: 657) 
Forward: TATGGATGGGCAAATGGC 
Reverse: GCTTTCCTTGGGTGCCATAA 
324bp 94 
Integrin αv 
(ID: 3685) 
Forward: ACTCGCCAGGTGGTATGTG 
Reverse: GTTCTCCTTGTGCTCCCAGT 
270bp 97 
Integrin α3 
(ID: 3675) 
Forward: CTGCCGACCACCTGGAGAC 
Reverse: CAGCAGCCAGAGTGACAGGT 
143bp 91 
Integrin α4 
(ID: 3676) 
Forward: AGCAACAGGTTTTCCAGAGC 
Reverse: ACAATAAGTCCAAGTAGCAAGC 
156bp 92 
Integrin β1 
(ID: 3688) 
Forward: GTGCAATGAAGGGCGTGTT 
Reverse: GTTGCACTCACACACACGACA 
277bp 98 
Integrin β3 
(ID: 3690) 
Forward: CCCAGAGGGTGGCTTTGAT 
Reverse: ACACTGCCCGTCATTAGGCT 
166bp 99 
Integrin β5 
(ID: 3693) 
Forward: GGAACCCAACAGTGCCAGG 
Reverse: CGGCACAGGTTCTGGTACA 
135bp 96 
SMAD1 
(ID: 4086) 
Forward: TTTCCAGCAACCCAACAG 
Reverse: TCAGGAGGCAGGTAAGCA 
168bp 91 
SMAD5 
(ID: 4090) 
Forward: TGTCAAGGGTTGGGGAGC 
Reverse: TATGGGGTTCAGAGGGGAG 
136bp 89 
LRP5 
(ID: 4041) 
Forward: CGTGTGTGACAGCGACTACA 
Reverse: GCGGGAAGAGATGGAAGTAG 
179bp 91 
DLX5 
(ID: 1749) 
Forward: GACCCAATGGCGTGTAA 
Reverse: GCTGCACTTGTGTACCAGGA 
161bp 93 
MSX2 
(ID: 4488) 
Forward: GACGAGGAGGGCCCAGCAGT 
Reverse: GCCTCCACGCTGAAGGGCAG 
113bp 95 
Tab1 
(ID: 10454) 
Forward: TCCACCAACACGCACACGCA 
Reverse: CGCCATGGTCCACGCTCCAG 
157bp 94 
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Table 2.4 Primers for miRNAs. 
Gene name Primer sequence PCR 
product 
size 
Efficiency 
(%) 
MiR-23a 
(ID: 4070100) 
Forward: CTGGGGTTCCTGGGGAT 
Reverse: TGGTAATCCCTGGCAATGTG 
60bp 89 
MiR-23b 
(ID: 407011)	  
Forward: AAGCCCAGTGTGTGCAGAC 
Reverse: ACCACGGTTTCTGGAGGA 
75bp 92	  
MiR-96 
(ID: 407053)	  
Forward: AGAGAGCCCGCACCAGT 
Reverse: CTTGAGGAGGAGCAGGCT 
75bp 95	  
MiR-93 
(ID: 407050)	  
Forward: GGGCTCCAAAGTGCTGTT 
Reverse: GGGCTCGGGAAGTGCTA 
72bp 87	  
MiR-143 
(ID: 406935)	  
Forward: TCCCAGCCTGAGGTGC 
Reverse: CCCAACTGACCAGAGATGC 
41bp 94	  
MiR-203 
(ID: 406986)	  
Forward: TCCAGTGGTTCTTAACAGTTCA 
Reverse: GGTCTAGTGGTCCTAAACATTTC 
66bp 96	  
U6 snRNA 
(ID: 26827) 
Forward: CTCGCTTCGGCAGCACA 
Reverse: AACGCTTCACGAATTTGCGT 
94bp 95 
	  
2.4 Total RNA extraction 
RNA extraction was carried out in a nuclease-free environment using RNeasy Mini 
columns according to the manufacturer’s protocol (Qiagen UK). The cell pellet 
was washed with 1xPBS and then lysed in RLT buffer vortexing for 1 minute. The 
lysates were homogenized using ultrasonic cell disruptor (Misonix, Inc., USA). 
The rest of the procedures of total RNA extraction were according to the Qiagen 
kit, including the on column DNA digestion step to reduce genomic DNA 
contamination. RNA was eluted using 16 µl of nuclease-free water from the 
column and it was stored at -80oC until further use. 
2.5 Complementary DNA (cDNA) synthesis 
2.5.1 Total RNA reverse transcription 
cDNAs for qRT-PCR were synthesised using 5-50 ng of total RNA. Recombinant 
reverse transcriptase (SuperScript® II; Invitrogen UK) was used to reverse 
transcribe the RNA in a total of 20 µl of reaction volume. 50 ng of random 
primers, 5 to 50 ng of total RNA and 1 µl of dNTP (10 mM each of dCTP, dGTP, 
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dATP and dTTP) and sterile distilled water to make up to 12 µl total volume 
were combined in a nuclease-free PCR tube. The mixture was heated at 65oC for 
5 minutes and quickly chilled on ice. The contents were collected by brief 
centrifugation and mixed with 4 µl of 5x first strand buffer, 2 µl of 0.1 M DTT 
and 1 µl (40units) of RNaseOUT. The reaction mixture was then incubated at 
25oC for 2 minutes. After incubation, 1 µl (200 units) of SuperScript® II RT was 
added and mixed by pipetting gently up and down. Then incubated at 42oC for 
50 minutes and the reaction terminated by heating to 70oC for 15 minutes. The 
reaction was briefly centrifuged to collect the cDNA contents and stored at -20oC 
for further use. 
2.5.2 MicroRNA reverse transcription 
cDNAs for microRNA qRT-PCR were synthesised using 5-50 ng of total RNA. 
ThermoScript reverse transcriptase (ThermoScript®; Invitrogen UK) was used to 
reverse transcribe the RNA in a total of 20 µl of reaction volume. 20 pmol of 
gene specific primer, 5 to 50ng of total RNA, 1 µl of dNTP (10 mM each of dCTP, 
dGTP, dATP and dTTP) and sterile distilled water to make up to 12 µl total 
volume were assembled in a nuclease-free PCR tube. The mixture was heated at 
65oC for 5 minutes and chilled on ice im mediately. Contents of the tube were 
collected by brief centrifugation and mixed with 4 µl of 5x first strand buffer, 1 
µl of 0.1 M DTT and 1 µl (40units) of RNaseOUT, 1 µl of sterile H2O and 1 µl of 
ThermoScriptTM RT (15 unites). The reaction mixture was incubated at 65oC for 1 
hour, and then the reaction was terminated by heating to 85oC for 15 minutes. 
cDNAs were collected to the bottom of the tube by brief centrifugation and 
stored at -20oC. 
2.6 Nucleic acids quantification and quality control 
Quantification of DNA and RNA was carried out using a Nanodrop 1000 
spectrophotometer (Thermo UK). The Nanodrop 1000 uses 1.0 mm and 0.2 mm 
paths that have capacity to measure samples as small as 1 µl and 50 times higher 
concentrated samples than the standard cuvette spectrophotometer. For nucleic 
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acid quantification, the Nanodrop 1000 spectrophotometer was blanked by 
reading the absorbance of water, then background absorbance was read using 
the reference (water or the buffer in which the nucleic acid was diluted) and 
zeroed for background. Sample absorbance was read at two wavelengths A260 and 
A280 nm. The reading at A260 was used for quantification and the ratio of A260/A280 
was used for nucleic acid purity assessment. A ratio of ~1.8 for DNA and ~2.0 for 
RNA were used as a guide for sample purity.  
Further quality assessment for RNA samples was carried out using an Agilent 
2100 Bioanalyzer (Agilent UK). This is a computer assisted nanogel 
electrophoresis tool for total RNA. The integrity of an RNA sample can be 
measured using the ratio of 28s integrity/18s integrity, which is called the RIN 
number. Lower RIN numbers indicate degraded RNA, and the threshold setting 
for intactness of RNA is 8.0. 
2.6.1 Quantitative reverse transcription PCR (qRT-PCR) 
qRT-PCR was performed on an ABi7500 thermal cycler using the SYBR Green 
relative standard method (Larionov et al., 2005). SYBR Green master mix was 
purchased from Applied Biosystems, which contained SYBR Green I dye, 
AmpliTaq DNA polymerase, dNTPs with dUTP, and PCR reaction buffer. The 
SYBR Green I dye detects the double-stranded DNA, AmpliTaq DNA polymerase  
minimizes nonspecific product formation, and the dUTP reduces carryover 
contamination. The starting materials for qRT-PCR were cDNAs, each sample was 
scaled down to its corresponding RNA concentration of 5ng/µl. 2 µl of SYBR 
Green master mix, 2 µl of primer pair (forward and reverse primer) and 1 µl of 
cDNA sample were mixed up to 20 µl of final reaction volume for each well. 
Negative controls (samples without reverse transcriptase) and blanks (reactions 
without cDNA samples) were set for each experiment to monitor genomic DNA 
contamination and substrate fluorescence background respectively. Three 
technical and biological replicates were applied for each experiment. The qRT-
PCR cycling parameters used are presented in the table 2.5. 
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Table 2.5 PCR cyclic parameters for SYBR Green qRT-PCR. 
 Number of cycle Temperature Time 
Holding stage 1 50oC 2 minutes 
1 95oC 10 minutes 
Cycling Stage 40 95oC 15 seconds 
60oC 30 seconds 
75oC 10 seconds 
Melting curve 
stage 
Melting curve 
was recorded for 
each cycle. 
95oC 15 seconds 
60oC 1 minute 
95oC 30 seconds 
650C 15 seconds 
 
Standards were made by serial dilution of cDNA with dilution factor of 2. Figure 
2.1, as an example, showed the standard curve generated for the osteopontin 
(OPN) gene, which gave slope of -3.3124, Y-inter of 21.192 and correlation 
coefficient R2 = 0.984. 
	  
Figure 2.2 Example of relative standard curve for the OPN gene. 
cDNA was diluted with dilution factor of 2. qRT-PCR for the OPN 
gene was carried out and a relative standard curve was generated 
for the OPN gene quantification (standard curve: slope, -3.3124, Y-
inter, 21.192 and correlation coefficient R2 = 0.984). 
To further control the qRT-PCR reaction quality, a melting curve step was used 
to monitor if primers amplified one specific PCR product. If a primer pair 
generates one specific PCR product, the melting curve from the reactions will be 
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a single homogeneous melt peak for all sample reactions, and the data from 
these reactions can be considered reliable and meaningful for gene expression 
analysis. Figure2.2, as an example, shows the melting curve of the osteopontin 
gene (OPN) primers used in this work, which present a single melt peak at the 
expected melting temperature of 81.5oC predicted for its PCR product.  
The GAPDH gene and small nuclear RNA U6 were used as a reference controls for 
protein coding RNA and microRNA respectively to normalize the data. Gene 
differential expression was then expressed as fold change after comparison to 
control samples. The standard deviation (SD) and p-value for statistical 
significance were analyzed using GraphPad Prism software. 
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Figure 2.3 Example of SYBR green qRT-PCR melting curves generated during 
OPN gene amplification. 
 Melting curves of OPN in different cDNA samples were generated 
using SYBR green qRT-PCR, demonstrating OPN was specifically 
amplified by the primers used. 
2.7  Protein analysis 
2.7.1 Protein preparation 
2.7.1.1 Total protein preparation 
Cells frozen at -80oC were taken out of the freezer and thawed on ice. 100 µl of 
RIPA buffer (Table 2.7) was added to the cells and kept on ice for 15 minutes. 
The lysates were homogenized on ice using ultrasonic cell disruptor (Misonix, 
Inc., USA) and then were clarified by centrifugation at 13000 rpm for 5 minutes 
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at room temperature. The supernatant was transferred to a fresh eppendorf 
tube and the pellet was discarded. Protein concentration was assessed and 
stored at -80oC until required. 
Table 2.6 The components of RIPA lysis buffer. 
Component Volume (10 ml) 
100 mM Tris/HCl, 300 mM NaCl 5 ml 
10% Triton X100 1 ml 
10% Na deoxycholate 1 ml 
10% SDS 100 ul 
200 mM PMSF 50 ul 
0.01 M EDTA (pH 7.4) 100 ul 
Protease and phosphatase inhibitor 1 tablet 
H2O 2.75 ml 
2.7.1.2 Membrane protein preparation 
Pellets of cells were thawed on ice and resuspended in ice-cold TE buffer (10 
mM Tris/HCl, pH 7.4, and 0.1 mM EDTA) supplemented with protease inhibitor 
cocktail, and homogenized on ice using ultrasonic cell disruptor, followed by 
centrifugation at 600xg for 10 minutes at 4oC to remove unbroken cells and 
nuclei. The supernatant was transferred to a new vial and subjected to 
centrifugation at 10000 X g for 30 minutes at 4oC. The pellet was collected and 
resuspended in ice-cold TE buffer. Protein concentration was assessed and 
stored at -800C until required. 
2.7.2 Protein quantification 
Proteins were quantified using a Bio-Rad Protein Assay Kit (BIO-RAD, 500-0006). 
The Bradford dye reagent was diluted at a ratio of 1:5 with distilled water. 
Appropriate standard concentrations (Quick StartTM Bovine Serum Albumin 
Standard Set (BIO_RAD, 500-0207)) were used to obtain sample concentration; 
typically eight BSA standards of 0 - 3.0 mg/ml were set up. 10 µl of standards 
and protein samples were pipetted in respective wells of microtiter plate. 200 µl 
of diluted Bradford dye was added to each well and mixed by pipetting. The 
plate was then incubated at room temperature for 10 minutes. The absorbance 
at 595 nm was read using plate reader and standard absorbance was plotted 
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against the known concentration to interpolate the unknown protein sample 
absorbance to calculate their concentration. 
2.7.3 Protein separation (SDS-PAGE separation) 
Proteins were separated using Novex NuPAGETM electrophoresis system. Protein 
samples were diluted with 4X NuPAGE LDS loading buffer and denatured at 95oC 
for 5 minutes. The denatured protein samples and prestained protein marker 
were loaded on 12-well of 4-12% Bis-Tris-HCl polyacrylamide gel and run in 
1xNuPAGETM MOPS SDS running buffer at 200V constant for 50 minutes. 
2.7.4 Protein analysis (I) – Immunoprecipitation 
Proteins were isolated using lysis buffer and then centrifuged at 13000 rpm for 
15 minutes at 4oC. The supernatant was transferred to a fresh tube with protein 
A agarose beads (Sigma) to preclean the samples. After 1 hour incubation at 4oC, 
samples were recentrifuged and collected into new tubes. Protein A agarose 
beads were incubated with primary antibody at 4oC for 1 hour and centrifuged at 
4oC for 2 minutes and discarded the supernatant. The mixture of primary 
antibody and agarose beads was washed with lysis buffer and then centrifuged, 
repeated this for three times. Equal amount of protein samples were added into 
mixture of primary antibody and agarose beads and incubated under rotation at 
4oC overnight. Samples were subsequently washed four times with lysis buffer 
and then proteins were eluted with SDS buffer for western blot analysis. 
2.7.5 Protein analysis (II) – Western blotting 
Proteins separated on SDS-PAGE were transferred on to Hybond-N+ membrane 
(Amersham Bioscience). Membrane was dried and then dipped in methanol for 30 
seconds, and then blocked in blocking buffer (table 2.7) overnight at 4oC. The 
overnight blocked membrane was washed three times (10 minutes for each) with 
PBST buffer and then the membrane was incubated with primary antibody (table 
2.8) against the protein of interest (diluted 1:1000 in blocking buffer) at room 
temperature for 2 hours followed by three times washes (each for 10 minutes) 
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with PBST buffer. Membrane was then incubated with secondary antibody (table 
2.8) linked to a reporter enzyme horseradish peroxidase (HRP) (dilution 1:10000 
or 1:15000 in blocking buffer) at room temperature for 1 hour followed by three 
times washes (each for 10 minutes) with PBST buffer. The dried membrane was 
then covered by detection reagents (Amersham Bioscience) for 30 seconds and 
then dried on soft tissue for X-ray developing. 
2.8 Immunocytochemistry (ICC) 
2.8.1 ICC for proteins of interest 
Cells cultured on substrates were washed once with 1XPBS, then PBS removed 
and added fixative solution (table 2.7) to cover cell surface. Cells were then 
incubated at 37oC for 15 minutes. After incubation, fixative was removed and 
the cells washed with 1XPBS once. Cells were then permeabilized by adding 
perm buffer (table 2.7) and incubated at 4oC for 5 minutes. Excess solution was 
removed and cells were blocked in blocking buffer (table 2.7) at 37oC for 5 
minutes. Cells were washed with 1XPBS twice and then incubated with primary 
antibody (table 2.8) at 37oC for one hour followed by washing three times with 
PBST buffer (table 2.7) (each for 5 minutes). Biotinylated secondary antibody 
(table 2.8) was added and incubated at 37oC for one hour followed by another 
three times PBST buffer wash (each for 5 minutes). Cells were then incubated at 
4oC for 30 minutes with streptavidin-FITC. Excess streptavidin-FITC was removed 
and cells were washed three times with PBST buffer (each for 5 minutes). For 
nucleus visualization, a small drop of vectroshield-DAPI was placed and sealed 
with microscope coverslip for imaging. Note that for actin counterstain, 
rhodamine-phalloidin at 1:500 in blocking buffer was added at the same time as 
the primary antibody. 
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2.8.2 Imaging 
Immunostained cells were imaged using a Zeiss immunofluorescence microscope. 
Images were processed using imageJ or LMS imaging software, and images that 
were to be compared against one another were taken with the same exposure. 
2.9 Buffers and antibodies in protein work 
Buffers used in immunostaining and Western blotting are listed in table 2.8. 
Antibodies used in immunostaining, Western blotting and immunoprecipitation 
are presented in table 2.9. 
Table 2.7 Buffers used for protein work. 
Buffer Name Concentration Components 
Fixative 10% (v/v) 10 ml formaldehyde and 2 g sucrose in 
90 ml 1XPBS 
Blocking buffer 1% (w/v) 1 g BSA in 100 ml 1XPBS. 
PBST 0.5% (v/v) 0.5 ml Tween 20 in 99.5 ml 1XPBS. 
Perm buffer 0.5% (v/v) 10.3 g sucrose, 0.292 g NaCl, 0.06 g 
MgCl.6H2O and 0.476 g Hepes in 99.5 
ml 1XPBS with pH 7.2, then adding 0.5 
ml Triton X-100. 
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Table 2.8 Antibodies used for protein work. 
Antibody and Source Dilution and Use 
Anti-Integrin β5 (Rabbit monoclonal) 1:250 ICC 
1:50 blocking 
Anti-GAPDH (Rabbit polycolonal) 1:2000 Western 
Anti-BMP2 (Mouse monoclonal) 1:250 ICC 
1:1500 Western 
Anti-Integrin αvβ5 (Mouse monoclonal) 1:250 ICC 
1:1500 Western 
1:1000 Immunoprecipitation 
Anti-BMPR1A (Mouse monoclonal) 1:250 ICC 
1:1500 Western 
Anti-RUNX2 (Mouse monoclonal) 1:250 ICC 
1:1500 Western 
Anti-OPN (Mouse monoclonal) 1:250 ICC 
Anti-OCN (Mouse monoclonal) 1:250 ICC 
Anti-mouse IgG-HRP 1:10000 Western 
Anti-rabbit IgG-HRP 1:10000 Western 
Anti-goat IgG-HRP 1:10000 Western 
Biotinylated anti-mouse IgG 1:250 ICC 
Biotinylated anti-rabbit IgG 1:250 ICC 
Biotinylated anti-goat IgG 1:250 ICC 
2.10 Alizarin Red Staining 
Cells cultured on NSQ50 surface embossed PCL and plannar PCL were washed 
with 1xPBS and fixed with 10% formaldehyde at room temperature for 15 
minutes. Fixative was then removed and cells were rinsed three times (5 
minutes each) with distilled water. The plates were then left at an angle for 
couples of minutes to remove excess water. 1 ml/well Alizarin Red Stain Solution 
was then added and incubated at room temperature for 30 minutes. Excess dye 
was removed and cells were carefully washed five times with deionized water (5 
minutes each). Calcium (Ca2+) mineralization was visualized using an inverted 
microscope (Nikon). 
2.11 Metabolomics 
Metabolites from cells cultured on NSQ50 surfaces and control samples for 3, 5 
and 7 days were extracted using ice cold chloroform:methanol:water (1:3:1,v/v) 
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on a shaker for 1 hour and maintained at 4°C. Samples were centrifuged and 10 
µl of the supernatant was injected in to the LC-MS system. 
The LC separation was carried out using hydrophilic interaction chromatography 
with a ZIC-pHILIC 150 mm x 4.6 mm, 5 µm column (Merck Sequant), operated by 
an UltiMate liquid chromatography system (Dionex, Camberley, Surrey). Mass 
spectrometric detection was performed using an Orbitrap Exactive (Thermo 
Fisher Scientific, Hemel Hempstead, U.K.) within the mass range m/z 70 – 1400 
in polarity switching mode (Creek et al., 2011). 
Chromatographic peak selection and metabolite identification were done using 
XCMS/Ideom/MzMatch analysis pipeline (Creek et al., 2011; Creek et al., 2012; 
Scheltema et al., 2011), and peak intensities were normalized by protein 
content as measured using the Bradford assay (Compton and Jones, 1985). 
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Chapter 3. Temporal sequence gene expression 
of MSCs on NSQ50 surface 
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Summary 
It has been previously established that the NSQ50 surface is osteogenic inducing 
MSCs commitment to osteoblast differentiation (Dalby et al., 2007d). This 
chapter introduces the functional relationship of temporal gene expression 
patterns and MSC fate determination on the NSQ50 surface. In the methodology 
and the experiment design, I will discuss the fitness of SYBR Green quantitative 
real time PCR (qRT-PCR) for quantifying gene expression, and genes assessed 
according to their functions demonstrated in previous research (Boskey, 1998; 
Denhardt et al., 2001; Wan et al., 2010). The results presented include the 
temporal expression pattern of osteoblast marker genes (ALP, OPN and OCN) 
encoding bone cell ECM components for hMSCs on the NSQ50 surface compared 
to control. Experimental data demonstrates hMSC osteogenic commitment on 
the NSQ50 surface is transcriptionally controlled. Protein expression of key genes 
to confirm the gene expression pattern is also shown and bone nodule formation 
is observed at longer time points. Finally, a discussion of the roles of 
transcription factors, the functions of osteoblast marker genes and the possible 
transition points of hMSC osteogenic commitment is presented and conclusions 
drawn.  
3.1  Introduction 
The fate of MSC populations is determined by their intrinsic characteristics and 
microenvironmental factors which govern MSC populations’ gene expression at 
very early stage and through their differentiation toward a specific lineage. 
Global gene expression profile of MSC populations shows that MSCs multilineage 
differentiation involves selective gene expression (Baksh et al., 2004). To keep 
multipotentiality, promiscuous genes are expressed in uncommitted MSCs, which 
characterize diverse lineages actively expressed. Upon extrinsic stimulation, 
certain groups of genes are selectively suppressed and those responsible for a 
lineage specific phenotype are activated, resulting in tissue specific 
differentiation (Figure 3.1)(Song et al., 2006). 
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Figure 3.1 The selective mode of gene expression in MSC multilineage 
differentiation. 
(A) Principal component analysis of global gene expression. 
Differentiated cells (AD: Adipocytes, CH: Chondrocytes, OS: 
Osteoblasts) exhibited a significantly different global gene 
expression profile compared with undifferentiated MSCs and 
dedifferentiated cells (De-AD, De-CH, and De-OS). (B) Venn 
diagrams showing the genes that changed their expression levels 
during differentiation and dedifferentiation processes by at least 
twofold (p < 0.05). (Picture taken from Song et al., 2006). 
The study on MSC commitment development shows that multipotent MSC 
undergo asymmetric division to give rise to multipotent precursors and these 
precursors are under transcriptional control to symmetrically divide into 
unipotent precursors that eventually differentiate into tissue specific lineage 
(Baksh et al., 2004). 
For the osteoblast differentiation, a classic model was established by Lian and 
Stein (Lian and Stein, 1992). In this model it was proposed that the development 
of the osteogenic phenotype couples with a sequence of gene regulations and 
expressions. These genes were identified as cell cycle and growth genes c-fos 
and/or C-MYC, genes encoding ECM proteins, (i.e. ALP, OPN and OCN). The 
temporal sequence expression of these genes defined three principal periods of 
osteoblastic phenotype development (i.e. proliferation, ECM maturation and 
mineralization). Two transition points are pivotal elements of this osteoblast 
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developmental process to support cell proliferation and differentiation. The first 
transition point occurs at the end of proliferation where cell cycle and growth 
genes are down-regulated, and genes encoding ECM proteins start to become up-
regulated. The second transition point is marked as ECM mineralization 
occurred. This osteoblast growth and differentiation model combined with other 
research implies the existence of temporal sequence gene expression and / or 
regulation controls for MSCs functional capabilities, (i.e. self-renew, osteogenic 
differentiation and osteoblast maturation) (Lian and Stein, 1992; Lian et al., 
2006; McMurray et al., 2011). 
Modification of biomaterial surfaces with well-defined nanoscale features, which 
mimic the structure of ECM can guide MSC linage specific commitment in terms 
of tissue engineering (Stevens and George, 2005). As described in section 1.6.1, 
previous work from our group demonstrates that the near square 50 surface 
(NSQ50) which has an offset of up to +/_ 50 nm in X and Y from a perfect square 
lattice arrangement of 120 nm diameter, 100 nm deep pits with 300 nm centre-
centre spacing can specifically promote MSC osteogenesis. The NSQ50 surface 
printed on biocompatible and biodegradable PCL is a noninvasive stimulator for 
MSC osteogenesis, hence providing an ideal tool to get insight into the underlying 
mechanisms of the MSC differentiation process in vitro. Thus, in this chapter the 
NSQ50 nanotopography is used to modulate the expression of genes directing and 
going through MSCs osteogenic differentiation over a time course. Aims were to: 
1. Assess temporal sequence of gene expression pattern during MSCs 
osteogenic differentiation on the NSQ50 surface. 
2. Identify key points at which MSC turn from stemness into the osteogenic 
lineage-specific commitment and differentiation. 
3.2 Methodology and experimental design 
To date, there are several methods that can be used for semi-quantitative and 
quantitative measurement of gene expression, from northern blot (Streit et al., 
2009), reverse transcription PCR (RT-PCR) (Riedy et al., 1995), quantitative real 
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time PCR (qRT-PCR) (Arya et al., 2005) to gene expression microarray (Schulze 
and Downward, 2000) and the new development of next generation sequencing 
(NGS) (Mardis, 2008). Northern blot uses DNA or RNA hybridization probe 
complementary to part of or entire of gene sequence of interest. The probe is 
labelled either with radioactive isotopes or with chemiluminescent substrates to 
produce detectable signals. This method has been broadly used for gene 
detection, gene expression, function and localization in tissues, organs and their 
developmental stages due to its high sensitivity (Streit et al., 2009). However, 
compared to RT-PCR and / or qRT-PCR, this method has low sensitivity, suffers 
RNA sample degradation, and uses potentially more risky chemicals for the 
users. Compared to northern blotting and qRT-PCR, RT-PCR (or semi-quantitative 
PCR, as described in section 2.6.1) provides low accuracy data quantification. 
Thus, this method is only suitable for rapid, primary screening of bulk of samples 
or ‘on/off’ genes (Ferre, 1992). Gene expression microarray and NGS are 
powerful tools for global genes analysis, but are high cost. Due to the number of 
genes being investigated, the RT-PCR was used for primary screening and qRT-
PCR was applied for accurate gene expression detection and comparison in this 
work. 
3.2.1 Quantitative real time PCR (qRT-PCR) 
3.2.1.1 Taqman and SYBR Green qRT-PCR 
QRT-PCR is, nowadays, widely applied in research and clinical diagnosis for gene 
detection, mutation and gene expression comparison as it is a powerful, 
sensitive and accurate method for quantification of RNA expression. This method 
allows for the direct measurement of PCR products during the exponential phase 
of a PCR reaction and combines the amplification and detection in one single 
step. This technology is a fluorescence - based reverse transcription PCR system, 
and many methods have been developed in the last couple of decades. 
The fluorescence - based qRT-PCR reporter system can be classified into two 
principal groups based on fluorescent agent used and the specificity of PCR 
product detection: DNA binding dyes and Fluorophore-labelled oligonucleotides. 
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There are a variety of commercial available DNA binding dyes for PCR product 
detection, including SYBR Green I (Ririe et al., 1997), SYBR Green Gold (Tuma et 
al., 1999), SYTO (Monis et al., 2005), and EvaGreen (Wang et al., 2006). These 
dyes bind to doubled strand DNA (dsDNA) resulting in increase in fluorescent 
signal that can be measured in the extension phase of each PCR cycle (Wittwer 
et al., 1997). Among these, the SYBR Green I is the most commonly used in qRT-
PCR. SYBR Green I is undetectable fluorescence when it is in its free form. In the 
PCR process, the fluorescence emission is propagated with the increase of PCR 
product as SYBR green dye binds to dsDNA (Figure. 3.2A and B). The major 
drawback of SRBR Green qRT-PCR is that SYBR Green qRT-PCR has less specificity 
as SYBR Green dye can bind to any dsDNA including nonspecific PCR products, 
primer-dimers, at the same time it binds to specific PCR product in amplification 
process. However, this problem can be handled in a couple of ways: (1) carefully 
designing primers and optimizing reaction conditions that can minimize the 
formation of primer dimers. (2) Nonspecific PCR products and / or primer dimers 
can be distinguished from specific PCR product by analyzing the melting curve. 
Once melting curves are set up, the fluorescence signal can be acquired above 
the dimer melting temperature (Tm) and below specific PCR product Tm. 
The fluorophore-labelled oligonucleotides are small fluorophore molecules 
attached to oligonucleotides servicing as probes for the detection of PCR 
product. In general, these probes use two types of fluorophore molecules, the 
reporter and quencher which are within specific distance (10 to 100 Å), through 
fluorescence resonance energy transfer (FRET). The emitted fluorescence from 
reporter fluorophore transfers to the quencher fluorophore. There are many 
these probes in commercial market (Navarro et al., 2015), the Taqman probe is 
a typical and commonly used in qRT-PCR. Taqman probe is a dual-labeled probe 
flanked by a fluorescence reporter dye at the 5’ end and a quencher dye at the 
3’ end. As long as the probe is in its free form, or annealed on its 
complementary sequence on target template, the reporter dye and quencher 
dye are intact and the fluorescence signal emission from the reporter dye is 
absorbed by the quenching dye through FRET (Clegg, 1992). In the Taqman PCR 
extension phase, Taq DNA polymerase, which possesses the 5’  3’ exonuclease 
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activity, cleaves the 5’ end nucleotides of the Taqman dual-labeled probe and 
separates reporter and quencher dyes, resulting in an increase of reporter 
fluorescence emission. This process occurs in every cycle and does not interfere 
with the exponential accumulation of PCR products (Wong and Medrano, 2005) 
(Figure. 3.2C and D). 
SYBR Green qRT-PCR can be used with any pair of primers for any target of 
interest, this makes it less expensive than Taqman probes. Currently, the market 
price of one SYBR Green qRT-PCR assay is only 1/5 of a Taqman assay. Moreover, 
SYBR Green qRT-PCR provides high comparable results in gene expression 
measurement to data gained with Taqman qRT-PCR, as long as specific primers 
are designed and primer-dimers are minimized (Arikawa et al., 2008).  
A
B
C
D
	  
Figure 3.2 Fluorescent chemistries used in TaqMan and SYBR Green qRT-
PCR. 
(A) SYBR Green I dyes that are free in the PCR reaction do not emit 
a fluorescent signal. (B) Once SYBR Green I dyes bind to the dsDNA, 
target fluorescent signal occurs. (C) In Taqman, primers and probe 
anneal to the target but fluorescent signal does not occur due to 
the proximity between fluorophore and quencher. (D) During the 
PCR extension phase, the probe is cleaved by Taq Polymerase. 
Thereby, fluorophore and quencher are separated, allowing 
fluorescence emission from the report dye (Picture modified from 
(Giulietti et al., 2001).	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3.2.1.2 Three modes of SYBR Green qRT-PCR 
To quantify the results obtained from real time qRT-PCR, three modes of 
quantification are commonly used which are; the absolute standard curve 
method, the relative standard curve method and the comparative method. The 
absolute standard curve method is used for quantifying absolute RNA copy 
numbers in a sample. It needs more RNA sample to amplify the genes of interest, 
which are then used for making standard curves. The main drawback of this 
method is time and material consuming, especially for multiple gene 
quantification. The comparative method is the simplest way to quantify amount 
of RNA. However, this mode needs the same PCR reaction efficiency (or a 
difference of less than 10%) of sample RNA as of endogenous control gene for 
accurate measurement. In practice, it is almost impossible for multiple genes of 
interest to have the same PCR efficiency as the endogenous control gene. 
Relative standard curve method was used in this work to compromise for the 
drawbacks of the absolute and comparative methods (Larionov et al., 2005). The 
relative standard curve method uses a set of relative standards derived from any 
stock cDNA containing appropriate target genes. The target gene quantity is 
determined by interpolating from standard curve.  
3.2.1.3 Endogenous control gene GAPDH 
Quantitative gene expression data are often normalized to the expression levels 
of endogenous control genes whose expression remains constant in the cells or 
tissues under investigation. GAPDH is one of the most commonly used 
endogenous control gene in comparisons of gene expression (Gorzelniak et al., 
2001) and it is widely used for bone marrow derived stem cells research (Ponte 
et al., 2007) (Raaijmakers et al., 2002). To investigate whether GAPDH as 
endogenous control suits this work, the expression of GAPDH mRNA was 
measured in a course for MSCs cultured on the NSQ50 and planar surfaces. The 
expression of GAPDH was constant during MSC osteogenic lineage specific 
commitment. Significant differences of GAPDH expression in different time 
points and samples were not observed (Figure 3.3). 
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Figure 3.3 Ct value of GAPDH measured for MSCs cultured on NSQ50 and 
planar surfaces at different time points. 
GAPDH expression levels are constant during NSQ50 surface induced 
osteogenic process. The graph illustrates that there is no significant 
change in the expression of GAPDH on NSQ50 and planar surfaces at 
different time point. 
3.2.2 Experimental design 
3.2.2.1 Assessment of bone marrow derived mesenchymal stromal cells 
Bone marrow derived MSCs without surface antigen markers selection are a 
heterogeneous cells population that contains stem cells, multipotent precursors 
and uncommitment precursors as well as mature cells. Therefore, these cells 
must first be assessed to confirm that they were not in a lineage specific 
commitment state before using them as cell resources to investigate the 
temporal sequence of gene expression for osteo specific differentiation on the 
NSQ50 surface.  
86	  
	  
A B
C D
 
Figure 3.4 MSCs expanded in tissue culture flask negatively express tissue 
specific markers after two passaging. 
Immunostaining for (A) myod (muscle), (B) sox9 (cartilage), (C) 
pparg (fat) and (D) RUNX2 (bone) (red: actin, blue: nuclear, green: 
tissue specific markers). 
The assessments were carried out by immunostaining using tissue specific 
transcription factors which putatively are the earliest markers of tissue specific 
commitments (i.e., myod for myogenesis, RUNX2 for ostegenesis, pparg for 
adipogenesis and SOX9 for chodrogenesis)  before they seeded on the test 
surface. The negative expression of these markers indicated that MSCs maintain 
their uncommitted state after expansion, and can be used for the follow-up 
experiments (Figure 3.4). 
3.2.2.2 Work flow of gene expression measurement 
To investigate the temporal sequence of gene expression pattern for NSQ50 
induced MSCs osteogenic differentiation, the experiment was designed to 
produce gene expression comparison for MSCs on the NSQ50 surface to those on 
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planar control surface. 1 x 104 MSCs were seeded on NSQ50 modified PCL and 
planar PCL (at given surface roughness 0.5 nm) separately, and follow-up 
experiments were carried out in parallel (Figure 3.5). Three biological replicates 
were carried out for all experiments (i.e., N=3, N refers to MSCs from different 
donors bone marrow). Data was analyzed by analysis of variance (ANOVA) using 
GraphPad 5 software, and the final gene expression results are presented in fold 
change after compared to planar control. 
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Figure 3.5 Diagram of parallel work flow for gene expression measurement. 
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3.2.2.3 Genes and time points chosen for temporal sequence gene 
expression 
MSCs isolated from human bone marrow maintain their multipotent property 
after one or two passages culture and to maintain a highly proliferative 
phenotype. Therefore, seeded onto osteogenic materials, we may characterize 
expression of cell growth and proliferation genes at the earliest stages of the 
culture on the NSQ50 surface with osteogenic marker genes expression expected 
to follow the down-regulation of such proliferative genes. However, osteogenic 
marker genes are regulated by specific transcription factors. Thus, the order of 
genes being examined was designed to capture proliferation genes, osteogenic 
transcription factors and finally osteogenic markers (table 3.1). 
Gene expression was then validated at protein level. In this work, key proteins 
expression including RUNX2, OPN and OCN was assessed by western blot and / or 
immunostaining using their specific antibodies.  
To confirm mature osteoblast phenotype occurred on NSQ50 after the osteogenic 
markers were observed, bone nodule formation was assessed using Alizarin red 
staining (described in section 2.10). 
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Table 3.1 Genes associated with MSCs functional relationship between 
proliferation and osteogenic differentiation. 
Gene name Gene function References 
C-MYC Cell growth and 
proliferation regulation. 
(Park et al., 2012), (Sawada 
et al., 2006). 
RUNX2 Osteogenic transcription 
factor regulating osteogenic 
marker genes for pre-
osteoblast commitment. 
(Ducy et al., 1997), (Komori 
et al., 1997), (Zheng et al., 
2004). 
OSX Osteogenic transcription 
factor regulating osteogenic 
marker genes for mature 
osteoblast commitment. 
(Nakashima et al., 2002), 
(Nakashima and de 
Crombrugghe, 2003), (Tu et 
al., 2006). 
ALP An ectoenzyme involved in 
the formation of 
hydroxyapatite of bone 
matrix. 
(Whyte, 1994), (Boskey, 
1998), (Buchet et al., 2013). 
OPN Non-collagenous protein 
secreted by osteoblast 
cells, expressed during 
bone matrix formation and 
mineralization. Also 
contains an RGD group and 
is involved in cell 
adhension. 
(Pedraza et al., 2008), 
(Giachelli, 2001), (Denhardt 
et al., 2001) 
OCN An osteoblast specific 
protein, binding to 
hydroxyapatite in mature 
osteogenisis. 
(Ducy et al., 1996), (Wang et 
al., 2007), (Wan et al., 
2010). 
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3.3 Results 
3.3.1 Effect of NSQ50 topography on C-MYC expression  
C-MYC is a proto-oncogene encoding transcription factor that supports cell 
growth and proliferation in many cell types, including MSCs derived from human 
bone marrow and hematopoietic stem cell (Sawada et al., 2006). C-MYC 
expression is switched on and increased when cells are in growth and 
proliferation stage, and switched off while cells start to differentiation (Deng et 
al., 2008). 
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Figure 3.6 Gene expression analysis of C-MYC in MSCs on NSQ50 compared 
to those on planar control. 
Relative qRT-PCR shows C-MYC expression on NSQ50 is almost 
unchanged compared to those on planar control before day 5. 
Significant down-regulation of C-MYC on NSQ50 was observed by 
day 5. (N=3, ± SD) ANOVA analysis, * p value < 0.05. 
The expression of C-MYC in cells on NSQ50 was measured using qRT–PCR after 
MSCs had been cultured on the NSQ50 and planar control from 1 day to 5 days. 
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The relative expression of C-MYC on the NSQ50 surface compared to on planar 
surface is shown in Figure 3.6. At day 1 and day 2, expression of C-MYC on NSQ50 
was roughly the same as for cells on the planar surface. After day 3, expression 
of C-MYC on the NSQ50 surface was decreased and significantly suppressed 
relative to planar surface was observed at day 5. 
3.3.2  RUNX2 temporal sequence expression pattern during NSQ 
50 induced MSC osteogenic differentiation 
RUNX2 is a master osteogenic transcription factor regulating osteoblast 
commitment and osteogenic differentiation of mesenchymal stromal cells (Deng 
et al., 2008; Ducy et al., 1997). RUNX2 temporal sequence expression pattern in 
MSCs cultured on NSQ 50 surface was examined by qRT-PCR (Figure. 3.7). 
The expression of RUNX2 in nanotopographically induced MSCs was only slightly 
modulated after 3 days of culture relative to planar controls. However, the 
results showed that RUNX2 was about 2 to 3 fold enriched in MSCs on the NSQ50 
surface compared to those on planar surface at days 5 and 7, and peaked at day 
5. RUNX2 then gradually decreased and showed no difference to the planar 
control at day 13. The up-regulation of RUNX2 indicated that the NSQ50 surface 
induced MSCs lineage specific commitment and was osteogenic. However, the 
data also demonstrated that the master osteogenic transcription factor was 
induced by NSQ50 in a transient manner and the up-regulation only occurred at 
the early stage of MSC osteogenic lineage commitment. 
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Figure 3.7 Temporal sequence gene expression analysis of RUNX2 in MSCs 
on NSQ50. 
The fold change of RUNX2 in MSCs on NSQ50 compared to those on 
planar controls were assessed by qRT-PCR for cells cultured from 3 
to 13 days. The expression of RUNX2 was significantly up-regulated 
at day 5 and day 7, with the peak at day 5. After 7 days cell 
culture, RUNX2 gradually decreased to an equal level to that on 
planar control at day 13. (N=3, ± SD) ANOVA analysis, ** p < 0.01, 
*** p < 0.001. 
3.3.3 Osterix (OSX) temporal sequence expression pattern 
during NSQ 50 induced MSC osteogenic differentiation 
NSQ50 induced MSC osteogenesis showed RUNX2 was significantly up-regulated at 
the early stages of MSC osteoblast lineage commitment (day 5 and 7). To test 
whether OSX expression is required in NSQ50 surface induced MSC osteogenesis, 
the temporal expression pattern of OSX was assessed by qRT-PCR from time 
points 7 to 20 days (Figure 3.8). The data showed that OSX expression was 
gradually up-regulated before day 11, and was significantly abundance at days 
11 and 13 with about three fold enrichment comapred to cells on planar control. 
Then reduced until it was statistically the same as the planar control at day 20. 
The temporal expression pattern of OSX was similar to that of RUNX2 with time 
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course shifted on, suggesting the NSQ50 induced MSC osteogenesis requires both 
osteogenic transcription factors, RUNX2 and OSX, and potentially demonstrating 
that MSC osteogenic differentiation on the NSQ50 surface shares the same 
transcriptional control of bone development in vivo. 
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Figure 3.8 Temporal gene expression analysis of OSX in MSCs on NSQ50. 
The fold change of OSX in MSCs on NSQ50 compared to those on 
planar control were assessed by qRT-PCR for cells cultured 7 days 
to 20 days. The expression of OSX shows a wave pattern in which 
OSX gradually increased and peaked at day 11 and then gradually 
decreased to an equal level of that on planar control at day 20.  
Significant increases of OSX on NSQ 50 was observed at day 11 and 
day 13. (N=3, ± SD) ANOVA analysis,* p < 0.05, *** p < 0.001. 
MSC differentiation into mature osteoblasts is a multistage process which is 
controlled at transcriptional level by a number of regulatory factors. Besides 
RUNX2 and OSX, some homeodomain proteins (HDs), such as MSX2 and DLX5 
regulate osteoblast differentiation by interacting with RUNX2 and / or OSX. 
Moreover, OSX expression is either dependent on or independent of RUNX2. The 
RUNX2-independent expression of OSX is mediated by either MSX2 or DLX5 (Liu 
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et al., 2007a; Matsubara et al., 2008). To test whether OSX was controlled by 
RUNX2 or not, gene expression of MSX2 and DLX5 was assessed using qRT-PCR for 
cells cultured on the NSQ50 surface and planar control for 9 days immediately 
prior to OSX up-regulation (Figure 3.9). The data, after comparing to planar 
control showed that the expression of MSX2 and DLX5 were not significantly 
changed, indicating these two HD factors were not involved in the 
transcriptional regulatory network induced by the NSQ50 surface and indicating 
that OSX expression was RUNX2-dependent controlled. 
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Figure 3.9 Effects of NSQ50 surface on homeodomain factors MSX2 and 
DLX5. 
 MSCs were cultured on NSQ50 and planar surfaces for 9 days before 
expression of MSX2 and DLX5 on NSQ50 surface were assessed by 
qRT-PCR and compared to those on planar surface. MSX2 and DLX5 
were unchanged relative to planar control. (N=3, ± SD) ANOVA 
analysis, p > 0.05. 
3.3.4 ALP expression pattern during NSQ50 induced MSCs 
osteogenic differentiation 
ALP is an ectoenzyme secreted by osteoblast, which hydrolyzes extracellular 
pyrophosphate (PPi) to phosphate (Pi) leading to the formation of hydroxyapatite 
(HA) (Orimo, 2010). To examine whether NSQ50 surface induces MSC 
osteogenesis into mature osteoblasts, the expression of ALP assessed using qRT-
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PCR after the induction of osteogenic transcription factors RUNX2 and OSX. The 
expression of ALP was measured at days 11, 16 and 28. ALP expression on the 
NSQ50 surface showed significant increase at day 16 and continuously increased 
upto day 28 with a fold change up to about 40, compared to MSCs on planar 
control (Figure 3.10).  
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Figure 3.10 Gene expression analysis of ALP in MSCs on NSQ50. 
The fold change of ALP in MSCs on NSQ50 compared to those on 
planar control was assessed by qRT-PCR for cells cultured for 11, 16 
and 28 days. ALP on NSQ 50 was significantly up-regulated at day 16 
and about 40 fold change was observed at day 28. (N=3, ± SD) 
ANOVA analysis,* p < 0.05, *** p < 0.001. 
3.3.5 OPN expression pattern during NSQ50 induced MSC 
osteogenic differentiation 
Unlike ALP, which is expressed at the matrix maturation stage of osteoblast 
development, OPN, a phosphorylated sialic acid-rich non-collagenous protein 
secreted by osteoblast cells, expresses at both matrix maturation stage and at 
the onset of mineralization (Lian and Stein, 1992). OPN bridges osteoblast cells 
to their matrix minerals, as its amino acid sequence contains arg-gly-asp (RGD) 
which mediates  cell attachment (Bautista et al., 1994). The expression of OPN 
in MSCs cultured on the NSQ50 surface was measured and compared to those on 
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planar control at days 11, 16, 20 and 28 (Figure 3.12). ALP on NSQ50 showed 
significant increase at day 20 and continuously increased upto day 28 with fold 
change up to ≥100. 
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Figure 3.11 Gene expression analysis of OPN in MSCs on NSQ50. 
The fold change of OPN in MSCs on the NSQ50 surface compared to 
those on planar control was assessed by qRT-PCR for cells cultured 
from 11 to 28 days. OPN on NSQ50 was significantly up-regulated at 
day 20, and a ≥ 100 fold change was observed at day 28. (N=3, ± 
SD) ANOVA analysis,* p < 0.05, *** p < 0.001. 
3.3.6 OCN expression pattern during NSQ50 induced MSC 
osteogenic differentiation 
OCN is an osteoblast specific protein containing 3-gammacarboxy-glutamic acid 
residues (Gla). The gammacarboxylated form of OCN binds hydroxyapatite and is 
abundant in bone ECM (Kapustin and Shanahan, 2011). The expression of OCN in 
MSCs cultured on the NSQ50 surface was measured and compared to those of 
planar control through day 11 to day 28 (Figure 3.12). OCN showed no significant 
up-regulation until day 28 on the NSQ50 surface compared to control. 
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Figure 3.12 Gene expression analysis of OCN in MSCs on NSQ50. 
The fold changes of OCN in MSCs on NSQ50 compared to those on 
planar control was assessed by qRT-PCR for cells cultured 11 days 
to 28 days. OCN on NSQ50 was significantly up-regulated at day 28 
with a fold change about 5. (N=3, ± SD) ANOVA analysis, *** p < 
0.001. 
3.3.7 The validation of key genes expression 
Protein expression of master osteogenic transcription factor RUNX2 and ECM 
components of OPN and OCN in MSCs cultured on NSQ50 were assessed. The 
abundance of RUNX2 on NSQ50 was detected by both western blotting and 
immunostaining when cells cultured for 9 days (Fugure 3.13). Immunostaining of 
RUNX2, using RUNX2 specific antibody, showed RUNX2 was abundant on NSQ50 
surface (Figure 3.13A) and the expression of RUNX2 on planar surface (Figure 
3.13B) was almost null after 9 days cell culture. The enrichment of RUNX2 on the 
NSQ50 surface compared to that on planar surface was also observed using 
Western blotting. The same amount of total proteins (10 µg) from cells on NSQ 
50 surface and planar surface were separated on a SDS-PAGE gel. RUNX2 was 
detected using its specific antibody for cells cultured on the NSQ50 surface 
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(Figure 3.13C) and the same amount of total protein loaded into wells of SDS-
PAGE gel was controlled by GAPDH (Figure 3.13D). Both immunostaining and 
Western blotting showed the same result with RUNX2 being most abundant on 
the NSQ50 surface and negligible on the planar surface after cells were cultured 
for 9 days, which confirmed the gene expression of RUNX2 assessed in section 
3.4.2. 
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Figure 3.13 RUNX2 is abundant in cells cultured on the NSQ50 surface for 9 
days. 
MSCs cultured on NSQ50 and planar surface for 9 days. 
Immunostaining using anti-RUNX2 showed RUNX2 was abundant in 
cells cultured on NSQ50 surface (A) compared to cells on planar 
surface (B). (Green: RUNX2, Red: actin, Blue: DAPI). The overall 
expression of RUNX2 was also detected using Western blot. (C), 
again illustrating greater expression on NSQ50 while GAPDH levels 
remained the same (D).  
The abundance of OPN and OCN on NSQ50 surface compared to that on planar 
control was observed using immunostaining after 28 days of culture (Figure 
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3.14). OPN (Figure 3.14A, green) and OCN (Figure 3.14C, green) expression on 
the NSQ50 surface are observed while expression remained negligible on the 
planar control (Figure 3.14B: OPN and D: OCN). The protein expression of OPN 
and OCN were therefore in agreement with their gene expression, which is 
described in section 3.3.5 and section 3.3.6 respectively. 
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Figure 3.14 OPN and OCN are abundant in cells cultured on NSQ50 surface 
for 28 days. 
MSCs cultured on NSQ50 and planar surface for 28 days. 
Immunostaining using anti-OPN showed OPN was abundant in cells 
cultured on the NSQ50 surface (A) compared to cells on planar 
control (B) (Green: OPN, Red: actin, Blue: DAPI). The over-
expression OCN was also detected on NSQ50 surface (C) compared 
to that on planar control (D) using anti-OCN (Green: OCN, Red: 
actin:, Blue: DAPI). 	  
3.3.8 The formation of bone nodules 
The formation of bone nodules characterized by calcium deposition in the ECM 
of osteoblast cell, indicates the presence of mature osteoblasts at the 
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mineralization stage (Lian and Stein, 1992). Calcium deposition of MSCs cultured 
on the NSQ50 surface after 32 days was observed using Alizarin red staining 
(Figure 3.15). After 32 days of cell culture, cells on the NSQ50 surface exhibited 
calcium deposition. 
	  
Figure 3.15 Calcium deposition by MSCs on NSQ50. 
MSCs cultured on the NSQ50 surface for 32 days were stained with 
Alizarin red. Bone nodule formation could be seen in vitro on the 
NSQ50 surface. 
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3.4 Discussion and conclusion  
3.4.1 The transcriptional control of MSCs on NSQ50 surface.  
In this chapter, the effects of the NSQ50 surface on expression of transcription 
factor C-MYC, RUNX2, OSX, MSX2 and DLX5 were investigated and it was seen 
that C-MYC expression was down-regulated at the early stage of cells cultured on 
NSQ50, while up-regulation of RUNX2 and OSX in a sequential manner was 
observed before osteoblast marker genes were induced. These data indicated 
that NSQ50 surface induced MSCs osteogenic differentiation and that this 
osteogenesis was transcriptionally controlled. 
C-MYC is a key regulator of cell growth and proliferation in many cell types. 
Over-expression of C-MYC drives cell proliferation and growth, inhibits cell 
differentiation and reduces cell adhesion. In contrast, down-regulation of C-MYC 
results in the inhibition of cell proliferation and growth, enhancement of cell 
differentiation and enlargement of cell adhesion (Aizawa et al., 1999). Previous 
studies have also demonstrated that C-MYC exerts regulatory effects on MSC 
proliferation and growth. For example, C-MYC was down-regulated by the up-
regulation of TGFs and their receptors via SMAD protein, resulting in MSC 
proliferation being arrested (Sawada et al., 2006). C-MYC was also characterized 
as a marker gene for osteoblast proliferation in osteogenic culture system (Lian 
and Stein, 1992). The expression of C-MYC in MSCs cultured on the NSQ50 
surface rapidly decreased after day 3 of culture compared to MSCs on planar 
surfaces, and was reduced to about half of those on planar control at day 5. 
Statistical analysis using ANOVA showed the reduction at day 5 was significant (p 
< 0.05). This data suggested that proliferation activity of MSCs on NSQ 50 was 
repressed. 
The down-regulation of C-MYC on NSQ50 was coupled with the up-regulation of 
the osteogenic master transcription factor RUNX2 and subsequently OSX. RUNX2 
expression was in a wave pattern in the time frame of day 3 to day 13, 
significant enrichment of RUNX2 on NSQ50 compared to planar surface was 
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observed at days 5 and 7. The significant up-regulation of RUNX2 was coincident 
with down-regulation of C-MYC on NSQ50 at day 5 suggesting that MSCs on the 
NSQ50 surface had initiated osteoblast commitment. However, the up-regulation 
of RUNX2 was not persistent and gradually decreased to the same level as that 
of MSCs on the planar surface. The temporal wave expression pattern of RUNX2 
suggested that the effect of RUNX2 on its osteogenic transcriptional control is 
stage-dependent. Previous studies on RUNX2-overexpression in mice 
demonstrated that enriched expression of RUNX2 at late stage osteoblastic 
development in fact abrogated bone formation and enhanced bone resorption 
(Liu et al., 2001). Therefore, the up-regulation of RUNX2 at an early stage  
(rather than late stage) promised the initiation of osteogenic lineage specific 
commitment of MSCs on NSQ50 surface but without disruption of bone formation 
at later stages. Furthermore the observation of enriched expression of RUNX2 
coincident with down-regulation of C-MYC at day 5 also supported the role of 
RUNX2 in NSQ50 surface induced osteogenic differentiation. RUNX2 null cells 
have been shown to exhibit higher proliferation rates than wild type cells 
(Galindo et al., 2005). Also, RUNX2 has been demonstrated to target CDK 
inhibitors p21 and p27 in order to promote cell cycle exit (Galindo et al., 2005; 
Thomas et al., 2004). Therefore, RUNX2 was the earliest switch molecule to turn 
MSCs towards osteogenic differentiation on the NSQ50 surface. 
RUNX2 expression is necessary for the initiation of osteoblast differentiation. 
However, RUNX2 alone is not sufficient for mature osteoblast development. 
Previous studies have demonstrated that OSX was required for osteoblast 
differentiation, and acted downstream of RUNX2 (Matsubara et al., 2008; 
Nakashima et al., 2002). RUNX2 and OSX may play different roles in the 
regulation of osteogenic differentiation and bone formation. Unlike RUNX2-
deficient lethal phenotype, OSX-deficient mice showed perinatal lethal 
phenotype due to  nonmineralized bone formation, suggesting OSX functionalizes 
mature osteoblast development (Zhang, 2010). In NSQ50 surface induced 
osteogenic differentiation, up-regulation of OSX was observed downstream of 
RUNX2, which filled in the temporal gap between RUNX2 expression (at day 5 
and 7) and induction of osteoblasts marker genes (ALP, OPN and OCN, initiated 
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at day 16). Further analysis indicated that OSX expression was RUNX2 
dependent, as the induction of MSX2 and DLX5 on the NSQ50 surface was not 
observed. These data suggested that NSQ50 surface induced osteogenic 
differentiation required regulation from both RUNX2 and OSX, and these two 
transcription factors acted at temporal, sequential manner. 
3.4.2 Bone marker genes expression on NSQ50 surface 
Bone tissue specific marker genes (ALP, OPN, and OCN) are downstream of, and 
regulated by osteogenic transcription factors. These bone markers are secreted 
by osteoblasts in osteogenesis. Expression of ALP and OPN on the NSQ50 surface 
was significantly enhanced at day 16 and were highly expressed at day 28 (about 
a 40 fold change for ALP and over 100 fold change for OPN). OCN was also 
significantly induced at day 28, however its expression level (about 4 fold 
change) was lower than those of ALP and OPN. MSCs are known to form super-
mature adhesions (>5 µm long) on the NSQ50 surface (Biggs et al., 2009). This 
could perhaps explain the use of OPN rather than OCN as OPN contains the RGD 
motif required for integrin ligation and hence would aid focal adhesion 
formation. 
3.4.3 Temporal sequence gene expression couples with MSC 
osteogenic differentiation on NSQ50 surface 
MSCs cultured on the NSQ50 surface showed repressed expression of C-MYC by 
day 5, concomitant with up-regulation of RUNX2, indicating MSCs growth and 
proliferation were being arrested and the cells orientated towards osteogenic 
lineage specific commitment. The up-regulation of RUNX2 alone in a transient 
manner on the NSQ50 surface could lead MSCs to form other cell phenotypes, 
such as chondrocyte (Takeda et al., 2001). However, the subsequent induction 
of OSX by RUNX2 helps assure the osteoblastic lineage direction on the surface, 
because OSX is a more specific transcription factor in directing pre-osteoblast to 
mature osteoblast differentiation (Nakashima et al., 2002). Therefore, it is 
logical to interpret the temporal genes expression pattern on the NSQ50 surface 
as the different stages of MSCs osteogenic differentiation (Figure 3.16). It is thus 
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likely that the NSQ50 surface induces MSCs into a pre-osteoblast phase after 
cells have been cultured on the surface for about a week. The pre-osteoblasts 
were governed by the RUNX2 recruited OSX which led pre- and immature 
osteoblasts into mature osteoblasts and eventually a mineralization phase. The 
transit point (around a cell culture period on NSQ50 of 21 days) could be viewed 
as the immature osteoblast marker ALP had been significantly increased and OCN 
had started to be up-regulated. 
 
 
 
 
 
 
105	  
	  
runx2
MSCs	  and	  multipotent
precursors	  proliferation
osx Bone	  markers
Pre-­‐ and	  immature	  osteoblasts
The	  onset	  of	  
osteoblast	  commitment
The	  onset	  of	  
mature	  osteoblast
Mature	  osteoblasts
and	  mineralization
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28
2
25
50
75
80
100
120
runx2c-myc osx ocn alp opn
NAQ50 surface stimulation days
Ge
ne
s e
xp
re
ss
ion
 le
ve
l
A
B
 
Figure 3.16 Temporal sequence genes expression pattern functionalized 
NSQ50 surface induced osteogenic differentiation. 
 (A): The summation of temporal gene profile expression as 
reported individually in section 3.4.1 to 3.4.7. (B): According to 
gene expression pattern, the NSQ50 surface induced MSC 
osteogenic differentiation process can be viewed as three phases, 
the MSCs and multipotent precursors proliferation stage, the pre- 
and immature osteoblasts stage and the mature and mineralization 
stage. In general, MSCs were under transcriptional control before 
their progression into the mature osteoblasts phase. The transit 
point between proliferation and the pre-osteoblasts phase can be 
viewed as the onset of osteoblast commitment at which point 
RUNX2 was significantly up-regulated and C-MYC down-regulated. 
The transit point from pre-osteoblasts to mature osteoblasts 
occurred around 21 days after cells cultured on the surface, at 
which time the immature osteoblast marker ALP had been 
significantly up-re-regulated and the mature osteoblast markers 
OCN and OPN were starting to increase. 
3.4.4 The effect of planar control on osteogenic gene expression 
The biocompatible and biodegradable characterization of PCL rise the question 
that whether the up-regulation of osteogenic genes on the NSQ50 
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nanotopography was owing to the down-regulation of these genes on the planar 
surface or the alteration of the NSQ50 nanotopography by degradation of PCL, 
especially the gene fold change format used for the presentation of genes 
expression in this work.  
Study on transcriptome of MSCs on PCL by Sabine Neuss (Neuss et al., 2011) 
demonstrated PCL is osteoinductive polymer compared to tissue culture 
polystyrene. PCL moderately induces broader osteogenic genes expression and 
lead to osteogenic differentiation, indicating osteogenic genes in MSCs cultured 
on PCL planar surface would not be down-regulated. Furthermore, protein 
expression of the osteogenic genes on PCL planar surface and nanofeatures in 
this work and others (Mavis et al., 2009; Porter et al., 2009) also demonstrated 
that it is unlikely that the increased fold changes comparing genes expression 
level on nanofeature to those on planar surface were resulted from the down-
regulation of these genes by PCL substrate.  
PCL is one of the most slowly degradation polymer with a degradation time of 
the order of two years (Middleton and Tipton, 2000). Study on PCL degradation 
rate and its effect on 2D and 3D structures by Sung et al (Sung et al., 2004) 
demonstrated that the significant degradation of PCL was occurred after 28 days 
cell culture. Cell viabilities on the PCL scaffolds were not significantly decreased 
after 28 days compared to those on cell culture flask (TCPS). Moreover, PCL 
scaffolds morphology was relatively little change at 14 days, and appeared less 
affected at 28 days. 
The time period of gene expression investigation in this work was within 28 days, 
and most of work was in early response of MSCs to the NSQ50 nanotopography. 
Thus, the impact of PCL degradation to gene expression could be negligible. 
However, it should be notice here, for accurate demonstration of differential of 
the genes expression on the NSQ50 and planar surfaces, it would be better to 
present the gene expression level in MSCs on both NSQ50 and planar surfaces.      
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3.4.5 Conclusions 
The results presented here indicate that NSQ50 surface induced osteogenic 
differentiation is transcriptionally controlled in which RUNX2 plays a centre role 
to switch on osteoblast commitment and recruit OSX. The temporal gene 
expression pattern also suggests that OSX is a pivotal element for mature 
osteoblast formation. Results from the expression of bone tissue marker genes 
indicate that NSQ50 surface induced osteogenic differentiation requires OPN 
expression more than OCN as OPN protein contains RGD motif. This would aid 
super-mature adhesion formation and buildup of intracellular cytoskeletal 
tension required in osteogenesis (Engler et al., 2006; Kilian et al., 2010; McBeath 
et al., 2004).	   Generally, MSCs on the NSQ50 surface demonstrate a similar 
osteogenic differentiation pattern described by Lian and Stein (Lian and Stein, 
1992), but I add more detailed information on transcription factors in this study. 	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Chapter 4. Molecular mechanisms underlying 
osteogenesis of MSCs on NSQ50 
surface 
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Summary 
In Chapter 3, the temporal sequence of genes expression pattern and their 
relationship to MSCs osteoblast differentiation on the NSQ50 surface was 
established. This chapter describes the molecular mechanisms that regulate 
the cascade of events leading to MSC osteogenic differentiation on the surface. 
This chapter begins by introducing known osteogenic signalling pathways which 
have been attributed to the osteogenesis of MSCs. Interactions between 
osteogenic signalling pathways and the regulatory effects of miRNAs on 
osteogenesis of MSCs are explored. The results presented include the findings 
of the roles of BMP2 signalling in NSQ50 induced osteogenic differentiation of 
MSCs. Further analysis indicates BMP2 signalling exerts the effect on 
osteogenesis of MSCs on NSQ50 surface via a SMAD dependent pathway. The 
effects of BMP2 signalling on other regulatory events are explored, including 
the physical and functional co-localization with integrins, and the regulation on 
miR-23b which targets RUNX2.  
4.1 Introduction 
MSCs fate determination and subsequent lineage specific differentiation are 
transcriptionally controlled. Multiple signalling molecules and pathways have 
been identified to modulate osteogenic transcription factors and their regulatory 
network in osteogenesis of MSCs. Studies have demonstrated the instrumental 
role of BMP2 signalling pathway in regulation of MSC osteogenic differentiation, 
in which the canonical pathway regulates the osteogenic transcription factor 
RUNX2 via SMAD proteins (Javed et al., 2009; Phimphilai et al., 2006), whereas 
the BMP non-canonical pathway triggers interaction of TAK1 and p38 MAPK to 
phosphorylate RUNX2 (Greenblatt et al., 2010) resulting in osteogenic 
differentiation (pathway details described in section 1.5.1). Studies have also 
evidenced that Wnt signalling can be involved in the transcriptional regulatory 
process of osteoegnic differentiation and bone formation. The canonical Wnt 
pathway regulates RUNX2 by the interaction of the β-catenin/LEF/TCF complex 
with the RUNX2 promoter (Gaur et al., 2005). Wnt signalling is initiated by the 
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binding of Wnt proteins to the Fz receptor and its co-receptor LRP5 (Hay et al., 
2005). Interestingly, LRP5 itself has been identified as crucial player in 
osteogenic differentiation and bone formation, and disruption of LRP5 activation 
results in suppression of Wnt signalling (Ai et al., 2005; Boyden et al., 2002). 
Studies on signalling pathways involved in MSC osteogenesis and bone formation 
have demonstrated the interplay of BMP signalling with other osteogenic 
pathways at different regulatory levels. BMP2 induces Wnt signalling activity in 
osteoblast differentiation of C2C12 cells via the interaction of the SMAD1/4 and 
β-catenin/LEF complexes (Nakashima et al., 2005). Fibroblast growth factor 
(FGF) signalling was reported to increase BMP2 and TGFβ1 expression in bone 
formation through modulation of RUNX2 activation (Choi et al., 2005; Naganawa 
et al., 2008). BMP signalling and the notch pathway have synergistic effects on 
bone formation: activation of notch signalling enhances BMP2-induced ALP 
activation (Nobta et al., 2005; Tezuka et al., 2002), whereas BMP2 and TGFβ 
regulated notch signalling induce genes related to signal transduction, including 
hey1 and hes1 in osteoblast differentiation (de Jong et al., 2004). Similar 
synergy is found between BMP2 and integrins in human osteoblasts. BMP2 
stimulates the levels of αv-containing (αvβ) integrins on osteoblast surface and 
enhances cell adhesion to the ECM, and blocking of integrins reduces BMP2-
induced SMAD signalling and subsequent osteogenic phenotype (Lai and Cheng, 
2005). 
Non-transcriptional regulation of osteogenesis of MSCs has been recently 
emerged with findings of microRNA (miRNA) regulatory functions in diverse 
pathways (Ambros, 2004; Hassan et al., 2010; Huang et al., 2010a). MiRNAs are 
endogenous, ~22 nucleotide non-coding RNAs. These small RNAs bind to the 3’-
untranslated region (3’-UTR) of their target messenger RNAs (mRNAs), including 
transcription factors, receptors, and kinases to negatively regulate the targets 
mRNA stability and/or translation (Sun et al., 2010). MiRNAs complementarily 
bind to their targets at highly conserved seed regions. These regions are miRNA 
segment sequences exactly matching the complementary sequences within the 
3’UTR of the targets, and are usually located at around the nucleotide 2-8 
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position. With this shorter sequence, one miRNA may target different genes, and 
one gene may be regulated by different miRNAs.  
The regulation of miRNAs on osteogenic differentiation of MSCs has been found 
to occur for different osteogenic genes in different pathways. MiR-204/211 and -
133 target RUNX2 in MSCs resulting in adipocyte differentiation and inhibition of 
osteoblast differentiation (Huang et al., 2010a; Li et al., 2008). MiR-26 and miR-
135 repress SMAD1 and SMAD5 translation, blocking the BMP-SMAD pathway and 
subsequently inhibiting osteogenic differentiation in adipose tissue derived MSCs 
(Luzi et al., 2008) and the C2C12 cell line (Li et al., 2008). MiR-141 and -200a 
were found to be involved in the regulation of preosteoblast differentiation by 
targeting their common gene DLX5 (Itoh et al., 2009). These findings 
demonstrate the negative regulatory effects of miRNAs on osteogenic 
differentiation of MSCs. However, some miRNAs target inhibitors of 
osteoblastagenesis and thus exert positive effects on osteogenic differentiation 
of MSCs. A typical example is miR-29b that targets multiple inhibitors of 
osteoblast differentiation, including histone deacetylase 4 (HACD4), activin A 
receptor II A (ACVR2A) and beta-catenin-interacting protein 1 (CTNNBIP1), and 
thereby enhances osteoblast differentiation (Li et al., 2009). 
MSCs growth on the NSQ50 surface results in an osteogenic phenotype. Studies to 
understand the process by which cells interpret the nanotopographical cues have 
been focused on focal adhesion interactions and the resulting changes in 
intracellular tension. It has been proposed that nanotopography can modulate 
integrin clustering and focal adhesion formation and that this, in turn, regulates 
MSC differentiation (Arnold et al., 2004; McMurray et al., 2011; Schvartzman et 
al., 2011; Tsimbouri et al., 2012). Such alterations may result in the modulation 
of interfacial forces to guide cytoskeletal organization and the organization of 
transmembrane receptors, and thus may subsequently regulate the intrinsic 
signalling of the cells (Ingber, 2006). This may occur through, for example, FAK 
and G-proteins feeding into signalling cascades such as the ERK 1/2 pathway 
(Kilian et al., 2010). However, other key pathways and regulatory events which 
involved in osteogenesis of MSCs have been less well studied in relation to 
nanotopography-driven osteogenesis. Thus, this chapter aims to: 
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1. Identify major signalling molecules and pathways which regulate osteogenesis 
of MSCs on NSQ50 surface. 
2. Dissect the relations of these molecules and pathways. 
4.2 Methodology 
Adhesive cells perceive extrinsic signals (biochemical and/or biophysical) in the 
ECM via their transmembrane receptors (Stevens and George, 2005). To examine 
the molecular mechanisms of MSC response to the NSQ50 surface, 
transmembrane receptors of MSCs, as the transducer of nanotopographical cues 
to transmit the extrinsic signals into intracellular and subsequently guide MSCs 
to response, should be first explored.  
Signalling pathways will be examined in three ways: 
1. Signalling molecules or ligands expression: for example BMP2 for BMP 
signalling, vinculin for integrin signalling. 
2. Pathway mediator expression: for example SMADs, tab1 for BMP pathway, β-
catenin for Wnt pathway. 
3. Manipulating signalling pathways to see the response of RUNX2, which has 
been identified as the earliest osteogenic transcription factor in osteogenesis 
of MSCs in this project (chapter3) and others (Lian et al., 2006). 
The genes and/or proteins that were assessed in this chapter for the analysis of 
osteogenic signalling pathways related to the NSQ50 surface are listed in table 
4.1. Methods for the assessments are briefly introduced in each experiment, and 
further details are described in chapter 2. 
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Table 4.1 Genes and/or proteins investigated for the analysis of osteogenic 
signalling pathway in MSCs on NSQ50 surface. 
Gene/Molecule Name Functions Reference 
BMPR1A BMP signalling receptor (Kua et al., 2012) 
BMP2 BMP signalling ligand (Javed et al., 2009) 
SMAD1 and 5 BMP-SMAD pathway 
signalling mediators 
(Javed et al., 2009) 
Tab1 BMP non-SMAD pathway 
mediator 
(Greenblatt et al., 
2010) 
LRP5 Wnt signalling co-receptor (Gong et al., 2001) 
Β-catenin Wnt signalling mediator (Moon et al., 2004) 
Integrin α3, α4, αv, β1, 
β3, β5 
Membrane receptors for 
cell adhesion. 
(Kanchanawong et al., 
2010) 
vinculin Focal adhesion molecule (Ziegler et al., 2006) 
RUNX2 Osteogenic transcription 
factor 
(Ducy et al., 1997) 
OPN Osteoblast marker (Manolagas, 2000) 
miR-23a, -23b, -93, -203 MiRNAs targeting RUNX2 www.targetscan.org 
miR-96, -143 MiRNAs targeting OSX www.targetscan.org 
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4.3 Results 
4.3.1 Transmembrane receptor response to the NSQ50 surface 
4.3.1.1 Effect of the NSQ50 surface on integrins 
Integrins are the main transmembrane receptors which primarily link adherent 
cells to the ECM and modulate multiple intracellular signalling pathways to 
regulate cell adhesion, spreading, migration and other cellular functions in many 
cell types (Arnaout et al., 2005). Integrin binding with ECM components depends 
on the paring of α and β subunits and it is widely accepted that the paring of αv 
with β1/β3/β5 binds to the RGD motif in osteopontin and with β3/β5 binds to VN 
(Kilian et al., 2010), α3 with β1 binds to laminin (Hynes, 2002), and α4 with β1 
binds to VCAM and fibronectin in the ECM (Goessler et al., 2008). To test 
whether integrins are directly involved in the initiation of MSC osteogenic 
differentiation on the NSQ50 surface, the expression of integrins β1, β3, β5, α3, 
α4, αv on NSQ50 and planar surfaces at early stages of culture were investigated 
using qRT-PCR. Cells cultured on the NSQ50 and planar surface for 3, 5 and 7 
days were assessed (Figure 4.1). The relative amounts integrins transcripts on 
NSQ50 and planar surfaces were normalized to endogenous control gene GAPDH, 
and then comparisons were made and analysed using ANOVA to obtain the fold 
change of integrin transcripts on NSQ50 relative to those on planar surface. 
The integrin subunits β1, β3 and α3 were not induced by the NSQ50 surface 
when MSCs cultured on the surface for 3, 5, and 7 days compared to planar 
controls, indicating these integrins were not differentially expressed in MSCs 
osteoblast commitment on the surface. However, the up-regulation of integrins 
β5, α4, αv was noted at day 5. The up-regulation of both αv and β5 in MSCs on 
NSQ50 surface suggested a key role for VN in adhesion to the surface. Although 
the enrichment of α4, αv was observed, the β1 and β3 were not stimulated 
significantly by the surface up to 7 days, indicating MSCs on NSQ50 initially used 
VN for adhesion rather than fibronectin. The expression of αvβ5 pair also could 
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possibly implicate a rationale for the strong expression of osteopontin at the late 
stage of MSCs osteogenic differentiation observed in section 3.3.5 
 
Figure 4.1 The effect of NSQ50 surface on the expression of integrins in 
MSCs. 
mRNA fold change of integrins (itgs) β1, β3, β5, α3, α4, αv in MSCs 
on NSQ50 surface compared to those on planar surface was 
assessed by qRT-PCR for cells cultured at 3, 5 and 7 days. Itgβ5, 
α4, and αv on NSQ50 were significantly up-regulated, and about 4, 
4, 2.5 fold changes were observed respectively at day 5. The 
expression of itgβ1, β3 and α3 was not affected by the surface. 
(N=3, ± SD) ANOVA analysis,* p < 0.05, ** p < 0.01. Arrows on graphs 
show the control level. 
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4.3.1.2 Effect of NSQ50 surface on Wnt signalling 
Recent findings have clearly established the causal link between LRP5, a co-
receptor for Wnt proteins, and bone mass in human and mice (Boyden et al., 
2002; Gong et al., 2001). LRP5 regulates bone mass by determining MSC 
osteoblast commitment and / or osteoblast differentiation through the canonical 
Wnt pathway (described in section 1.5.2). To test whether Wnt signalling is 
implicated in the early events that initiate MSCs osteogenic differentiation on 
the NSQ50 surface, the expression of LRP5 and beta-catenin were examined at 3, 
5 and 7 days using qRT-PCR. The relative amounts LRP5 and beta-catenin 
transcripts on NSQ50 and planar surfaces were normalized to endogenous control 
gene GAPDH, and then comparisons were made and analysed using ANOVA to 
obtain the fold changes of LRP5 and beta-catenin transcripts on NSQ50 relative 
to those of planar surface (Figure 4.2A). The expression of LRP5 on the NSQ50 
surface did not show a significant difference from those on planar surface, 
indicating Wnt signalling receptor did not change in response to the NSQ50 
surface at the early stage of osteoblastogenesis. Moreover, the canonical Wnt 
pathway mediator, beta-catenin, did not change in response to NSQ50 at day 3 
and day 5 (Figure 4.2B). This helps to confirm that Wnt signalling did not 
influence the early events that initiate MSC osteogenic commitment and 
differentiation on the NSQ50 surface. 
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Figure 4.2 The effect of the NSQ50 surface on Wnt signalling at early stage 
MSCs osteogenic differentiation.  
Wnt protein co-receptor LRP5 and Wnt pathway mediator beta-
catenin were not affected by NSQ50 surface. (A): qRT-PCR targeted 
at mRNA of LRP5 at 3, 5, and 7 days showed insignificant fold 
change compared to those planar surfaces. (B): qRT-PCR targeted 
at mRNA of beta-catenin at 3 and 5 days showed insignificant fold 
change compared to those planar surfaces. (N=3, ± SD) ANOVA 
analysis,* p < 0.05, ** p < 0.01, *** p < 0.001. Arrows on graphs show 
the control level. 
4.3.1.3 Effect of the NSQ50 surface on BMPs receptor expression 
The essential role of BMP2 signalling for osteoblastic differentiation of MSCs and 
subsequent bone formation has been established. BMP2 triggers intracellular 
pathways through binding to its type I and type II transmembrane 
serine/threonine kinases receptors to form a ligand-receptor complex (Nohe et 
al., 2004). BMPR1A receptor possesses high binding affinity to BMPs, including 
BMP2, and recent studies indicate the BMPR1A receptor plays important roles for 
osteogenic differentiation of MSCs (Kaps et al., 2004; Kua et al., 2012).  
In this thesis, the effect of the NSQ50 surface on BMPR1A expression was 
assessed at different time points, starting from the first 24 hours to day 11 using 
qRT-PCR. The relative amounts BMPR1A transcripts on NSQ50 and planar surfaces 
were normalized to endogenous control gene GAPDH, and then comparison was 
made and analysed using ANOVA to obtain the fold change of BMPR1A transcripts 
on NSQ50 relative to those of planar surface (Figure 4.3). 
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BMPR1A expression in MSCs on the NSQ50 surface showed no significant 
difference from those on planar at first 2 days. Significant up-regulation was, 
however, observed at day 3 and day 5. Then, the expression levels of BMPR1A at 
day 7 and day 9 dropped back towards control levels. At day 11, BMPR1A 
expression on the NSQ50 surface was back to the same level as that on planar 
surface. It appears that BMPR1A expression on the NSQ50 surface shared the 
same pattern as RUNX2 (Figure 3.7), but the time course was shifted to be 
slightly earlier, i.e. just ahead of RUNX2 expression. This data indicates that the 
transmembrane serine/threonine kinases receptor was stimulated by NSQ50 
surface at an early stage of MSC osteogenic differentiation. 
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Figure 4.3 The effect of the NSQ50 surface on BMP receptor, BMPR1A at 
the early stages of MSCs osteogenic differentiation. 
Bone morphogenic proteins receptor, BMPR1A was measured by 
qRT-PCR to MSCs cultured on NSQ50 and planar surfaces for time 
course up to 11 days. MSCs response to NSQ50 surface with about 
2.5 folds change of BMPR1A mRNA compared to on planar surface at 
day3 and day5. (N=3, ± SD) ANOVA analysis,* p < 0.05. Arrow on 
graph shows the control level. 
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4.3.2 Induction of the BMP2 – SMAD pathway on the NSQ50 
surface 
4.3.2.1 Activation of BMP2 (ligand of BMPR1A) signalling 
The temporal gene expression analysis in section 4.4.1 has demonstrated that 
BMPR1A, one of the osteoblast related transmembrane receptors, responds very 
quickly to the NSQ50 surface, suggesting that BMP2 signalling is involved in the 
early events of MSCs osteoblast commitment and differentiation. To confirm the 
activation of the signal, the expression of BMP2, one of the BMPR1A ligands, was 
assessed from the first 24 hours of culture to day 11 by qRT-PCR. The relative 
amounts BMP2 transcripts on the NSQ50 and planar surfaces were normalized to 
endogenous control gene GAPDH, and then comparison was made and analysed 
using ANOVA to obtain the fold change of BMP2 transcripts for cells on NSQ50 
relative to those on the planar surface (Figure 4.4). The significant up-regulation 
of BMP2 on NSQ50 surface was noted from day 3 to day 7. The temporal 
expression pattern of BMP2 was similar to that of its receptor, BMPR1A, 
following the same time course.  
BMP2 protein expression was also examined by Western blot and 
immunostaining. Total proteins were extracted from MSCs cultured on NSQ50 
and planar surfaces at 7 days respectively, and isolated on a SDS-PAGE gel. By 
using an anti-BMP2 antibody, it was found that expression of BMP2 by MSCs on 
the NSQ50 surface was substantially increased when compared to that on the 
planar surface (top row in figure 4.5A, BMP2 approximately 45 KDa). Equal 
amounts of total protein (10 µg) were loaded on the gel and demonstrated by 
anti-GAPDH immuno-reactivity (bottom row in figure 4.5A, GAPDH approximately 
36 KDa).  
BMP2 expression in MSCs was also observed by immunostaining. MSCs cultured on 
NSQ50 and planar surfaces for 5 days were washed by 1xPBS and fixed on the 
surfaces. By using a monoclonal anti-BMP2 antibody, it was found that BMP2 on 
NSQ50 surface (green in figure 4.5B) was substantially enriched when compared 
to that on planar surface (green in figure 4.5C). BMP2 staining was apparent in 
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the cytoplasm and out towards the membrane, indicating endogenous BMP2 was 
up-regulated by the NSQ50 surface. 
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Figure 4.4 The effect of NSQ50 surface on BMP2 expression at the early 
stage of MSC osteogenic differentiation. 
	   BMP2 was measured by qRT-PCR to MSCs cultured on NSQ50 and 
planar surfaces for time course up to 11 days. MSCs responsed to 
the NSQ50 surface with about a 3 fold change in BMP2 mRNA 
compared to on planar surface through day 3 to day 7. (N=3, ± SD) 
ANOVA analysis, * p < 0.05, ** p < 0.01. Arrow on graph shows the 
control level. 
	   	  
121	  
	  
NSQ50
NSQ50 Planar
BMP2,	  45KD
GAPDH,	  36KD
A
B C
	  
Figure 4.5 BMP2 protein expression in MSCs cultured on the NSQ50 and 
planar surfaces. 
	   Total protein was extracted from MSCs cultured on NSQ50 and 
planar surfaces at day 7, and Western blot performed using an anti-
BMP2 antibody (Millipore, catalog number: ABN303). BMP2 was 
detected on the NSQ50 surface at the size of 45 KDa. GAPDH, as 
control for equal amounts of loaded protein, was detected on both 
NSQ50 and planar surfaces at the size of 36 KDa (A). MSCs cultured 
on NSQ50 (B) and planar surfaces (C) were stained for F-actin (red) 
using phalloidin, for cell nucleus (blue) using DAPI and for BMP2 
(green) using monoclonal anti-BMP2 antibody (R&D system, Catalog 
number: MAB3551). BMP2 was expressed in cytoplasm and spread 
towards the membrane on the NSQ50 surface.  
4.3.2.2 Induction of SMADs - the mediators of canonical BMP2 signalling 
BMP2 binds with its receptors to form ligand-receptor complexs, hence evoking 
the BMP2 signal. The signal may transduce through the canonical pathway in 
which SMAD proteins are required to be phosphorylated and subsequently 
translocate into the nucleus to regulate gene expression (described in detail in 
section 1.5.1). To test whether NSQ50 induces the BMP2 canonical pathway, 
receptor-regulated SMAD transcripts SMAD1 and SMAD5 were measured by qRT-
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PCR when MSCs were cultured on NSQ50 and planar surfaces for 3 and 5 days. 
The relative amounts SMAD1 and SMAD5 transcripts on NSQ50 and planar surfaces 
were normalized to endogenous control gene GAPDH, and then comparison were 
made and analysed using ANOVA to obtain the fold changes of SMAD1 and SMAD5 
transcripts on NSQ50 relative to those on planar surface (Figure 4.6).  
	  
Figure 4.6 The induction of the BMP2 canonical pathway mediator SMAD on 
the NSQ50 surface. 
 The expression of the BMP2 receptor-regulated SMAD1 and SMAD5 
transcripts were examined by qRT-PCR. SMAD1 and SMAD5 were 
significantly up-regulated by the NSQ50 surface at day 5 when 
compared to those on planar surface with their mRNA fold changes 
of about 2.5 and 9 respectively. Expression of SMAD5 on the NSQ50 
surface was about 4 times enriched compared to SMAD1 at day5, 
indicating SMAD5 maybe the predominant mediator of the BMP2 
canonical pathway in this case. (N=3, ± SD) ANOVA analysis,* p < 
0.05, ** p < 0.01, *** p< 0.001. Arrow on graph shows the control 
level. 
SMAD1 and SMAD5 did not exhibit up-regulation on the NSQ50 surface at day 3. 
However, the significant up-regulation of both SMADs occurred at day 5. The 
same temporal genes expression of BMP2, BMPR1A and SMADs indicated the 
induction of BMP2 canonical pathway on NSQ50 surface. Furthermore, SMAD5 
demonstrated about 4 times higher expression than SMAD1 at day5, suggesting 
samd5 is perhaps the predominant mediator of BMP2 canonical pathway for 
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nanotopography. However, it should notice that up-regulation of the SMAD genes 
expression is inadequate for affirmation of the BMP2 canonical pathway 
activation; phosphorylation SMAD proteins should be assessed for the samples.  
4.3.2.3 Lack of change in the SMAD independent pathway of BMP2 
signalling in MSCs on the NSQ50 surface 
The SMAD independent pathway, also known as non-canonical pathway of BMP2 
signalling, can trigger multiple downstream cascades, including p38 MAPK, ERK, 
and NFкB which are supposed to regulate MSCs differentiation and bone 
formation. The BMP2 SMAD independent pathway is achieved by the activation of 
tak1 and tab1 (described in details in section 1.5.1). Tab1 is the binding protein 
of tak1, thus BMP2 signalling will not transduce through the SMAD independent 
pathway without the induction of tab1. Expression of the tab1 on NSQ50 and 
planar surfaces was investigated by qRT-PCR after 5 days cell culture. The 
relative amounts of tab1 transcripts on NSQ50 and planar surfaces were 
normalized to the endogenous control gene GAPDH, and then comparison was 
made and analysed using ANOVA to obtain the fold change of tab1 on NSQ50 
relative to that on planar surface (Figure 4.7). The data showed that no effect of 
NSQ50 surface on tab1 expression in MSCs, indicating that NSQ50 surface induced 
BMP2 signalling was not transduced through the SMAD independent pathway. 
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Figure 4.7 Lack of activation of TGF-beta activated kinase 1 binding protein 
tab1 in the SMAD independent pathway of BMP2 signalling. 
	   Tab1 was not affected by NSQ50 surface. qRT-PCR targeted at the 
mRNA of tab1 at 5days showed insignificant fold change compared 
to that planar surface. (N=3, ± SD) ANOVA analysis,* p < 0.05, ** p < 
0.01, *** p < 0.001. Arrow on graph shows the control level. 
4.3.3 The effect of BMP2 signalling in MSCs on NSQ50 surface 
on osteogenic differentiation 
4.3.3.1 The effect of BMP2 signalling on early bone marker RUNX2 
expression 
Since BMP2-SMAD signalling is induced by the NSQ50 surface, and previous 
studies have demonstrated that this signal directly functionalise MSCs osteogenic 
differentiation and bone formation both in vivo and in vitro, this was 
investigated here. The relation of the BMP2 signal to the induction of MSC 
osteogenic differentiation on NSQ50 surface was investigated using noggin, the 
antagonist of BMP2. MSCs were seeded on NSQ50 and planar surfaces in culture 
medium and after allowing cells to settle down on the surfaces; 10 µl noggin 
solution with concentration of 5 ng/µl was added on to make up 50 ng/ml of 
final noggin concentration in culture medium. Cells were treated with and 
without noggin on NSQ50 and planar surfaces for 5 days. RUNX2 expression was 
examined by qRT-PCR. The RUNX2 fold change on NSQ50 surface compared to 
that on planar surface without noggin treatment was about 2.2 (Figure 4.8A 
noggin(-)), after normalization to endogenous control of GAPDH respectively, 
whereas RUNX2 fold change on NSQ50 surface compared to that on planar 
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surface with noggin treatment was less than 1.0 (Figure 4.8A noggin(+)), after 
normalization to endogenous control of GAPDH respectively. Statistical analysis 
with ANOVA showed that noggin significantly down-regulated RUNX2 expression 
in MSCs on the NSQ50 surface. 
The down-regulation of the RUNX2 protein in MSCs on the NSQ50 surface by 
noggin was also observed by Western blot analysis when MSCs were cultured on 
the NSQ50 surface for 7 days with and without noggin treatment (Figure 4.8B). 
These data demonstrated that the NSQ50 surface induced RUNX2 expression was 
through the activation of BMP2 signalling. 
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Figure 4.8 RUNX2 responses to the BMP2 antagonist noggin. 
Noggin down-regulates RUNX2 expression on the NSQ50 surface. 
MSCs cultured on the NSQ50 and planar surfaces were treated with 
and without noggin for 5 days (noggin treatment at 50ng/ml final 
concentration in cell culture medium). (A): qRT-PCR results show 
the fold change of RUNX2 when compared of MSCs on NSQ50 to 
planar surfaces in the present of noggin (noggin(+)) and in the 
absent of noggin (noggin(-)). (N=3, ± SD) ANOVA analysis, ** p < 
0.01. Arrow on graph shows the control level. (B): Western blot 
shows RUNX2 protein expression on NSQ50 surface with noggin 
treatment (noggin(+)) and without noggin treatment (noggin(-)). 
4.3.3.2 The effect of BMP2 signalling on the mature osteoblast marker gene 
OPN expression 
BMP2 signalling induced osteogenic differentiation on the NSQ50 surface was 
further confirmed by examining expression of the mature osteoblast marker OPN 
MSCs on NSQ50 and planar surfaces were cultured in the presence of noggin for 
the first 7 days, and then the medium was replaced with normal medium without 
noggin for the rest of the culture period, up to 28 days. OPN expression was 
examined by qRT-PCR. OPN was significantly up-regulated with a fold change 
127	  
	  
about 125 on the NSQ50 surface compared to that on the planar surface without 
noggin treatment (Figure 4.9A noggin(-)), after normalization to endogenous 
control of GAPDH respectively. However, OPN expression was unchanged on the 
NSQ50 surface compared to that on planar surfaces with noggin treatment 
(Figure 4.9A noggin(+)), after normalization to endogenous control of GAPDH 
respectively. Statistical analysis with ANOVA showed that noggin significantly 
down-regulated OPN expression on NSQ50 surface. The down-regulation of the 
OPN protein on the NSQ50 surface by noggin was also observed by 
immunostaining when MSCs were cultured on the NSQ50 surface for 28 days with 
noggin treatment (Figure 4.9B). These data again demonstrated that 
osteogenesis on NSQ50 surface was regulated by BMP2 signalling. 
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Figure 4.9 OPN responses to the BMP2 antagonist noggin. 
Noggin down-regulated osteopontin expression on the NSQ50 
surface. MSCs cultured on NSQ50 and planar surfaces were treated 
with and without noggin for the first 7 days of culture (noggin 
treatment at 50ng/ml final concentration in cell culture medium), 
and then the medium was replaced with normal medium without 
noggin for the rest of the culture period, up to 28 days (A): qRT-
PCR results show the fold change of OPN when compared of MSCs 
on NSQ50 to planar surfaces in the presence of noggin (noggin(+)) 
and in the absent of noggin (noggin(-)). (N=3, ± SD) ANOVA analysis, 
*** p < 0.001. Arrow on graph shows the control level. 
Immunostaining using anti-OPN shows lack of OPN protein 
expression on NSQ50 surface with noggin treatment (B)(red: actin, 
blue: DAPI). 
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4.3.3.3 The effect of low serum on RUNX2 expression in MSCs on the NSQ50 
surface 
The above data demonstrated osteogenic genes were induced by BMP2 signalling 
on the NSQ50 surface. BMP2 belongs to the largest subfamily of the transforming 
growth factor β (TGFβ) superfamily. It is noted that the typical components of 
fetal bovine serum (FBS), making up 10% of cell culture medium in this work, 
contains hormones, adhesion molecules and growth factors, including TGFβ. 
These proteins in FBS, specifically TGFβ having the similar regulatory effect to 
BMP2 might influence MSCs fate determination and subsequent differentiation on 
the NSQ50 surface.  
To test whether serum components influence the osteogeneic effect of the 
NSQ50 surface on MSCs, RUNX2 expression was examined using both low serum 
cell culture medium (containing 1% FBS) and normal culture medium (containing 
10% FBS). It should note that complete serum free medium resulted in MSCs 
apoptosis in 24 hours. MSCs seeded on NSQ50 surfaces were cultured in low 
serum and normal medium for three days, then the medium were replaced by 
fresh normal medium for cell culture up to five days. RUNX2 expression in both 
serum free and normal medium was examined by immunostaining using a 
monoclonal anti-RUNX2 antibody (Figure 4.10). The NSQ50 surface induced 
RUNX2 expression was apparently slightly affected by the low serum culture 
medium. It appeared that there was a reduced intensity and expression pattern 
(predominantly localised in nucleus) of RUNX2 in low serum conditions compared 
to normal medium. This indicates that the protein components of FBS in the cell 
culture medium used in this work play a part in NSQ50 surface induced 
osteogenesis, but that the cells are stimulated by endogenously induced BMP2 on 
the NSQ pattern.  
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Figure 4.10 RUNX2 expressions in low serum and normal medium. 
The expression of RUNX2 was slightly reduced in terms of both 
staining intensity and expression pattern in the culture medium 
containing 1% of FBS (low serum) and 10% of FBS (normal). MSCs 
seeded on NSQ50 surfaces were cultured in low serum and normal 
medium for three days respectively, and then media was replaced 
by fresh normal media for cell culture up to 5 days. Immunostaining 
for RUNX2 using monoclonal anti-RUNX2 (Millipore, Cat. No 05-
1478) and DAPI for cell nuclei were carried out and results were 
viewed by Zeiss microscope (green: RUNX2, blue: DAPI). 
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4.3.4 The expression of miRNAs in MSCs on the NSQ50 surface 
4.3.4.1 Prediction analysis of miRNAs targeting RUNX2 and OSX genes 
MicroRNAs (miRNAs) have recently been recognised as key regulators of diverse 
biological processes by imperfect binding to their target mRNA 3’ UTRs to 
negatively regulating translations of the target genes. The impact of miRNAs on 
osteoblastic differentiation of various cell types have been investigated recently 
(Hu et al., 2010), and miRNAs targeting RUNX2 in MSCs have shown inhibition of 
osteogenic differentiation and stimulation of adipocyte phenotype (Huang et al., 
2010a). To gain further insight into the molecular mechanisms underlying BMP2-
induced osteogenic differentiation on the NSQ50 surface, miRNAs targeting 
osteogenic transcription factors RUNX2 and OSX were focused on here. A search 
for miRNAs that predictably target RUNX2 and OSX was performed using the 
bioinformatics program TargetScan, and the extent of sequence conservation 
was examined using University of California Santa Cruze genome browser. 
MiRNAs targeting RUNX2 and OSX were selected with sequence positions 2 to 8 
(seed sequences) exactly complementary to the targets 3’ UTR and highly 
conserved among vertebrates and/or mammals (Figure 4.11). The search results 
predicted miR-23a, -23b, -93 and -203 as potentially targeting RUNX2, and miR-
96, -143 as targeting OSX. 
4.3.4.2 The expression of miRNAs on NSQ50 surface 
Expression of the miRNAs selected using targetScan on the NSQ50 surface were 
examined using qRT-PCR. Since RUNX2 and OSX were up-regulated on the NSQ50 
surface at day 5 and day 11 respectively, miRNAs targeting RUNX2 were assessed 
at day 5 and day 7, and miRNAs targeting OSX were measured at day 9 and day 
11. The relative amounts of miRNAs in MSCs on NSQ50 and planar surfaces were 
normalized to the endogenous control gene, small nuclear RNA U6, and the fold 
change of the miRNA on NSQ50 was obtained by comparison to its planar control. 
Data was analysed using ANOVA in GraphicALPrism software. 
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MiR-23b (targeting RUNX2) was significantly down-regulated at day 5 and 7 with 
0.34 and 0.53 fold changes respectively (Figure 4.12b), whereas other miRNAs 
predicted to target RUNX2 remained unchanged compared to their planar 
controls (Figure 4.12a, c, d), indicating miR-23b contributes to the activation of 
RUNX2 in MSCs on the NSQ50 surface. However, miRNAs targeting OSX (miR-96, 
and -143) showed significant up-regulation at day 11 with fold changes of 3.2 
and 4.2 when compared to their planar control respectively (Figure 4.12e and f). 
The up-regulation of miR-96 and -143 to their controls at day 11 compared to 
those at day 9, specifically for miR-143 correlated to the significant increase of 
OSX expression at day 11, indicating miR-96 and -143 are involved in OSX 
expression on NSQ50 surface. However, unlike miR-23b that negatively targets 
RUNX2, miR-96 and 143 potentially target OSX in a positively regulatory way. 
 
Figure 4.11 The prediction of miRNAs targeting RUNX2 and OSX using 
TargetScan. 
Computational analysis shows the complementarities of miR-23a, -
23b, -93 and -203 seed sequences (blue) to the 3’ UTR (red) of 
RUNX2, and of miR-96, -143 (blue) to the 3’ UTR (red) of OSX.  
Position	  1061-­‐1067	  of	  RUNX2	  3'	  UTR
hsa-­‐miR-­‐23a
5' ...AGUUCAUCCAGGCACAAUGUGAU...
3' CCUUUAGGGACCG-­‐-­‐-­‐UUACACUA
|||||||
Position	  1061-­‐1067	  of	  RUNX2	  3'	  UTR
hsa-­‐miR-­‐23b
5' ...AGUUCAUCCAGGCACAAUGUGAU...
3' CCAUUAGGGACCG-­‐-­‐UUACACUA
|||||||
5' ...CAGUGUCUGGUUA-­‐-­‐CAUUUCAA...Position	  2345-­‐2352	  of	  RUNX2	  3'	  UTR
hsa-­‐miR-­‐203 3' GAUCACCAGGAUUUGUAAAGUUG
|||||||
Position	  2547-­‐2553	  of	  RUNX2	  3'	  UTR
hsa-­‐miR-­‐93
5' ...GCAGCAACCCAGAAACACUUUAG...
3' UGGACGUGCUUGUCGUGAAAC
||||||
Position	  537-­‐543	  of	  OSX	  3'	  UTR
hsa-­‐miR-­‐96
5' ...UGACCUGGCCAGAGGGUGCCAAG...
3' UCGUUUUUACACGAUCACGGUUU
|||||||
Position	  216-­‐222	  of	  OSX	  3'	  UTR
hsa-­‐miR-­‐143
5' ...GCUUUCCACAAACUCUCAUCUCA...
3' CUCGAUGUCACGAAGUAGAGU
|||||||
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Figure 4.12 The expression of miRNAs targeting RUNX2 and OSX in MSCs on 
the NSQ50 surface. 
Expression of the miRNAs targeting RUNX2 in MSCs cultured on 
NSQ50 and planar surfaces for 5, and 7 days at which time RUNX2 
was induced in MSCs on the NSQ50 surface, were assessed by qRT-
PCR. MiR-23b on NSQ50 showed significant down-regulation 
compared to that on the planar surface (b), whereas miR-23a (a), -
93 (c) and -203 (d) remained unchanged when compared to their 
controls. MiRNAs targeting OSX were measured at day 9 and 11 at 
which time OSX was over-expressed in MSCs on the NSQ50 surface. 
Both miR-96 (e) and -143 (f) showed significant increase in MSCs on 
the NSQ50 surface when compared to their planar controls at day 
11, whereas the increase of miR-143 on NSQ50 at day 11 was 
substantially higher than that at day 9. All data was normalized to 
the endogenous control gene, small nuclear RNA U6. (N=3, ± SD) 
ANOVA analysis, * p < 0.05, ** p < 0.01, *** p < 0.001. Arrows on 
graphs show the control level. 
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4.3.5 The relation of BMP2 signalling to other osteogenic 
regulatory events in MSCs on the NSQ50 surface 
4.3.5.1 BMP2 signal and miRNAs 
The effects of miRNAs targeting the osteogenic transcription factors RUNX2 and 
OSX in MSCs on NSQ50 surface was described in the above sections. To 
investigate the relation of BMP2 signal to the miRNAs, MSCs cultured on NSQ50 
and planar surfaces were exposed to noggin (50ng/ml of final concentration in 
medium) for 5 and 11 days. The expression of miR-23b was assessed at day 5, 
and miR-96, -143 were measured at day 11 by qRT-PCR (in line with RUNX2 and 
OSX expression profiles). MiR-23b expression returned to the basal levels 
observed in cells cultured on planar surface (Figure 4.13a), indicating miR-23b 
targeting RUNX2 in MSCs on the NSQ50 surface was regulated by the BMP2 signal. 
However, the expression of miR-96 (Figure 4.13b) and -203 (Figure 4.13c) were 
not affected by the present of noggin, suggesting the over-expression of miR-96 
and -143 were independent of the BMP2 signal. 
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Figure 4.13 The effects of BMP2 signalling on miRNAs. 
Expression of miRNAs was assessed for MSCs cultured on NSQ50 and 
treated with the BMP2 signal inhibitor noggin (noggin (+)) compared 
to cells in normal culture medium (noggin (-)). (a) MiR-23b 
targeting RUNX2 was up-regulated by noggin, indicating miR-23b 
targeting RUNX2 is BMP2 dependent. MiR-96 (b) and -143 (c) 
targeting OSX was unaffected by noggin, suggesting their 
expression on NSQ50 surface is BMP2 independent. (N=3, ± SD) 
ANOVA analysis,* p < 0.05, ** p < 0.01. 
4.3.5.2 Crosstalk of BMP2 and integrin αvβ5 signalling 
4.3.5.2.1 The effect of integrins αvβ5 on RUNX2 expression 
It has been evident that integrin binding exerts effects on osteogenic 
differentiation of MSCs (Biggs et al., 2009; Kilian et al., 2010), and the current 
study also demonstrated that the paring of integrins αvβ5 was up-regulated on 
NSQ50 surface at early stage of MSCs osteogenesis (section 4.3.1.1). The effect 
of αvβ5 on the early osteogenic marker RUNX2 was investigated using qRT-PCR. 
MSCs were seeded onto the NSQ50 and planar surfaces, and an integrin β5 
antibody was added to the cell media with the ratio of 1:50 in volume of 
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antibody to medium. Cells were cultured for 5 days on the surfaces and RUNX2 
expression was examined. It appeared RUNX2 expression was not significantly 
reduced after integrin β5 blocking when compared to cells in normal cultured 
medium (Figure 4.14A). 
To further investigate the effect of the pair of integrin αvβ5 on osteogenesis of 
MSCs on NSQ50 surface, the NSQ50 surface was coated with VN which is the 
ligand of integrin αvβ5. The PCL template embossed with the NSQ50 pattern was 
incubated with medium containing 5µg/ml of VN at 40C for 24 hours. The surface 
(NSQ50+VN) was washed with 1xPBS and pre-warmed at 370C before MSCs were 
seeded on to it. Immunostaining using anti-RUNX2 was carried out for cells 
cultured on NSQ50 and NSQ50+VN surfaces after 5 days cell culture, and 
enhanced RUNX2 expression on NSQ+VN surface was observed (Figure 4.14B), 
indicating the activation of integrin αvβ5 does stimulate RUNX2 expression.  
This is in line with the hypothesis that expression of the VN receptor, αvβ5, is 
important, but goes against results that blocking β5 does not impact on RUNX2 
expression (Figure 4.14A). However, looking at expression of β3 while β5 is 
blocked indicates up-regulation of this other beta subunit (Figure 4.14C). It is 
important to note that β3 can be used by cells instead of β5 for VN ligation. 
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Figure 4.14 The effect of integrins on RUNX2 expression. 
RUNX2 expression (A) was assessed for MSCs cultured on NSQ50 and 
treated with the blocking antibody of integrin β5 (β5 (+)) compared 
to cells in normal culture medium (β5 (-)). The data shows 
unaffected RUNX2 expression after blocking integrin β5. 
Immunostaining for RUNX2 (B) demonstrated that enhanced 
expression of RUNX2 was observed on NSQ50 surface coated with 
vitronection (NSQ50+VN) compared to cells on uncoated surface 
(NSQ50) (RUNX2: green, DAPI: blue). Integrin β3 (itgβ3) expression 
(C) was assessed while β5 was blocked by its antibody on NSQ50 
surface. The data shows significant up-regulation of β3 when β5 
was inhibited, suggesting a possible switch of β5 to β3 which paired 
with αv to bind to VN on the NSQ50 surface. For qPCR assay: (N=3, 
± SD) ANOVA analysis,* p < 0.05, ** p < 0.01. 
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4.3.5.2.2 The co-localization of the BMP2 receptor and integrins 
Since both BMP2 and integrin αvβ5 signalling occurred in the early stages of MSC 
osteogenesis on the NSQ50 surface, the relation of these two signals was 
investigated. Previous studies suggest the interplay between TGF receptors and 
integrins (Ivaska and Heino, 2010), and the crosstalk between BMP2 receptors 
and integrins (αβ) paring in osteoblastic functionalization (Lai and Cheng, 2005). 
To investigate the spatial relation of BMPR1A and integrin β5 on the NSQ50 
surface, immunostaining using antibodies specific to BMPR1A and integrin β5 was 
carried out for MSCs cultured on NSQ50 and planar surfaces for 5 days (Figure 
4.15A). On the NSQ50 surface, MSCs expressed β5 at focal adhesion sites and 
BMPR1A was expressed at the same site as the β5 subunits – i.e. close to 
adhesions. β5 subunits as part of adhesions were clear on the planar control 
surfaces, but no co-localisation with BMPR1A was seen (Figure 4.15A). The data 
demonstrated that the physical co-localization of the two receptors occurred on 
the osteogenic NSQ50 surface alone.  
To further demonstrate co-localization of BMPR1A and integrin β5 on the NSQ50 
surface, co-immunoprecipitation was performed using integrin αvβ5 paring 
antibody and protein A agarose beads to pull-down αvβ5. The subsequent 
western analysis using anti-BMPR1A and anti-αvβ5 demonstrated these two 
receptors were co-localised in MSCs on the NSQ50 surface only (Figure 4.15B). 
The integrin subunit αv was detected on NSQ50 and planar surfaces, but with 
more abundance on planar surface than on NSQ50. This is perhaps due to αv 
paired with other β subunits. The western blot of the immunoprecipitation also 
showed that the co-localization of BMPR1A and αvβ5 was enriched at day 5 more 
that at day 3 on the NSQ50 surface. 
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Figure 4.15 Integrins co-localize with the BMP2 receptor when MSCs are 
cultured on the NSQ50 surface. 
Double immunostaining after 5 days cell culture of MSCs on the 
NSQ50 and planar surface (A) using integrin (ITG) β5 (red) and 
BMPR1A (green) specific antibodies. MSCs cultured on the NSQ50 
surface demonstrated co-localization of these two receptors 
(yellow and arrows in the outset merge), whereas the co-
localization was not observed in cells on the planar surface. (B) The 
co-localization of ITG αvβ5 and BMPR1A on the NSQ50 surface was 
confirmed by co-immunoprecipitation using αvβ5 antibody (β5: red 
arrows) and BMPR1A (blue arrows) specific antibodies. 
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4.3.5.2.3 The functional relation of BMP2 signalling and integrins on 
NSQ50 
The BMP2 receptor and integrin αvβ5 have been shown to co-localize on the 
NSQ50 surface. The interplay of these two receptors was investigated to see if 
the co-localization affects osteogenesis of MSCs on the NSQ50 surface. 
MSCs were cultured on the NSQ50 surface and treated with noggin for 5 days to 
block BMP2 signalling on the surface. Expression of integrins αv and β5 was 
measured and compared to their expression in normal culture. Both αv and β5 
showed significant down-regulation on the NSQ50 surface after blocking the 
BMP2 signal, indicating BMP2 signalling enhances integrins αv and β5 expression 
on the surface (Figure 4.16a and b). 
Furthermore, expression of the focal adhesion molecule vinculin, a cell adhesion 
protein used as marker for cell-ECM adhesions (i.e. focal adhesions) (Ziegler et 
al., 2006) was investigated. Immunostaining for vinculin using an anti-vinculin 
antibody in MSCs cultured on the NSQ50 and planar surfaces for 5 days was used 
after noggin treatment. This demonstrated that BMP2 signalling modulates 
integrin expression in MSCs on the NSQ50 surface (Figure 4.16). MSCs cultured on 
the NSQ50 surface in normal culture medium showed larger focal adhesion 
formation (Figure 4.16c), whereas MSCs treated with noggin, which blocks BMP2 
signalling, showed a reduction in vinculin expression (Figure 4.16d). Expression 
of vinculin in MSCs cultured on planar surfaces with and without noggin remained 
almost unchanged (Figure 4.16e and f). This data, together with the gene 
expression of integrin αvβ5 demonstrated that BMP2 signalling regulates integrin 
expression on the NSQ50 surface. 
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Figure 4.16 The effect of BMP2 signalling on integrin expression. 
MSCs were cultured on the NSQ50 and planar surfaces for 5 days 
and treated with/without the BMP2 antagonist noggin. Gene 
expression of β5 and αv in MSCs on the NSQ50 surface was assessed 
by qRT-PCR, and β5 and αv were down-regulated by blocking BMP2 
signalling (a and b). Immunostaining for vinculin in MSCs cultured in 
normal medium on NSQ50 showed larger focal adhesion formation 
(c), whereas the cells treated with noggin on the surface 
demonstrated a reduction in vinculin expression (d). Vinculin in 
MSCs cultured on planar surfaces with and without noggin remained 
almost unchanged (e and f). For qPCR assay: (N=3, ± SD) ANOVA 
analysis,* p < 0.05. Immunostaining, red: actin, blue: DAPI, green: 
vinculin. 
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4.3.5.2.4 The functional relation of integrins to BMP signalling 
The effects of integrins on BMP2 signalling and subsequent osteogenic 
differentiation of MSCs on the NSQ50 surface was further investigated by 
functionalising the surface with the αvβ5 ligand, VN. This resulted in enhanced 
expression of RUNX2 on the surface (Figure 4.14B). To see whether the increased 
RUNX2 expression induced by the activation of integrin αvβ5 resulted from the 
co-localization of BMP2 receptors and integrin αvβ5, expression of these two 
receptors was examined by immunostaining. 
MSCs cultured on VN coated and standard NSQ50 surfaces were stained with anti-
BMPR1A and anti-αvβ5 antibodies (Figure 4.17). Expression of BMPR1A and αvβ5 
on the VN coated NSQ50 surface was enhanced when compared to expression on 
the uncoated surface. This data indicates that activation of αvβ5 stimulates 
BMPR1A expression and augments the interplay of BMP2 and integrin signalling. 
This data together with figure 4.14B demonstrates that integrins regulate BMP2 
signalling via receptors co-localising and subsequently modulate osteogenesis of 
MSCs on the NSQ50 surface. 
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Figure 4.17 The effect of VN on integrin αvβ5 and BMPR1A expression. 
Immunostaining for BMPR1A and integrin αvβ5 in MSCs on VN coated 
and standard NSQ50 surfaces using anti-BMPR1A and anti- αvβ5 
antibodies. Enhanced expression of these two receptors and 
enhanced co-localisation was observe on the vitronection coated 
surface (NSQ50+VN). (blue: DAPI, green: BMPR1A, red: αvβ5, 
yellow: co-localization). 
4.4 Discussion and conclusion 
4.4.1 BMP2 signalling 
BMP2 has been characterised as osteoinductive, inducing bone formation in vivo 
and in vitro (Bandyopadhyay et al., 2006; Javed et al., 2009). In the context of 
bone tissue engineering, biomaterials combining BMP2 represent a powerful 
strategy for enhancing MSCs osteogenic differentiation and bone formation (Kim 
et al., 2014). Furthermore, recombinant human BMP2 (rhBMP2) has been used 
for spinal fusion and open fracture treatment in clinic (Gautschi et al., 2007). 
The results presented in this chapter add a new finding to the field by showing 
that nanotopography induces BMP2 expression and enhances BMP2 signalling, and 
subsequently contributes to osteogenesis of MSCs. 
Both BMP2 and its receptor BMPR1A in MSCs on NSQ50 surface were found to be 
up-regulated at the time (day 3) where C-MYC was starting to become decreased 
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and the increase of osteogenic transcription factor RUNX2 was not yet observed 
(section 3.4.1 and 3.4.2). The downstream signalling molecules of BMP2, SMAD1 
and SMAD5 were highly expressed at day 5, indicating BMP2 signalling was 
activated in MSCs on the NSQ50 surface. Thus, it is rational to expect BMP2 as an 
early stage event in NSQ50 induced osteogenesis. The effect of BMP2 signalling 
on osteogenesis of MSCs was demonstrated by manipulating the signal: when 
BMP2 signalling was blocked by noggin, the up-regulation of RUNX2 on NSQ50 
was inhibited, and furthermore, the osteoblast marker OPN expression was 
abrogated on the surface. These data indicated that osteogenesis of MSCs on 
NSQ50 surface was induced by BMP2 via RUNX2. 
BMP2 signalling may go through the SMAD-independent pathway in which the 
downstream pathways of BMP2, including ERK, p38MAPK, and JNK are initiated 
(Guicheux et al., 2003; Nohe et al., 2004). It is thought that this pathway is 
transduced by the interaction of BRAM1 and TAK1/TAB1 complex (Shim et al., 
2009). However, the TAK1 binding protein TAB1 showed no significant difference 
between MSCs on the NSQ50 and planar surfaces. This suggests that the NSQ50 
induced osteogenesis is not reliant on SMAD-independent BMP2 signalling. 
Recent studies demonstrate that MSCs can secrete growth factors and BMP2 
(Huang et al., 2007; Kim et al., 2010; Kim and Ma, 2013) during proliferation and 
differentiation. Immunostaining BMP2 in MSCs on the NSQ50 surface after 7 days 
of cell culture demonstrated that BMP2 is localised in the cytoplasm. 
Furthermore, when MSCs were cultured on the NSQ50 surface in low serum 
conditions, expression of RUNX2 was only slightly reduced comparing to that in 
normal medium cell culture. These data suggests NSQ50 surface induces 
endogenous BMP2 expression and may sequester BMP2 to guide osteogenesis of 
MSCs (Hudalla et al., 2011; Impellitteri et al., 2012). 
4.4.2 The role of integrins in osteogenesis of MSCs on NSQ50 
surface. 
Integrins play an essential role in nanotopographical cue-induced osteogenesis of 
MSCs – while they themselves have no enzymatic activity, they scaffold for 
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signalling proteins like FAK and Src. It has been proposed that nanotopography 
can modulate integrins clustering and focal adhesion formation, and in turn 
regulate cell function and differentiation (Arnold et al., 2004; McMurray et al., 
2011; Schvartzman et al., 2011). Expression of the integrins αvβ5 and the effect 
on up-regulation of the RUNX2 were observed in MSCs on the NSQ50 surface. This 
data together with previous studies (McMurray et al., 2011; Tsimbouri et al., 
2012) indicate integrins are involved in the regulation of osteogenesis of MSCs. 
Integrins exert effects by binding with components of ECM through pairing of α 
and β subunits. It is widely accepted that the paring of αv with β1/β3/β5 and α5 
with β1 binds to the RGD motif in OPN, and fibronectin (mainly αvβ3) and VN 
(maily αvβ5 but also αvβ3) in ECM (Hynes et al., 2002). The up-regulation of 
αvβ5 in MSCs on the NSQ50 surface, and immobilising VN on NSQ50 surface, 
resulted in the up-regulation of RUNX2, suggesting a key role for VN in adhesion 
to the surface of osteo-differentiating cells. Blocking of the subunit β5 resulted 
in up-regulation of β3, whereas RUNX2 remained unchanged compared to the 
those in normal culture medium on MSCs, suggesting MSCs recruit β3 instead of 
β5 for VN binding, and thus demonstrate the indisputable role of integrins for 
osteogenesis of MSCs on NSQ50 surface. 
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4.4.3 Cross-talk between BMP2 signalling and integrins. 
The roles of BMP2 signalling and integrins (αvβ5) for the osteogenesis of MSCs on 
the NSQ50 surface presents interesting questions about how and where these 
two signals function in MSCs osteogenesis on the surface. This interest was 
further encouraged by the finding that BMP2 signalling modulates focal adhesion 
formation on the surface. Vinculin expression was down-regulated by inhibition 
of the BMP2 signalling by adding noggin to the culture on the NSQ50 surface 
when compared to those on the surface without noggin, and on planar surfaces 
with and without noggin. This result supports the evidence that BMP2 promotes 
cell adhesion and stimulates osteoblast differentiation (M et al., 1996; Nissinen 
et al., 1997; Shah et al., 1999). 
The co-localization of the BMP2 receptor BMPR1A and integrins αvβ5 was found 
on the surface when double immunostaining was applied using specific 
antibodies for these two receptors, and the result was further confirmed by 
immunoprecipitation. The physical co-localisation of the two receptors results in 
synergic effects stimulating osteogenesis on NSQ50. Enhancing activation of the 
αvβ5 by immobilising NSQ50 surface with VN stimulated both BMPR1A and αvβ5 
expressions and the co-localization of these two augmented RUNX2 expression on 
the surface compared to the standard NSQ50 surface. Inhibition of BMP2 
signalling reduced αv and β5 gene expression and focal adhesion formation, as 
well as the subsequent reduction of RUNX2 and OPN on the surface. 
4.4.4 MiRNAs. 
Studies have shown miRNAs play important roles in the regulation of skeletal 
differentiation (Chen et al., 2006; Mizuno et al., 2009; Mizuno et al., 2008), and 
are involved in the osteogenic differentiation via targeting of RUNX2 (Huang et 
al., 2010a) and OSX (Shi et al., 2013). MiRNAs targeting RUNX2 and OSX were 
predicted using the targetscan programme which is the first computing tool to 
use the concept of seed-region matches to predict highly conserved miRNA 
sequences that are perfectly complementarity to the small segment sequence 
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(usually 7 nt) in 3’-UTR of mRNA. MiR-23a, -23b, -93 and -203 were predicted to 
target RUNX2, and miR-96 and -143 to target OSX. 
Expression of the miRNAs targeting RUNX2 showed that miR-23b was down-
regulated, whereas others tested remained similar to those on the planar 
surface when RUNX2 was stimulated in MSCs on the NSQ50 surface. Further 
examining by addition of noggin indicates that the down-regulation of miR-23b 
on the surface is regulated by BMP2. Thus, miR-23b is involved in osteogenesis of 
MSCs as a negative regulator in BMP2-dependent manner. However, miR-96 and -
143 targeting OSX were shown to have positive correlation to their target. This 
could be that miR-96, and -143 target inhibitors of OSX as well, because one 
miRNA can target different genes, and one gene can be targeted by different 
miRNAs (Kim, 2005), and indeed further search in TargetScan found miR-96 can 
target parathyroid hormone (PTH) which is an inhibitor of OSX (Barbuto and 
Mitchell, 2013). Furthermore, noggin showed no effect on the expression of miR-
96, and -143, thus miR-96 and -143 are positive regulators to OSX and also BMP2-
independent on NSQ50 surface. 
4.4.5 Conclusions. 
MSCs differentiation is a highly regulated process. Nanoscale materials possess 
the potential capacity for dissecting stem cell mechanisms without recourse to 
the use of soluble factors to drive differentiation. Membrane receptor signalling 
plays essential roles in osteogenic differentiation of MSCs on the NSQ50 surface, 
in which BMP2 and integrin αvβ5 are important, but Wnt appears not to be.  
BMP2 signalling appears an initial regulatory event required to stimulate 
osteogenesis on the NSQ50 surface.  
RUNX2 which controls the osteogenic fate of MSCs is directly associated with 
BMP2 signalling, either by BMP2-SMAD pathway or BMP2-miR-23b, or both. BMP2 
signalling induced RUNX2 is sufficient for the induction of its downstream 
transcription factor OSX. Thus, MSC osteogenesis on the NSQ50 surface starts 
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with increased BMP2 sensitivity and then enters a well-orchestrated cascade of 
growth, transcriptional and ECM-modulating events. 
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Chapter 5. Metabolomics 
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Rationale 
NSQ50 nanotopographies ability to activate BMP2 and other signalling molecules 
resulting in MSCs osteogenic differentiation was established in chapter 4. To 
extend the understandings of mechanisms of nanotopography induced MSC 
differentiation, a systematic approach-metabolomic investigation was employed. 
In this chapter, previously characterized metabolic features of undifferentiated 
MSCs and differentiated MSCs are introduced, and this is followed by a 
description of metabolomics experiments and data analysis procedures. The 
results presented in this chapter include shifting the balance of bioenergetics 
from anaerobic to aerobic when MSCs on the NSQ50 surface switch stemness to 
differentiation. Specific metabolic pathways identified by the KEGG database 
are also presented. The findings of significant down-regulation of unsaturated 
fatty acids lead me to discuss their roles in MSC osteogenic lineage commitment 
and differentiation on the NSQ50 surface. Finally, a discussion of metabolic 
features, the possible roles of metabolites involved in the regulation of MSC 
osteogenesis on the surface is presented and conclusions made. 
5.1 Introduction 
Recent advances of metabolomics and computing analysis have implicated the 
pivotal role of metabolism in determining whether stem cells proliferate, 
differentiate or remain quiescent. Metabolism regulates stem cell function and 
fate by alteration of cell specific metabolic pathways (Pattappa et al., 2011), 
and subsequent integration with epigenetic and genetic programmes (Shyh-
Chang et al., 2013b). The metabolic regulatory mechanisms underlying stem cell 
fate may vary in different stem cell types. 
5.1.1 Metabolic profile of pluripotent stem cells (ESC and iPSCs) 
Pluripotent stem cells (PSCs) are characterized by a short G1 phase of cell cycle 
to limit cell growth and differentiation potential (Singh and Dalton, 2009). In the 
proliferative state, PSCs have to balance the bioenergetic and biosynthetic 
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activities to support the rapid cell duplication. In the proliferating process, cells 
uptake nutrients to achieve a high rate of glucose flux resulting in an increase in 
glucose transporter 1/3 (GLUT1/3) expression, and the activation of hexokinase 
(HK) and phosphofructokinase 1 (PFK1), which activate glycolytic pathways. As a 
result, adenosine triphosphate (ATP) is generated by glycolytic phosphoglycerate 
kinases (PGKs) and pyruvate kinases (PKs), and decoupled from oxygen 
consumption by the mitochondrial Electron Transport Chain (ETC). Although rate 
of ATP synthesis is low in the glycolytic pathway (2 mol ATP per mol glucose), it 
is sufficient for nucleotide, amino acid and lipid biosynthesis to maintain PSC 
pluripotency and proliferation (Locasale and Cantley, 2011; Manganelli et al., 
2012).  
It is thought that proliferating cells under anaerobic glycolysis (inefficient ATP 
synthesis) prefer to shunt glycolytic intermediates into nucleotide, amino acid 
and lipid synthesis (Vander Heiden et al., 2009), and indeed the increased 
activity of the pentose phosphate pathway (PPP) which allows rapid nucleotide 
synthesis observed in undifferentiated mouse ESCs (Manganelli et al., 2012; 
Varum et al., 2011). The low efficiency of ATP synthesis in proliferating PSCs is 
also in favour of consuming oxygen through the ETC to oxidize Nicotinamide 
adenine dinucleotide (NADH) into NAD+ and maintain the Krebs cycle flux, which 
is a cyclic series of chemical reactions to generate energy, as well as providing 
precursors for generating certain amino acids in the mitochondria. This allows 
PSCs to maintain an optimal redox potential for lipid synthesis from citrate and 
for amino acid synthesis from α-ketoglutarate (Shyh-Chang et al., 2011; Zhang et 
al., 2011). Thus, anaerobic glycolysis is a common feature of metabolism in 
proliferating PSCs. 
However, glycolytic flux dramatically decreases and mitochondria activities 
increase in differentiating PSCs. This indicates that energy production shifts to 
the mitochondrion resulting in a decrease in the PPP pathway and an increase in 
oxygen consumption as ECT recouples to ATP synthesis to fulfil the requirements 
from cell differentiation (Cho et al., 2006; Chung et al., 2007; Prigione et al., 
2010). In mitochondria, ATP is generated by increased Oxidative Phosphorylation 
(OxPhos) activity which oxidizes nutrients, such as pyruvate via proton gradients 
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at the mitochondrial membrane. The increased ECT activity results in increase in 
Reactive Oxygen Species (ROS) which oxidizes highly unsaturated structures such 
as unsaturated lipids to form eicosanoids which promote differentiation (Yanes 
et al., 2010). 
5.1.2 Metabolic profile of MSCs 
MSCs share the same metabolic profile of PSCs when the cells are in a quiescent 
state in which MSCs express higher levels of glycolytic enzymes and increase 
lactate production rate, and lower levels of OxPhos proteins, suggesting MSCs 
are reliant on glycolysis (Chen et al., 2008). However, MSCs expanded under 
normoxia which increase in OxPhos and ROS, result in three to four fold increase 
in senescence. This indicates that glycolysis maybe an environmental adaptation 
(Pattappa et al., 2011; Pattappa et al., 2013). In vivo, MSCs reside in more 
hypoxic environments, thus hypoxia-induced glycolysis helps maintain MSC long 
term self-renewal (Chen et al., 2008; Pattappa et al., 2013). 
Metabolic profiles of MSCs differentiation rely on lineage-specific commitment. 
During adipogenesis, a lipogenic programme involving in ATP citrate lyase is 
activated, which converts glucose-derived citrate into acetyl coenzyme A 
(acetyl-CoA) to increase glucose metabolism and synthesize lipids for fat storage 
(Wellen et al., 2009). This suggests that the increased mitochondrial activity in 
OxPhos and ROS is necessary for adipogenesis (Tormos et al., 2011). Similarly, 
the bioenergetics and biosynthesis in osteogenesis of MSCs leads to an increase 
in mitochondrial biogenesis and oxygen consumption resulting in a rise of OxPhos 
in osteoblasts. However, the increase in OxPhos is accompanied by up-regulated 
expression of antioxidant enzymes (oxidoreductases) such as catalase and 
superoxide dismutase, leading to cellular ROS decrease in osteogenesis of MSCs 
(Chen et al., 2008; Lonergan et al., 2006). 
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5.1.3 The links of metabolism to epigenetics and gene 
expression 
The integration of metabolism with epigenetic and genetic programs in co-
ordinated regulation of stem cell function and fate has emerged. Recent studies 
have demonstrated that metabolite flux can be controlled by enzymes regulated 
by cellular mediators of signalling transduction and gene expression, including 
transcription factors such as C-MYC and hypoxia-inducible factor 1 (HIF-1), and 
signalling network molecules such as phosphatidylinositol 3-kinase (PI3K) 
(DeBerardinis et al., 2008), whereas intermediate metabolites can be used as 
substrates or cofactors for enzymes to regulate chromatin structure and gene 
expression. Examples include acetyl-CoA generated by catabolism in 
mitochondria can be transported into the cytosol and enter into the nucleus and 
promote the acetylation of histones specifically at growth genes (Cai et al., 
2011), and that the metabolites in the S-adenosyl methionine cycle contain 
methyl groups which are the most common substrate for DNA methylation and 
are highly present in iPSCs (Panopoulos et al., 2012). Therefore, metabolites 
integrate into the epigenome, and thereafter may influence chromatin 
structure, gene expression, miRNAs, non-coding elements, and posttranslational 
modification of histone (Katada et al., 2012) to determine stem cell fate. 
NSQ50 nanotopography, as a non-invasive osteoinduction tool for MSCs, has 
demonstrated the capacity for systematic investigation of mechanisms that 
determine stem cell fate and linage-specific differentiation (Dalby et al., 2007b; 
McMurray et al., 2011). The emergence of metabolomics like other ‘omics’ (e.g. 
transcriptomics, proteomics) provides a new systematic approach to extend our 
understanding of NSQ50 induced osteogenesis of MSCs. Thus, in this chapter, 
metabolites changed in MSCs on the NSQ50 surface at early stage commitment, 
which has been characterized in this thesis as a crucial time period for MSC 
osteogenic differentiaiton, were investigated with the aims of: 
1. Characterize the bioenergetics and biosynthesis of MSCs on NSQ50 surface. 
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2. Attempt to probe the relations of specific metabolites to the regulatory 
mechanisms of osteogenesis of MSCs on the NSQ50 surface. 
3. Help validate the time point at which MSCs switch to osteogenic 
differentiation. 
5.2 Methodology and data analysis 
5.2.1 Methodology 
The gene expression and signalling analysis have illustrated that MSCs shift from 
stem cell state towards osteogenic phenotype at around 5 to 7 days on the 
NSQ50 surface. Thus, the roles of metabolism for osteogenic differentiation of 
MSCs on the surface should be investigated around this time period.  
Untargeted metabolic analysis was used with the aim of measureing (ideally) all 
metabolites in MSCs on the NSQ50 surface, and comparing different time point 
samples (biological groups) to identify potential metabolites of interest, and find 
the differences among those samples. Thus, MSCs cultured on the NSQ50 and 
planar surfaces for 3, 5 and 7 days had metabolites extracted, and liquid 
chromatography and mass spectrometry (LC-MS) performed in the Glasgow 
Polyomics Centre. The LC-MS platform (UltiMate 3000 RSLC (Thermo Fisher)) 
consists of hydrophilic interaction liquid chromatography (HILIC) (Thermo Fisher) 
using a 150 x 4.6mm ZIC-column to separate polar compounds like sugars, amino 
sugars, amino acids, vitamins, carboxylic acids, and nucleotides etc., and 
Exactive Orbitrap mass analyser (Thermo Fisher) for metabolite identification 
and quantification. 
5.2.2 Data analysis 
The raw MS data from three biological samples (MSCs cultured on NSQ50 
surfaces) and three control samples (MSCs cultured on planar surfaces) at each 
time point was pre-processed using analysis pipeline generated in Glasgow 
Polyomics Centre. The pipeline consists of XCMS (Smith et al., 2006) for peak 
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picking, MzMatch (Scheltema et al., 2011) for filtering and grouping, and IDEOM 
(Creek et al., 2012) for further filtering and identification. Metabolite 
identifications were validated against a panel of unambiguous standards by mass 
and retention time. Additional putative identifications were assigned by mass 
and predicated retention time (Creek et al., 2011). 
Further data analysis was performed manually, including: 
1. Data merging: merging all tables from all datasets in IDEOM (i.e. 
identification, rejected, allBasePeaks, alldata) for consistency checks, 
identical value checks and redundancies. This resulted in a peak-list of 1697 
peaks, of which 617 have been associated with metabolite names. 
2. Data associations: About 400 known metabolites were associated with KEGG 
accession identifiers (KEGG ID#). 
3. Fold changes and p-values were calculated by comparing three biological 
samples on NSQ50 to three biological samples on planar surfaces at each time 
point.  
4. The profile of metabolite changes at different time points was mapped using 
log-transformed fold change to generate heatmaps in R. 
5. Pathway mapping: all KEGG accession numbers were submitted to the KEGG 
database (http://www.genome.jp/kegg/tool/map_pathway1.html) and 
potentially relevant pathways were noted. Pathways associated with 
bioenergetics, biosynthesis and mitochondrial activities were paid particular 
attention, and associated metabolite changes among three time points were 
further analyzed using ANOVA. 
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5.3 Results 
5.3.1 Clustering analysis of metabolites in MSCs on NSQ50 
The metabolic profile of MSCs on the NSQ50 surface at the early stage of 
nanotopography induced osteogenesis was analysed by clustering in a heatmap 
matrix (Figure 5.1). Metabolic data generated from LC-MS and then the IDEOM 
pipeline was further checked for consistency, identical value and redundancies, 
which resulted in about 400 metabolites with KEGG accession numbers. 
Metabolite fold changes in MSCs on the NSQ50 surface at 3, 5 and 7 days 
obtained by comparing to those on planar surfaces respectively, and were 
subjected to heatmap analysis. For better visualization, the total metabolites 
were cataloged into four groups namely lipids (Figure 5.1), amino acids (Figure 
5.2), nucleotides and others (Figure 5.3), and non-pathway mapping metabolites 
(Figure 5.4) according to metabolite properties. All lipids and amino acids were 
classified into lipid and amino acid groups respectively. Nucleotides, 
carbohydrates, cofactors etc., were all included in the nucleotides and others 
group. Metabolites with KEGG identification and accession number but without 
pathway mapping were classified into non-pathway mapping metabolites group. 
The clustering analysis showed that metabolites in MSCs on the NSQ50 surface 
were clustered for cells cultured for 5 and 7 days and differed from those for 
cells cultured for 3 days, indicating metabolic profile changed during the 3 to 5 
day time progression on the NSQ50 surface. The main difference in the lipid 
group occurred in the fatty acyls sub-group (Figure 5.1), and about all of amino 
acids were showing difference between 3 and 5 to 7 days cell culture (Figure 
5.2). About 60% of metabolites changed in the nucleotide group (Figure 5.3), and 
about 30% of metabolites without KEGG pathway mapping were changed (Figure 
5.4). 
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Figure 5.1 The lipids profile of MSCs on the NSQ50 surface for cells cultured 
at 3, 5, and 7 days. 
Heatmap clustering shows lipids fold change  in MSCs cultured for 3 
days (D3), 5 days (D5) and 7 days (D7), (biological replicates:  N=3). 
The color range (top left corner) indicates the log-transformed fold 
change from down-regulation (red) to up-regulation (green). Lipids 
in MSCs at 5 and 7 days show co-clustering and differ from those at 
3 days. 
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Figure 5.2 The amino acid profile of MSCs on the NSQ50 surface for cells 
cultured at 3, 5, and 7 days. 
Heatmap clustering shows amino acid fold change  in MSCs cultured 
for 3 days (D3), 5 days (D5) and 7 days (D7), (biological replicates: 
N=3). The color range (top left corner) indicates the log-
transformed fold change from down-regulation (red) to up-
regulation (green). Amino acids in MSCs at 5 and 7 days show co-
clustering and differ from those at 3 days. 
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Figure 5.3 The nucleotides and other metabolites profile of MSCs on the 
NSQ50 surface for cells cultured at 3, 5, and 7 days. 
Heatmap clustering shows nucleotides and other metabolites fold 
change in MSCs cultured for 3 days (D3), 5 days (D5) and 7 days 
(D7), (biological replicates: N=3). The color range (top left corner) 
indicates the log-transformed fold change from down-regulation 
(red) to up-regulation (green). Nucleotides and others in MSCs at 5 
and 7 days show co-clustering and differ from those at 3 days. 
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Figure 5.4 The non-pathway mapping metabolites profile of MSCs on the 
NSQ50 surface for cells cultured at 3, 5, and 7 days. 
Heatmap clustering shows non-pathway mapping metabolites fold 
change in MSCs cultured for 3 days (D3), 5 days (D5) and 7 days 
(D7), (biological replicates: N=3). The color range (top left corner) 
indicates the log-transformed fold change from down-regulation 
(red) to up-regulation (green). Non-pathway mapping metabolites 
in MSCs at 5 and 7 days also show co-clustering and differ from 
those at 3 days. 
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5.3.2 Bioenergetics of MSCs on the NSQ50 surface 
Metabolic profiles changed in MSCs on NSQ50 surface between 3 days to 5 and 7 
days cell culture, and previous studies have demonstrated that the bioenergetics 
of proliferating stem cells differ from that of differentiating stem cell (Cho et 
al., 2006; Pattappa et al., 2011). This led to further analysis of bioenergetics in 
MSCs on the NSQ surface. 
5.3.3 The lack of anaerobic glycolytic phenotype of MSCs on 
NSQ50 at early stage osteogenesis 
Stem cells utilize glycolysis for ATP generation to support proliferation and other 
cell activities. The anaerobic glycolysis pathway starts with glucose flux and 
goes through serial enzymatic reactions to the final product of lactate (Shyh-
Chang et al., 2013a). In this pathway, glucose may flux into PPP for nucleotide 
synthesis. To see whether the glycolytic bioenergetics altered in MSC on the 
NSQ50 surface, carbohydrate metabolites with KEGG accession identification 
numbers were submitted to the KEGG database. The output of KEGG pathway 
searches showed that D-glucose and pyruvate, the two major components of the 
glycolysis pathway, were observed in MSCs on NSQ50 surface (Figure 5.5A, red 
arrow), and that three metabolites including D-glucose and pyruvate were 
observed in PPP (Figure 5.5B, red arrow). Further quantitative analysis for those 
components being made by comparing these metabolites in MSCs on the NSQ50 
to those on planar surfaces for 3, 5 and 7 days cell culture, and the fold changes 
were statistically analysed by ANOVA (Figure 5.6). The data showed that D-
glucose was significantly decreased at day 5 relative to day 3 (Figure 5.6a). 
However, pyruvate (a key intermediate metabolite of the pathway) and lactate 
(the final product of the pathway) (Figure 5.6b, d) remained almost unchanged 
during 3, 5 and 7 days of cell culture. Furthermore, the insignificant change of 
D-gluconic acid, which is involved in the PPP pathway, was also observed (Figure 
5.6c). These data indicate that glycolysis was not affected by the increased 
consumption of D-glucose at day 5, and suggests shifts in cell energetics to other 
pathways at day 5. 
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Figure 5.5 Metabolites in MSCs on the NSQ50 surface involved in the 
glycolysis pathway. 
D-glucose and pyruvate (red arrow) are noted in glycolysis pathway 
by searching the KEGG database. The pathway is also indicates 
lactate (pointed by yellow arrow) is its final product (A). D-glucose, 
pyruvate and D-gluconic acid (red arrow) are marked in a sub-
pathway of glycolysis, namely the pentose phosphate pathway by 
which cells synthase nucleotides (B). 
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Figure 5.6 The effect of the NSQ50 surface on the glycolytic bioenergetics 
pathway in MSCs. 
Metabolites in MSCs on the NSQ50 surface were compared to those 
on the planar surface. D-glucose was significantly decreased on the 
NSQ50 surface at day5 relative to day3 (a). Pyruvate (b), D-gluconic 
acid (c) and D-lactate (d) remained almost unchanged from day 3 
to day 5 and 7. (biological replicates: N=3, ± SD) ANOVA analysis, * 
p < 0.05. Arrows on graphs show the control level. 
5.3.4 The increased mitochondrial activity for bioenergetics of 
MSCs on NSQ50 surface 
The significant decrease of D-glucose was not followed by an increase in 
glycolytic level in MSCs on the NSQ50 surface, suggesting cells exploit other 
pathways in bioenergetics. Mitochondria have been long recognised as playing 
important roles for the production of ATP and synthesizing lipids. Recent studies 
have demonstrated the regulatory roles for a variety of cellular processes such 
as proliferation and differentiation in many cell types (McBride et al., 2006), 
including MSC (Chen et al., 2008).  
The Krebs cycle (TCA cycle) occurs in the mitochondria, in which carbohydrates 
and fatty acids are oxidized and OxPhos level is increased for ATP generation. 
Pathway analysis for metabolites of MSCs on the NSQ50 surface showed that 
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changes in fumarate (produced by mitochondria complex II and also an 
intermediate metabolite of TCA) and orthophosphate were noted (Figure 5.7A). 
Further analysis demonstrated fumarate and orthophosphate were significantly 
increased at day 5 and day 7 when compared to planar control (Figure 5.7B). 
Fumarate is the product of OxPhos by mitochondrial complex II, and 
orthophosphate is involved in mitochondrial complex V for the final step of ATP 
generation. Thus, these data indicates mitochondrial OxPhos level is significantly 
increased and the bioenergetics process shift to mitochondrial OxPhos when 
MSCs are cultured on the NSQ50 surface for 5 days. 
 
 
 
 
 
 
 
 
 
165	  
	  
A
Fumarate
Da
y3
Da
y5
Da
y7
0.0
0.5
1.0
1.5
2.0
2.5
**
*
Fo
ld
 c
ha
ng
e 
of
 m
et
ab
ol
ite
 c
om
pa
re
d 
to
 p
la
na
r 
co
nt
ro
l
Orthophosphate
Da
y3
Da
y5
Da
y7
0
2
4
6
8
*
*
Fo
ld
 c
ha
ng
e 
of
 m
et
ab
ol
ite
 c
om
pa
re
d 
to
 p
la
na
r 
co
nt
ro
l
B
	  
Figure 5.7 NSQ50 surface shifting bioenergetics of MSCs to mitochondria. 
Fumarate and orthophosphate are marked in the TCA pathway by 
KEGG pathway search (A, red arrows)). Both fumarate and 
orthophosphate were significantly increased after 5 days cell 
culture on the NSQ50 surface (B). (biological replicates: N=3, ± SD), 
ANOVA analysis, * p < 0.05, ** p < 0.01. Arrows on graphs show the 
control level. Panel A: Oxidative phosphorylation pathway (KEGG 
map: oo190). The top panel shows the electron transport chain in 
the inner membrane of mitochondrion, which consists of five 
enzymatic complexes (through complex I to complex V) to oxidase 
NADH. The blue rectangles at the bottom panel of A show the 
genes encoding the enzymatic complexes and enzymes involved in 
the oxidative phosphorylation. 
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5.3.5 The down-regulation of unsaturated fatty acids 
Recent study has found stem cells possess different unsaturated fatty acid 
profiles from differentiated cells, which demonstrated unsaturated fatty acids 
are decreased in stem cell differentiation (Yanes et al., 2010). To get insight 
into the profile of unsaturated fatty acids in MSCs on the NSQ50 surface, fatty 
acid metabolites noted by identification in IDEOM were submitted to the KEGG 
database, and 12 metabolites involved in KEGG biosynthesis of unsaturated fatty 
acids were returned, which represent the features of unsaturated fatty acids in 
MSCs on the NSQ50 surface (Figure 5.8). Among those, 7 metabolites are 
unsaturated fatty acids and 5 are saturated fatty acids. Heatmap clustering 
analysis of fatty acids also demonstrated that most of fatty acids were down-
regulated on the NSQ50 surface after 3 days cell culture and the fatty acids 
involved in KEGG biosynthesis of unsaturated fatty acids were noticed in the 
heatmap clustering (Figure 5.9). 
Statistical analysis of these 12 fatty acids show that 3 out of 5 saturated fatty 
acids were significantly down-regulated from 3 days to 7 days cell cultured on 
NSQ50 surface when compared to their planar controls (Figure 5.10a, c, e), and 
one showed a clear downwards trend without statistically significant difference 
(Figure 5.10d) and the other appeared no different to control during the 7 day 
cell culture on the NSQ50 surface (Figure5.10b). For the 7 unsaturated fatty 
acids, 6 of them were significantly down-regulated from 3 days to 7 days in cells 
cultured on NSQ50 surface when compared to their planar controls (Figure 5.10f, 
g, I, j, k, l), and one showed no difference at 7 days (Figure 5.10h). These data 
indicate that the profile of unsaturated fatty acids has changed and been 
characterized as down-regulation from MSCs cultured on the NSQ50 surface for 3 
days. 
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Figure 5.8 Fatty acids involved in biosynthesis of unsaturated fatty acids in 
MSCs cultured on NSQ50 surface for 3, 5 and 7 days. 
12 fatty acids were noted by KEGG pathway search which were 
involved in biosynthesis of unsaturated fatty acids in MSCs on the 
NSQ50 surface. Among those, 5 were saturated fatty acids (blue 
arrow) and 7 were unsaturated fatty acids (red arrow). Left panel: 
Δ number: desaturase, blue arrows: enzymatic reaction steps. Right 
panel: blue rectangle: enzyme with KEGG accession number. 
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Figure 5.9 Heatmap clustering of fatty acids in MSCs on the NSQ50 surface 
for cells cultured at 3, 5, and 7 days. 
Heatmap clustering shows fatty acids fold change in MSCs cultured 
for 3 days (D3), 5 days (D5) and 7 days (D7), (biological replicates: 
N=3). The color range (top left corner) indicates the log-
transformed fold change from down-regulation (red) to up-
regulation (green). Fatty acids involved in KEGG biosynthesis of 
unsaturated fatty acids were noticed at the right corner. 
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Figure 5.10 Down-regulation of fatty acids involved in biosynthesis of 
unsaturated fatty acids in MSCs cultured on NSQ50 surface for 3, 
5 and 7 days. 
Seven unsaturated fatty acids were found in MSCs cultured on 
NSQ50 surface that were involved in biosynthesis of unsaturated 
fatty acids. Among them, six unsaturated fatty acids showed 
significant down-regulation (f, g, I, j, k and l), and one had no 
change (h) after 3 days cell culture. Five saturated fatty acids 
noted as being involved in the biosynthesis of unsaturated fatty 
acids were also highlighted. Three of them showed significant 
down-regulation (a, c and d) and one showed no change (b) after 5 
days cell culture. The other one showed a clear downwards trend 
but no statistical significant difference was observed (e). 
(biological replicates: N=3, ± SD) ANOVA analysis: * p < 0.05, ** p < 
0.01, *** p < 0.001. Arrows on graphs show the control level. 
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5.3.6 The relation of unsaturated fatty acids to signalling 
pathways 
5.3.6.1 Unsaturated fatty acids induce Peroxisome proliferator-activated 
receptor gamma (PPARG) activity 
KEGG pathway search of the differentially regulated fatty acids showed 
eicosanoids have direct links to PPARG (Figure 5.11A). Eicosanoids are a group of 
compounds derived from polyunsaturated fatty acids, predominantly from 
arachidonic acid (Smith, 1989). 9(S)-HODE derived from linoleic acid metabolism 
is one of the eicosanoids noted by KEGG. Statistical analysis showed 9(S)-HODE 
was significantly down-regulated in MSCs on the NSQ50 surface after 3 days of 
cell culture (Figure 5.11B). 
PPARG is nuclear receptor involved in transcriptional network to induce 
adipocyte commitment (Takada et al., 2009). Eicosanoids activate PPARG 
transcriptional cascades by binding to the receptor and subsequently result in 
MSC adipocyte differentiation (Tontonoz et al., 1994a; Tontonoz et al., 1994b). 
Thus, the significant down-regulation of 9(S)-HODE may reduce the activation of 
PPARG and inhibit adipocyte differentiation for MSCs on the NSQ50 surface. 
However, PPARG transcriptional activation is not only instigated by binding to 
eicosanoids, but also by binding to unsaturated fatty acids, such as linoleic acid, 
oleic acid and arachidonic acid (Kliewer et al., 1997; Kuniyasu, 2008). These 
unsaturated fatty acids showed significant down-regulation in MSCs on the NSQ50 
surface in section 5.3.5 (Figure 5.10f, g, I and j). The down-regulation of these 
PPARG ligands indicates NSQ50 surface inhibits PPARG activity and thus inhibits 
adipocyte differentiation on the surface. 
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Figure 5.11 The down-regulation of PPARG ligands in MSCs on the NSQ50 
surface. 
PPARG ligands, the eicosanoids, are noted in the PPAR signalling 
pathway by KEGG pathway searching for MSCs cultured on the 
NSQ50 surface for 3, 5 and 7 days, which directly link to PPARG 
signalling (A, red arrow). 9(S)-HODE, one of eicosanoids, showed 
significant down-regulation after MSCs were cultured on the NSQ 
surface. (biological replicates: N=3, ± SD) ANOVA analysis: *** p < 
0.001. Arrow on graph shows the control level. Panel A: PPAR 
signaling pathway (KEGG map 03320). The adipocyte differentiation 
pathway (bottom panel in A) shows PPARG ligands binding with 
PPARG and PRX which interact to DNA to regulate down-stream 
adipocyte genes (the blue rectangle with gene symbol). 
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5.3.6.2 The roles of fatty acids on Ca2+ signalling 
Fatty acids regulating Ca2+ signalling have been characterized by modulation of 
voltage-gated L-type Ca2+ current and long-chain fatty acids and polyunsaturated 
fatty acids appeared having different effects on the current (Xiao et al., 1997). 
It has been reported that polyunsaturated fatty acids inhibit this signalling, 
whereas long-chain fatty acids, such as lauric acid, can enhance Ca2+ signalling 
(Shimada and Somlyo, 1992; Xiao et al., 1997). Polyunsaturated fatty acids, such 
as oleic acid and arachidonic acid were found to be significantly down-regulated 
in MSCs on the NSQ50 surface after 3 days of cell culture (section 5.3.5, Figure 
5.10f, I). Three long chain saturated fatty acids associated with Ca2+ signalling 
were changed in MSCs on the NSQ50 surface (lauric acid, myristic acid and 
nonadecanoic acid) and statistical analysis illustrated downwards trends for  
lauric and myristic acids in MSCs on NSQ50 surface after 3 days cell culture, and 
upwards trends were noted in nonadecanoic acid but no statistical significance 
was found (Figure 5.12). 
Ca2+ signalling has been recently found to enhance BMP2 expression and hence 
augment osteogenesis (Zayzafoon, 2006). Moreover, another recent study found 
Ca2+ signalling exerts effects on BMP2 expression by the voltage-gated L-type 
Ca2+ channel (Barradas et al., 2012). Thus, the significant down-regulation of 
unsaturated fatty acids in MSCs on the NSQ50 surface after 3 days cell culture 
may activate Ca2+ signalling and subsequently contribute to BMP2 signalling as 
has been described in chapter 4. 
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Figure 5.12 The expression of long chain saturated fatty acids involved in 
the regulation of Ca2+ signalling in MSCs on the NSQ50 surface. 
Lauric and myristic acids in MSCs on the NSQ50 surface showed 
downtrends after initial up-regulation at 3 days of cell culture, and 
nonadecanoic acid was up-regulated but not in a statistically 
significance manner. (biological replicates: N=3, ± SD) ANOVA 
analysis: * p < 0.05. Arrows on graphs show the control level. 
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5.4 Discussion and conclusion 
5.4.1 Discussion 
Numerous studies on identifying stem cell self-renewal and lineage specific 
differentiation have been conducted on cell cycle regulators, transcription 
factors and their associated downstream pathways (Singh and Dalton, 2009). 
Recent advances in metabolomics have provided a systematic approach to get 
insight into stem cell metabolite features, their regulatory functions on stem 
cell fate determination and lineage specific differentiation, and potentially 
linking to transcriptional regulation and signalling pathways (Baumann, 2013; 
Ramm Sander et al., 2013). 
Metabolites in MSCs cultured on the osteoinductive NSQ50 surface at early stage 
of lineage commitment (i.e., after 3 to 7 days exposed to the surface) were 
detected and measured by LC-MS. It is possible due to the the cells being in a lag 
phase in this early stage of culture on the surface that a restricted number of 
400 metabolites were authentically or putatively identified. Clustering analysis 
of the metabolites in MSCs on the NSQ50 surface for the all-time points (3, 5 and 
7 days cell culture) showed all categories of metabolites in MSCs for 5 and 7 days 
cell culture clustered together and differed from those at 3 days of cell culture. 
These data demonstrate that the metabolome had stated to undergo large 
changes on the NSQ surface after this time point compared to control. 
Interestingly, the timing of this general  pattern change is concurrent with the 
down-regulation of cell cycle regulator C-MYC and up-regulation of osteogenic 
transcription factor RUNX2, and the activation of BMP2 signalling which was 
identified in previous chapters, suggesting metabolites may be involved in the 
MSCs fate determination and osteogenic lineage specific differentiation, and 
thus may help provide detailed insight into the roles of metabolites for early 
stages of MSCs growth on the NSQ50 surface. 
Stem cells switching from stemness to lineage specific commitment and 
subsequent differentiation is accompanied by a shift in the balance of anaerobic 
and aerobic bioenergetics to meet biosynthetic demands (Chung et al., 2007; 
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Varum et al., 2011). In MSCs cultured on the NSQ50 surface for 5 days, D-
glucose, the main resources of cell bioenergetics was significantly decreased 
compared to 3 days cell culture, indicating MSCs consumed more glycolysic flux. 
However, the output of glycolysis remained almost the same as that of day 3, 
suggesting the glycolysic flux was alternatively utilized by mitochondria for 
bioenergetics and biosynthesis. MSCs cultured on the NSQ50 surface for 5 days, 
however, showed increased mitochondrial activity as illustrated by significant 
up-regulation of fumarate and orthophosphate which are produced by 
mitochondrial OxPhos and specifically orthophosphate is involved in the final 
step of OxPhos for ATP generation. These data indicates the shifting of 
bioenergetics in MSCs from anaerobic glycolysis to aerobic glycolysis. Such a shift 
shift has been proposed as necessity for stem cell switching to lineage specific 
differentiation, as OxPhos is highly efficient way for energy release to support 
stem cell differentiation (Chen et al., 2008; Cho et al., 2006; Lonergan et al., 
2006). 
Previous studies have demonstrated that undifferentiated stem cells contain 
high levels of unsaturated fatty acids (Yanes et al., 2010). These unsaturated 
structures are characterized as highly reactive metabolites to respond to 
oxidative conditions (redox plasticity), and thus whose levels decrease upon 
differentiation. MSCs cultured on the NSQ50 surface not only exhibit 
bioenergetic shift but also demonstrated significant decrease in unsaturated 
fatty acids after 3 days of culture. The down-regulation of unsaturated fatty 
acids on the surface indicates these metabolites are involved in the regulation of 
redox status and activation of oxidative pathways in mitochondria which 
regulate the balance between stem cell self-renewal and differentiation change 
on activation to osteogenessis (Smith et al., 2000). Stem cells maintain self-
renewal under  a reduced state, whereas they promote differentiation under 
oxidative state (Ezashi et al., 2005; Tsatmali et al., 2005). Thus, these data 
suggess MSCs on the NSQ50 surface initiate differentiation after 3 days and, 
again, this is consistent with the the establishment of signalling molecules 
promoting MSCs differentiation at the same time period in previous chapters. 
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The involvement of metabolites, specifically unsaturated fatty acids in MSC 
differentiation on the NSQ50 surface presented interesting questions about how 
these metabolites contribute to MSC osteogenic lineage specific commitment 
and differentiation. Signalling pathway analysis demonstrated that eicosanoids 
derived from polyunsaturated fatty acids directly link to PPARG and serve as 
ligands to the nuclear receptor (Tontonoz et al., 1994b). Thus, the significant 
flux down-regulation of polyunsaturated fatty acids which was observed in MSCs 
on the NSQ50 surface after 3 days cell culture could perhaps inactivate PPARG 
expression and subsequently inhibit adipocyte commitment. Considering the fact 
that adipocytes and osteoblasts share the same precursor in MSCs, the inhibition 
of adipocyte commitment would simultaneously enhance osteogenic 
differentiation of MSCs. 
The roles of BMP2 signalling for osteogenesis of MSCs on the NSQ50 surface have 
been established in chapter 4. Recent study demonstrates that biomaterials 
which elicit high extracellular Ca2+ concentration enhance BMP2 expression by 
the regulation of type L voltage-gated Ca2 channels (Barradas et al., 2012). 
Previous studies have established the roles of fatty acids for Ca2+ signalling by 
regulation of type L voltage-gated Ca2 channels (Shimada and Somlyo, 1992; Xiao 
et al., 1997). Significant increases in long chain saturated fatty acids which 
possess the capacity of regulation on type L voltage-gated Ca2 channels, such as 
lauric acid were not observed in MSCs on the NSQ50 surface. However, 
unsaturated fatty acids, such as oleic acid, arachidonic acid, linolenic acid and 
linoleic acid were significantly down-regulated in MSCs on the surface and thus 
could contribute to Ca2+ signalling. Thus, it is rational to propose that the down-
regulation of unsaturated fatty acids could enhance Ca2+ signalling and 
subsequently help induce BMP2 expression to impact the osteogenic commitment 
of MSCs on the NSQ50 surface. 
5.4.2 Conclusion 
Metabolomics is a valuable approach providing insights on stem cell fate 
commitment and other functions. Early time point investigation of metabolism 
of MSCs on the NSQ50 nanotopography that induced osteogenesis of MSCs 
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revealed metabolites changed and implied potential roles for metabolites in MSC 
osteogenic lineage specific commitment and differentiation. 
Bioenergetics of MSC appears to shift to mitochondrial OxPhos for highly 
efficient ATP generation to meet the requirement of differentiating. This 
shifting results in the down-regulation of unsaturated fatty acids which play 
multiple regulatory roles for MSCs osteogenic fate determination and 
differentiation, and these observations are in line with the results of signalling 
molecules promoting MSCs osteogenic differentiation on the NSQ50 surface 
obtained in previous chapters. 
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Summary 
The major conclusions identified in this project are described in this chapter, 
including the functional coupling of gene expression with MSC osteogenic 
differentiation on the NSQ50 surface, and molecular regulatory events 
underlying the nanotopography induced osteogegenesis of MSCs. Conclusions are 
also drawn for the systematic features of MSCs investigated as a result of the 
original metabolomics data and the possible functional coupling of metabolites 
and signalling molecules in the regulation of osteogenesis of MSCs on the NSQ50 
surface. Possible directions of enquiry for future work are also described. 
6.1 Conclusions 
Non-invasive nanotopographical features provide a valuable tool which has been 
used to investigate the molecular mechanisms regulating MSC fate 
determination and lineage specific differentiation. The NSQ50 nanotopography 
has been characterized for osteogenic phenotype induction of MSCs, providing a 
promising instrument to functionally activate MSCs osteogenic lineage specific 
differentiation. The functional biology of MSCs on the osteoinductive NSQ50 
surface was investigated for three purposes: Firstly, to characterize functional 
relationship of the gene expression with the osteogenic differentiation process 
of MSCs on the surface, secondly to dissect the molecular regulatory events 
guiding MSC response to the surface, and finally to gain the insight of 
metabolism of MSCs on the surface with potential links to molecular signalling 
considered. 
6.1.1 Functional coupling of gene expression and osteogenic 
differentiation 
Genes involved in stem cell osteogenic differentiation can be categorised into 
two groups: genes encoding transcription factors and genes encoding osteogenic 
markers. Transcription factor genes such as C-MYC, RUNX2 and OSX, and 
ostegenic marker genes including ALP, OPN and OCN were selected for the 
study, whose temporal sequence expression would reflect the different stages of 
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MSCs osteogenic differentiation on the NSQ50 surface. This work was guided by 
the seminal work of Lian and Stein (Lian and Stein, 1992). 
6.1.2 Transcriptional control of MSC osteogenic differentiation 
MSC self-renewal requires C-MYC expression, and expression of RUNX2 and OSX 
control MSCs osteogenic lineage specific differentiation. The results of temporal 
sequence expression of these transcription factors in MSC on the NSQ50 surface 
revealed that the significant down-regulation of C-MYC correlated with 
significant up-regulation of RUNX2 when MSCs cultured on NSQ50 surface for 5 
days. These data suggest that MSCs switching the stemness to osteogenic lineage 
specific occurred at 5 days of culture on the surface. Significant up-regulation of 
OSX followed RUNX2 expression and occurred at 11 and 13 days cell culture, 
suggesting the OSX was required to complete the differentiation of osteoblast 
precursors to mature and functional osteoblasts. This ties in well with 
observations in the literature (Sinha and Zhou, 2013). 
Mature osteoblasts are marked by high levels of expression of osteogenic marker 
genes such as ALP, OPN and OCN which were observed in MSCs on the NSQ50 
surface after three weeks cell culture and followed by the matrix minerals 
produced by mature osteoblasts after 28 days cell culture on the surface. 
Further analysis by measuring expression of the transcription factors MSX2 and 
DLX5 which are mediated in RUNX2-independent of OSX expression (Liu et al., 
2007b; Matsubara et al., 2008) suggested that OSX modulation was reliant on 
RUNX2 in MSCs on the NSQ50 surface.  
6.1.3 BMP2 signalling and osteogenesis of MSCs on the NSQ50 
surface 
BMP2 signalling was identified as the earliest molecular signal to induce RUNX2 
and subsequent OPN expression. BMP2 and its receptor BMPR1A were 
significantly up-regulated after 3 days of culture on the surface. The results of 
down-regulation of RUNX2 by applying the BMP2 antagonist noggin which 
interacts with BMPR1A and inhibits BMP2 signalling (Gazzerro and Canalis, 2006) 
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indicated that the RUNX2 was regulated by BMP2 signalling. Furthermore, the 
inhibition of BMP2 signalling by noggin resulted in the down-regulation of OPN, 
suggesting the osteogenic differentiation of MSCs on the NSQ50 surface was 
stimulated by BMP2 signalling via RUNX2. 
The regulatory effects of BMP2 signalling on the NSQ50 surface induced 
osteogenesis of the MSCs was also demonstrated in the regulation of miR-23b 
which is predicted to target RUNX2 by TargetScan. MiR-23b was significantly 
down-regulated when RUNX2 was induced in MSCs on the surface. However, 
inhibiting BMP2 signalling by addition of noggin resulted in the recovery of miR-
23b and the down-regulation of RUNX2, indicating miR-23b targeting of RUNX2 
was regulated by BMP2 signalling. 
6.1.4 Implicating integrin αvβ5 in osteogenesis of MSCs on the 
NSQ50 surface 
Integrin αvβ5 was found up-regulated after 5 days of culture on the NSQ50 
surface. However, inhibition of β5 by applying an antagonising anti-β5 antibody 
in the culture medium resulted in almost unchanged expression of RUNX2. 
Further analysis indicated integrin β3 was up-regulated while β5 was inhibited 
suggesting that cells switched to using the alternative VN receptor (Hynes et al., 
2002). Functionalizing the NSQ50 surface with the ligand of αvβ5, VN by 
immobilization resulted in up-regulation of RUNX2, suggesting that integrins are 
involved in the regulation of osteogenic differentiation of MSCs on the NSQ50 
surface. 
6.1.5.1 Synergic effects of the interplay of BMP2 and integrin 
αvβ5 on osteogenesis of MSCs on the NSQ50 surface 
Integrin αvβ5 was found to be regulated by BMP2 signalling on the NSQ50 
surface. Expression of integrin αvβ5 was supressed by inhibiting BMP2 signalling, 
and subsequently resulted in down-regulation of vinculin. Further analysis of the 
relation of BMP2 signalling to integrin αvβ5 expression demonstrated that 
BMPR1A co-localized to αvβ5. VN immobilisation further enhanced activation of 
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αvβ5 and BMPR1A co-expression. The interplay of BMP2 signalling and integrin 
αvβ5 resulted in enhanced stimulation of RUNX2 in MSCs on NSQ50. 
6.1.6 Metabolism of MSCs on the NSQ50 surface 
Stem cell fate commitment and lineage specific differentiation is a systematic 
biological process. Metabolomics data obtained from MSCs cultured on the NSQ50 
surface at early stages of culture indicated that nanotopography induced MSC 
osteogenic differentiation was not only regulated by genetic modulation of MSCs 
but also synchronized by metabolism of the cells, and that was controlled by 
potential links between gene expression, signalling pathways and metabolic 
status of the cells (Katada et al., 2012). 
Metabolic data indicated that the bioenergetics of MSCs on the surface shifted 
balance from anaerobic to aerobic processes after 3 days of cell culture and 
resulted in activation of mitochondrial OxPhos (Chen et al., 2008). This was 
illustrated by reduction of the glycolysic flux of D-glucose without increase in 
the output of glycolysis, but instead, increases in fumarate and orthophosphate 
were noted which are the products of OxPhos were significantly increased after 
3 days of culture on the surface (Cho et al., 2006; Lonergan et al., 2006). 
The metabolic data provided by growth of MSCs on the surface also 
demonstrated that unsaturated fatty acids, which are highly reactive 
metabolites and that respond to oxidative conditions (Yanes et al., 2010), were 
significantly decreased after 3 days of cell culture. This reduction indicated 
MSCs on the NSQ50 surface switched stem state to differentiation, as stem cells 
maintain self-renewal under a reduced state, and promote differentiation under 
oxidative state (Ezashi et al., 2005; Tsatmali et al., 2005). 
The reduction of unsaturated fatty acids on the surface also suggested possible 
links of metabolism with PPARG and BMP2 signalling pathways. Unsaturated fatty 
acids such as 9(S)-HODE act as ligands for PPARG (Tontonoz et al., 1994b). 9(S)-
HODE was observed to be significantly down-regulation in MSCs on the NSQ50 
surface after 3 days of cell culture, indicating the inhibition of adipocyte 
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commitment of the MSCs. Furthermore, unsaturated fatty acids such as oleic 
acid, arachidonic acid, linolenic acid and linoleic acid negatively regulate Ca2+ 
signalling that can enhance BMP2 expression (Barradas et al., 2012; Shimada and 
Somlyo, 1992; Xiao et al., 1997). Thus, the reduction of unsaturated fatty acids 
in MSCs on the NSQ50 surface may contribute to osteogenic lineage-specific 
commitment and differentiation in two ways: inhibition of MSC adipocyte 
commitment resulting in simultaneous osteogenic commitment of MSC; and up-
regulation of Ca2+ signalling resulting in increased expression of BMP2. 
6.2 Future work 
Many aspects of the work in this thesis would be interesting to extend and could 
provide further insights into the interpretation of nanotopographical cues on MSC 
fate determination and lineage-specific differentiation. 
NSQ50 induced MSC endogenous BMP2 expression would be interesting to explore 
further by quantifying the amount of BMP2 secreted by the cells. This would 
enable us to quantitatively estimate the rate of BMP2 generated by the cells on 
the surface and provide useful information for further osteogenic 
nanotopography designing and clinical application. RhBMP2 has been applied in 
clinical administration. Thus, if nanotopography can induce MSCs to secrete 
BMP2 at the level of clinic requirement, it would increase its usefulness for bone 
graft generation in vitro, but also for in situ bone repair in vivo. This is 
particularly important as clinical use of soluble BMP2 at the high doses required 
for effect has been implicated in serious respiratory, neurological, and 
inflammatory complications and these led the FDA to issue a Public Health 
Notification of life threatening complications associated with this clinical gold 
standard for bone repair (Lo et al., 2012; Vo et al., 2012; Woo, 2012). 
The BMP2 signalling inducing RUNX2 via BMP2-SMAD1/5 and/or BMP2-miR-23b 
pathways and subsequently stimulates osteogenesis of MSCs on the NSQ50 
surface has been established in this thesis. It would be interesting to distinguish 
the contributions of BMP2-SMADs and BMP2-miR-23b pathways to RUNX2 
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induction, and this could be achieved by manipulating the expression of either 
SMAD1/5 or miR-23b. Furthermore, identification of pathways through which 
BMP2 signalling regulates miR-23b would also be interesting work in the context 
of molecular mechanisms of MSCs fate determination and differentiation. 
MiRNAs targeting osteogenic transcription factors, as investigated in this thesis, 
could also be extended. It would be interesting to investigate miRNA profiling for 
genome wide miRNA expression during different MSCs osteogenesis stages on the 
NSQ50 surface. This would enable us to identify more miRNAs which are involved 
in the regulation of MSC biological functions at different stages, and could be 
achieved by the high-throughput approaches as miRNA-array (Thomson et al., 
2007) and miRNA-seq (Luo, 2012). This would also enable a wider comparison at 
genome level of the miRNA similarities and differences between undifferentiated 
MSCs and osteoblasts derived from MSCs, after induction by different methods 
(i.e., chemical induction (Li et al., 2014a), stiffness induction (Engler et al., 
2006), confinement induction (McBeath et al., 2004), and nanotopography 
induction (Kilian et al., 2010)), and thus, provide unique miRNA signature for the 
insights into the regulatory mechanisms of nanotopographical cues. 
Metabolism of MSCs on the NSQ50 surface investigated in this thesis could also 
extend in future. It would be interesting to directly measure enzymatic reactions 
in MSCs on the NSQ50 surface. For example, lactate production assay could allow 
the glycolytic flux to be assessed, and catalase which is antioxidase to reduce 
ROS in MSC could be measured by activity assay (Li et al., 2014b). Mitochondrial 
activity of MSCs could also be assessed by measuring mitochondrial mass or the 
relative mitochondrial DNA copy numbers. These would specifically show the 
bioenergetic features of MSCs on the NSQ50 surface and validate the data 
obtained by LC-MS. It would also be interesting to investigate the changes of MSC 
cellular metabolites influencing the epigenome. This would enable us to link 
metabolism with gene expression and signalling pathways of the MSCs on the 
NSQ50 surface and provide a comprehensive view of nanotopography action on 
MSC fate determination and differentiation. 
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